PANCREATIC CANCER ACTION

England & Wales · Charity number 1137689

Details

Other names	PCA
Status	Registered
Legal form	Charitable company
Company number	07272699
Registered	2010-08-31
Register	View on the Charity Commission register

Contact

Address	Alliotts 3 London Square Cross Lanes Guildford Surrey GU1 1UJ
Phone	03030401770
Email	enquiries@panact.org
Website	www.pancreaticcanceraction.org

Activities

Objects: (1) TO PROMOTE AND PROTECT THE PHYSICAL AND MENTAL HEALTH OF PANCREATIC CANCER PATIENTS AND THEIR FAMILIES AND CARERS THROUGH THE PROVISION OF SUPPORT, EDUCATION AND PRACTICAL ADVICE.(2) TO ADVANCE THE EDUCATION OF HEALTH PROFESSIONALS AND THE GENERAL PUBLIC IN ALL AREAS RELATING TO PANCREATIC CANCER.

Activities: PROVIDE SUPPORT, EDUCATION AND PRACTICAL ADVICE.TO SUFFERERS OF PANCREATIC CANCER,THEIR FAMILIES AND CARERS, ACTIVITIES INCLUDE DEVELOPMENT OF WEBSITE , BOOKLETS, MEDIA ARTICLES.ADVANCE THE EDUCATION AND AWARENESS AMONGST HEALTH PROFESSIONALS AND THE GENERAL PUBLIC FROM DIAGNOSIS TO PALLIATIVE CARE. ACITIVITES HAVE INCLUDED GP LECTURES, GP TRAINING MODULES AND WRITTEN ARTICLES IN VAIROUS MEDIA.

Downloaded from opencharities.uk/ew/1137689

Classification

- **How:** Provides Advocacy/advice/information, Sponsors Or Undertakes Research
- **What:** The Advancement Of Health Or Saving Of Lives
- **Who:** The General Public/mankind

Geography

- **Area of benefit:** UNDEFINED. IN PRACTICE, NATIONAL AND OVERSEAS
- Northern Ireland
- Scotland
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2024-12-31	£633,973	£856,391	£369,961	13
2023-12-31	£752,504	£760,581	£592,379	13
2022-12-31	£488,089	£729,830	-	-
2021-12-31	£754,217	£841,957	£842,197	11
2020-12-31	£1,256,477	£746,453	£929,937	13

Trustees

Name	Role	Appointed
Giulio Codacci-Pisanelli	Chair	2024-03-18
DAVID CHARLES SLATER		2024-03-18
Dr Christopher Ross Carter		2020-04-01
Elspeth Millar Cowan		2021-08-24
Gabriella Lesca		2024-03-18
Louise Effuah Nylander		2021-08-24
NEVILLE NORBERT MENEZES		
Naomi Barbara Longworth		2021-08-27
Rachael Legg		2020-03-16

Downloaded from opencharities.uk/ew/1137689

PANCREATIC CANCER ACTION

England & Wales - Charity number 1137689

Accounts

Charity registration number 1137689 (England and Wales)

Charity registration number SC049777 (Scotland)

Company registration number 07272699

PANCREATIC CANCER ACTION

ANNUAL REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2024

PANCREATIC CANCER ACTION

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	N Menezes	
	R Legg	
	C Carter	
	E Cowan	
	N Longworth	
	L Nylander	
	G Codacci Pisanelli	(Appointed 18 March 2024)
	D Slater	(Appointed 18 March 2024)
	G Lesca	(Appointed 18 March 2024)
	T Matthews	(Appointed 20 August 2024)
Secretary	T Matthews	
Charity number (England and Wales)	1137689	
Charity number (Scotland)	SC049777	
Company number	07272699	
Registered office	3 London Square Cross Lanes Guildford GU1 1UJ	
Auditor	Alliotts LLP 3 London Square Cross Lanes Guildford GU1 1UJ	
Correspondence address	Suite 3.10 CoVault Fullarton Road Cambuslang Glasgow G32 8YL	

PANCREATIC CANCER ACTION

CONTENTS

	Page
CEO's report	1 - 2
Trustees' report	3 - 10
Statement of Trustees' responsibilities	11
Independent auditor's report	12 - 15
Statement of financial activities	16
Balance sheet	17
Statement of cash flows	18
Notes to the financial statements	19 - 31

PANCREATIC CANCER ACTION

CEO'S REPORT

FOR THE YEAR ENDED 31 DECEMBER 2024

DELIVERING REAL RESULTS NOW; BUILDING FOR GREATER SUCCESSES IN THE FUTURE

Our 2024 Annual Report highlights details of the real and tangible results Pancreatic Cancer Action has achieved over the past year. I am confident that readers will be inspired by the immense activity, creativity and sheer determination of ***all*** of the stakeholders of PCA who made these successes possible. Here is a snapshot of the content of this report:

Awareness: Working with professional companies, a network of pharmacy practices and coalitions of charities, PCA drove awareness of pancreatic cancer symptoms across the UK. Amongst this work was a national creative digital and community outreach campaign entitled #MISSEDmoments, which reached hundreds of thousands of people to raise awareness of how missing early symptoms can be devastating. We are grateful to *Free Partners*, the creative company who donated large valuable creative time and expertise, as well as all our other awareness raising partners.

Advocacy: PCA made its voice heard as a key partner in the SCOT-HPB pathway improvement project advocating for clearer, faster referral pathways to save lives. Working in partnership with MPs, MSPs and councils we pursued the common goal of improving diagnosis and care.

Education: 2024 saw a major drive to promote greater familiarity of symptoms and referral pathways amongst GPs and Pharmacists with our revised and enhanced eLearning modules. Working in partnership with the NHS learning hub, Royal Pharmaceutical Society, BOPA and ELE learning, PCA is well positioned to reach every GP and most Pharmacists in the UK to help them efficiently diagnose pancreatic symptoms amongst the general population.

Research: Research is the key to finding more effective methods of diagnosing pancreatic cancer early. We have outlined our continued partnership with the University of Surrey on how a diabetes-pancreatic cancer link supported the development of a new algorithm now being piloted across England. We prepared the relaunch of our Early Diagnosis Challenge Award to drive early diagnosis.

Support: People with Pancreatic Cancer, and their families are at the heart of PCA. In 2024 we continued to fund a Clinical Nurse Specialist in Glasgow, supporting over 2,500 patient interactions annually. We added to our highly popular accredited health information booklets and digital resources with a new guide on genetics and pancreatic cancer.

Fundraising: Fundraising is an area where it can be clearly seen how a whole range of companies, trusts and foundations, communities, families and individuals took PCA to their hearts. In 2024 they ran for PCA and took on challenges, including the London Marathon and Great North Run. They turned out in force at several Kiltwalks and participated in the virtual challenge '60milies in April'. In addition, supporters carried out many more fundraising events and activities. A truly touching initiative in 2024 was the production of a Tribute mural in Manchester to Andy Rourke, bassist of The Smiths who died of pancreatic cancer. The tribute to Andy joins with the many tributes family members made to loved ones. Sincere thanks to every person who gives their passion, time and resources.

BUILDING FOR FUTURE SUCCESS

Extensive efforts were undertaken throughout the year to build the basis for future success. You will see in these accounts that four new Trustees were appointed. Collectively they bring a wealth of knowledge and wisdom in the field of Business, Public Services, Marketing and Communications and Law to drive Pancreatic Cancer Action forward. We welcome all our new trustees to the PCA family, whilst thanking those who returned in 2024 for their dedicated service. To the trustees that resigned during 2024, we thank you for the incredible amount of time and commitment you dedicated to the charity.

I recognise the investment of time and resources to develop the assets needed to propel our organisation forward. Much creative work has enriched content and given greater functionality improvements to the PCA website. This website, the 'shop window' of our organisation will be at the centre of PCA's communications strategy.

A review of all our services began in 2024 and will continue apace in 2025. New and aspirational growth strategies are under development in all areas: Awareness, Advocacy, Education, Research, Support. I look forward to sharing, in due course, our new 5-year organisational strategy with exciting plans to put PCA on a growth pathway for the benefit of many more people with pancreatic cancer, and their families.

Anthony Cummings

Anthony Cummings (Sep 5, 2025, 11:11am)

Anthony Cummings
Chief Executive Officer

Date: 05 Sep 2025

PANCREATIC CANCER ACTION

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)

FOR THE YEAR ENDED 31 DECEMBER 2024

The Trustees present their annual report and financial statements for the year ended 31 December 2024.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charity's Articles of Association, the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)".

Objectives and activities

Our purpose

Pancreatic Cancer Action works to save lives through promoting earlier diagnosis of pancreatic cancer. We do this through promoting greater awareness of the symptoms of the disease, the funding and development of medical educational programmes, supporting patients through improved information about pancreatic cancer either on our website or in print and by funding research.

Our vision

Our vision is that everyone survives pancreatic cancer.

Our mission

Our mission is to improve survival rates of pancreatic cancer by ensuring more people are diagnosed early and that everyone has access to effective treatments, support, information and care.

Objectives

The charity's objectives are:

A	**Awareness -** increase public awareness and knowledge of pancreatic cancer and its symptoms to achieve early diagnosis
C	**Campaign** and lobby the government and key stakeholders for change to advance the standard of healthcare for individuals affected by pancreatic cancer
T	**Train** and provide pioneering educational resources for our medical and healthcare communities
I	**Innovative** research **-** we fund it, we support it **-** to improve early diagnosis and develop effective treatments to improve pancreatic cancer outcomes
O	**Offer** the provision of practical and emotional support and information to all affected by pancreatic cancer
N	**Now –** we are the action charity and action is needed more than ever before!

The Trustees have paid due regard to guidance issued by the Charity Commission in deciding what activities the charity should undertake.

The Trustees' activities

The Trustees meet regularly to develop and support strategies to meet the charitable objectives. The Trustees currently have a range of skills and experience that range from medical/scientific, legal, corporate governance, finance and PR, direct and indirect lived experience of pancreatic cancer.

Role of volunteers / PCA Action Ambassadors

The Charity receives the very welcome assistance of volunteers. who help support a range of projects to raise awareness of pancreatic cancer, provide support, review literature and fundraise in their communities.

The charity seeks volunteer assistance via the website, social media and by word of mouth.

Public benefit statement

The Trustees confirm that they have complied with the duty in Section 4 of the Charities Act 2011 to have due regard to the Charity Commission's general guidance on public benefit.

Achievements and performance

Using some of our objectives as headings and some other key areas not covered above, we have set out below highlights of activity and work in 2024 in our ongoing mission to improve survival rates of pancreatic cancer by ensuring more people are diagnosed early and that everyone has access to effective treatments, support, information and care.

***1. Awareness* - increase public awareness and knowledge of pancreatic cancer and its symptoms to achieve early diagnosis**

Pancreatic Cancer Action provides individuals, communities and organisations with resources to help raise and improve symptom awareness of the world's toughest cancer. We do this through providing posters, leaflets, booklets, online resources, and activities within communities. In our mission to improve early diagnosis and save lives, symptom awareness is key to ensuring people contact their GP for support with any concerns as soon as possible.

We continue to provide **quality accredited health information resources** for communities who do not have English as their first language. Our **translated online and print health education resources** are available to those who have **Polish, Urdu, Punjabi, Bengali, Arabic or Gujarati** as their first language. In 2024 we progressed distribution of our translated resources to multi-cultural centres across the UK.

As well as providing free educational resources to individuals and communities, Pancreatic Cancer Action proactively progresses innovative ways to engage with various communities in different ways, particularly targeting "hard-to-reach groups." In August 2024 we hosted a dedicated **"Awareness Week" in the East End of Glasgow**, as part of our ongoing **Action on The Ground** Project. Our incredible staff and volunteers were actively present within local community areas helping open more conversations with people about the importance of symptom awareness, to aid early diagnosis. Over the course of 7 days, activities included the distribution of information leaflets: "quick guides on pancreatic cancer" to aid discussions of symptoms with the public in shopping centres, foodbanks, community centres, churches, sports centres. Throughout August, we raised awareness in a variety of ways to complement the dedicated awareness week activity. This included our purple branded **"PanCanVan"** being positioned in prominent areas with high footfall, 25,000 **pharmacy bags** featuring symptom information distributed by community pharmacies, 5,000 Pancreatic Cancer Action branded cups distributed in local coffee shops, and symptom information on washroom panels in 30 pubs. Alongside our public engagement activities we invested in digital advertising to broaden our messaging, providing strong focused engagement in an area with particularly low levels of symptom awareness and survival. Amazing organic media activity was also achieved including online and digital news stories, interviews on local radio and Celtic TV.

November's **Pancreatic Cancer Awareness Month –** known across our community as "**PCAM"** provides an opportunity to amplify the importance of symptom awareness and share key health information with the public. Our innovative and groundbreaking **"MISSED"** campaign in 2023 was Pancreatic Cancer Actions biggest digital symptom awareness campaign, highlighting those who had passed away from pancreatic cancer because their symptoms were missed. These symptoms were either missed by healthcare professionals or by the individuals themselves. Building on the success of that campaign, PCAM 2024 evolved to **"MISSED moments".** When the symptoms of pancreatic cancer are missed, everything is missed: early diagnosis, life-saving treatment and precious moments with loved ones. Our **"MISSED moments"** campaign enabled people to share the moments they missed with their loved ones and highlight the urgent need for awareness, education and early diagnosis.

Following the success of our East End of Glasgow Awareness Week, we led another geographical specific symptom awareness campaign in November 2024, focused on **North East England, specifically Northumberland and Tyne & Wear.** Throughout the month, awareness of pancreatic cancer was raised with information on 50,000 pharmacy bags, 8,000 branded coffee cups and 48 washroom panels in pub restrooms. Our new campaign '**MISSED moments**' was advertised across the **Tyne and Wear Metro**, stories were shared through media outlets, and investment in targeted social media advertising to the general public and healthcare professionals. An amazing group of volunteers also kindly led an awareness stand at The Metrocentre.

We continued to support collaborative campaigns, with **Purple Lights UK** and **The World Pancreatic Cancer Coalition.** Supporters across the globe help arrange buildings and landmarks to light up purple to shine a light on the disease and share symptom information during November, particularly on **World Pancreatic Cancer Day,** which fosters an inspiring community spirit to improve global survival. A prime example of this is Pancreatic Cancer Actions' annual presence at **Glasgow Central Station** on World Pancreatic Cancer Day. Arranged by one of our amazing supporters and Network Rail, 2024's "**Purple Takeover**" of Scotland's busiest train station was another huge success. Entertainment from The Glasgow Rock Choir and various musicians throughout the day attracted attention, with music bringing people together. We are very grateful to our volunteers and team members who helped share information with the public and collect generous donations.

2. Campaign and lobby the government and key stakeholders for change to advance the standard of healthcare for individuals affected by pancreatic cancer.

With no significant improvement in pancreatic cancer survival rates in 50 years, and a predicted increase in future incidence levels, we continue to urge government and key stakeholders to take urgent action.

Our small but mighty team engage with MSPs, MPs and councillors to explain why action is necessary to improve patient experiences and pancreatic cancer survival rates. We continually advocate for patients and families, building on years of campaigning to raise awareness of pancreatic cancer and the urgent need to drive improvements in the early diagnosis of pancreatic cancer, across the UK.

Throughout 2024 we continued to work in partnership with Cancer 52, One Cancer Voice, The Less Survivable Cancers Taskforce, The Scottish Cancer Coalition, the North Cancer Alliance (Scotland), and a number of other coalitions of cancer charities. Partnership working strengthens our collective voices to ensure patient and carers are at the heart of decision-making by politicians and government.

Pancreatic Cancer Action continued to be key partner in the delivery of **SCOT-HPB: The SHPBN Pathway Improvement Project** for pancreatic and hepatocellular cancer. This was delivered by the **Scottish Government** and **NHS Scotland**, with support from cancer charities and partners such as ourselves. We have been actively involved in driving this important work to improve the timeframes from suspicion of cancer to diagnosis and treatment, with a particular focus on patient and carer experiences.

In November 2024 we provided briefings to all MSPs for the **annual Pancreatic Cancer Awareness Month debate at Scottish Parliament**, with a particular focus on the importance of SCOT-HPB and the positive results from the pilot. However, we were deeply disappointed at the pilot project ending in 2024 with no continuity funding. We will continue to campaign for the learnings to be taken forward to improve patient and carer experiences and outcomes.

We attended the annual **Scottish Cancer Conference** in November which brings together individuals, organisations, patients, pharmaceutical companies, clinicians, academics, policy makers and charities. Pancreatic Cancer Action had the privilege of hosting a breakout session titled **"Community Pharmacy – the new front line for detecting cancer early."** The aim of the session was to emphasise the crucial role that pharmacists play in the early diagnosis of cancer. We chaired a panel of pharmacists who spoke very passionately about the need for direct referral for community pharmacists and the challenges they face. Our Q&A session was very engaging, with discussions around pharmacy capacity, access to patient records and what more can be done to educate community pharmacists about cancer. We also hosted an exhibition stand providing a fantastic opportunity to share Pancreatic Cancer Actions health information and resources, including our accredited educational resources for healthcare professionals and patient information booklets.

Pancreatic Cancer Action contributed to the update of **The Scottish Cancer Referral Guidelines** and are pleased that our recommendations were taken forward for the updates that are expected to be published in 2025.

We continue to be an active partner campaigning for change in England and Wales. In 2024 this included contributing and supporting **The National Pancreatic Cancer Audit**, resulting in The National Cancer Audit Collaborating Centre (NATCAN) publishing a "**State of the Nation Report"** in September 2024, on care received by people diagnosed with pancreatic cancer in England (2020-2021) and Wales (2022). Pancreatic Cancer Action had recommended an audit of pancreatic cancer diagnosis and treatment for many years. Having fed into a feasibility study in 2022 and the development of a scoping document in 2023 to identify priorities of care, we are pleased to continue to be involved in this vital work. We shall continue to campaign for the insights and recommendations from the audit and report to be implemented, as the catalyst for positive change, reshaping of guidelines, improvements in early detection strategies and ultimately enhancing the lives of those affected by pancreatic cancer.

In September 2024, Pancreatic Cancer Action were delighted to support a gathering near **Westminster**, of the "purple family" of community campaigners marking the 10th anniversary of the first Parliamentary Debate on pancreatic cancer. This was a result of a successful petition appeal by campaigner Maggie Watts, which achieved over 100,000 signatures in 2014. While some progress is taking place, increased speed and action is urgently needed in our united mission to save lives. Pancreatic Cancer Action will continue to represent patients and carers, building on years of campaigning and collective activity by our community and together we will continue to make a difference. Patient experience and outcomes will be a key focus area for The UK governments development of a **National Cancer Plan**, to improve cancer prevention, diagnosis, treatment and aftercare. The commitment to the plan was announced in December 2024 and we will support the provision of evidence and contributions on behalf of patients, healthcare professionals and the public.

3. Train and provide pioneering educational resources for our medical and healthcare communities.

Pancreatic Cancer Action provides pioneering **accredited e-learning for GPs and Pharmacists.**

Following the update to our GP e-learning hosted by **The Royal College of General Practitioners (RCGP)** in 2023, we launched a new improved eLearning Module tailored for community pharmacists and their teams in 2024.

Pharmacy staff have daily interactions with their customers, often building relationships that allow them to recognise subtle changes in health. This familiarity puts them in a prime position to identify the warning signs of pancreatic cancer and a well-informed pharmacist can guide patients to seek urgent medical attention. By completing our comprehensive training module, pharmacy teams can gain critical insights and equip themselves with the knowledge to:

- Understand where the pancreas is and its functions in the body
- Identify the risk factors associated with pancreatic cancer and explore its impact on people
- Recognise the symptoms that may indicate pancreatic cancer and require urgent referral to a GP
- Build effective communication skills when speaking to customers showing symptoms or affected by pancreatic cancer.

As universally accessible healthcare professionals with regular trusted contact with their customers, community pharmacy teams are uniquely positioned to spot early signs of pancreatic cancer and have the confidence to take action that could directly lead to earlier diagnoses and make a lifesaving difference.

Our new Pharmacy Team eLearning module is hosted by the prestigious **Royal Pharmaceutical Society (RPS), British Oncological Pharmaceutical Association (BOPA)**, The **NHS Learning Hub** and **ELE Learn**, helping us reach and educate more pharmacists and pharmacy teams than ever before. Upon successful completion of the module, participants receive Continuing Professional Development (CPD) points and a certificate as a record of their achievement.

Pancreatic Cancer Action hosted an exhibition stand at **The Pharmacy Show** at NEC Birmingham in October 2024. With over 8,700 attendees, it was the perfect opportunity to promote our new and improved eLearning module for pharmacy teams, raise awareness of the crucial role they can play in the early diagnosis of pancreatic cancer and liaise with them face-to-face about the difference they can make to survival rates.

We also promote our eLearning at **The Scottish Cancer Conference** in November 2024 and as noted earlier, hosted a breakout session titled "Community Pharmacy – the new frontline for detecting cancer early". Pancreatic Cancer Action were proud to chair the active Q&A session which included discussions on current pilot programmes throughout the UK where pharmacists can directly refer patients onto the cancer pathway. Our resources in educating pharmacy teams will be vital in aiding awareness and understanding of pancreatic cancer.

Our focused awareness campaigns in the East End of Glasgow in August and North-East England in November included a total of 75,000 **pharmacy bags** featuring pancreatic cancer symptom information, attracting the attention of both members of the public and healthcare teams. Alongside our public awareness activities, we invested in targeted advertising, engagement and outreach to **Healthcare Professionals** in those geographical areas, helping maximise our impact of community engagement.

Throughout 2024 we continued to provide **GP and Pharmacy packs** across the UK, and we thank our community of volunteers who help disseminate information on our resources in their local communities.

We look forward to our ongoing work with medical and healthcare communities to continually drive forward improvements in awareness, education and earlier diagnosis of pancreatic cancer.

4. Innovative research - we fund it, we support it - to improve early diagnosis and develop effective treatments to improve pancreatic cancer outcomes.

Pancreatic Cancer Action has historic success providing pump-priming seed-funding to kick-start innovative research projects and opportunities that have then progressed to larger investment from additional funders.

As a small charity we are not in a position to invest millions into research on the same scale as larger organisations, however we are very proud to be driving **innovation** through smaller scale **research** projects that explore both data and science, to better understand pancreatic cancer, earlier diagnosis and effective treatments.

A fantastic example of this is our funding and ongoing partnership working with Dr Agnieszka Lemanska and the research team at **The University of Surrey**. Pancreatic Cancer Action provided initial research funding to examine the link between diabetes and pancreatic cancer. The project was a retrospective case-control study, examining a large sample of GP records of patients with diabetes, to understand those who went on to develop pancreatic cancer and those who did not develop the disease. Multiple variables could be examined including demographics, diagnostics, number of presentations to primary care, and disease management.

The research findings contributed to the development of a new **case finding protocol** for patients with new onset diabetes and weight loss: a new algorithm to identify patients faster and speed up diagnosis. We have continued working with The University of Surrey and **NHS England** to ensure the project developed further and are delighted that additional partners and funding were established to enable a multi-million-pound pilot, implementing the case finding protocol, to be rolled out across England in 2025. We will continue to support this incredible development which involves actively identifying individuals who may have pancreatic cancer, especially those at higher risk and then testing them to confirm or rule out the presence of cancer.

The seed-funding Pancreatic Cancer Action provided for the preliminary stages of this innovative research enabled further research to progress at scale, to enable even bigger **impact** in our united mission to save lives.

We continue to support the team at The University of Surrey as they explore further data interrogation opportunities to identify other factors and combinations of variables that could help potentially identify at-risk patients earlier.

We look forward to supporting more innovative research projects, and in 2024 our team progressed preparations for a relaunch of our **Early Diagnostic Challenge Award** scheme. This included attending training and events with The Association of Medical Research Charities (AMRC), seeking support and legal advice.

Alongside providing research funding, Pancreatic Cancer Action plays a vital role in supporting the wider research community and large research projects, by representing patient and carer voices. Ensuring lived experiences are considered at all stages of research projects is essential through **Patient and Public Involvement (PPI).**

5. Offer the provision of practical and emotional support and information to all affected by pancreatic cancer.

All of the health information that Pancreatic Cancer Action provides is certified and holds a UK-wide “quality mark” as trusted health information. Highly trained medical professionals review the information, and it is independently assessed and accredited by the Patient Information Forum.

Pancreatic Cancer Action are proud to provide a range of accredited high-quality **Health Information Booklets** that are easy to understand and offers useful support for patients, relatives and carers. Our booklets have been created in a modular form, covering a wide range of topics to ensure users get the information and advice they need. Our booklets are now available in a **digital format** on our website, with printed booklets continuing to be available for ordering free of charge from our online shop and are available to both individuals and organisations, including hospitals and cancer support centres. Our innovative **Recipe Book “Nourishing Your Body during Pancreatic Cancer Treatment”** continues to be extremely popular, with unique recipes and guidance specifically for those affected by pancreatic cancer.

In 2024 we produced **a new downloadable resource "The Role of Genetics in Pancreatic Cancer"** helping respond to questions and concerns from people. Our new guide covers everything people need to know about genes and genetic testing, support available for those eligible for testing, genetic conditions that increase the risk of pancreatic cancer and key signs and symptoms to watch out for.

We will continually review how we offer support for patients and families, to ensure there is a range of comprehensive quality information. Creating new world-class accredited health information is a lengthy process due to the need to involve and consult medical professionals, peer reviewers, lay reviewers, patients and their families, health leaders and other charitable organisations. However, this process is necessary to ensure we can provide the best possible support to the people who need us most.

Pancreatic Cancer Action continues to fund a dedicated **Pancreatic Cancer Clinical Nurse Specialist** within The West of Scotland Cancer Network. Based at Glasgow Royal Infirmary, the postholder provides vital additional resource to the specialist team who collectively support around 230 patients each year from across the West of Scotland. Over 2,500 interactions with patients and their families take place every year, with in-person support at clinics, wards and appointments, as well as telephone support. The post-holder also provides a vital role in weekly Multi-Disciplinary Team meetings, where healthcare professionals follow a holistic approach to assessing and diagnosing patients, and creating treatment plans to optimise outcomes.

Pancreatic Cancer Action are very grateful to our team and volunteers who host awareness stands at hospitals, providing an opportunity to talk to patients and carers and share our support information and resources.

Fundraising

In 2024, income was generated through a wide range of fundraising activities and donations, including our amazing supporters taking part in challenge events such as The London Marathon, The Great North Run and various Kiltwalks, to name but a few. Pancreatic Cancer Action also hosted a new virtual event challenge, "60 miles in April" that attracted people from across the UK to raise funds and awareness for pancreatic cancer.

A variety of **community and corporate fundraising** activities also took place and we are continually inspired by the passion, energy and enthusiasm of supporters determined to help Pancreatic Cancer Action in our mission of saving more lives through early diagnosis. From coffee mornings, bingo nights, charity dances, to golf days, distance challenges running, walking, swimming and climbing, we are incredibly grateful for the dedication of supporters arranging fundraising activities in their schools, workplaces and communities. **THANKYOU!**

A huge thank you, also to our incredible donors who support Pancreatic Cancer Action throughout the year and the kind generosity of **legacies** being bequeathed to our charity and **grant awards** to support our activities.

Pancreatic Cancer Action were honoured to the chosen charity beneficiary for an innovative crowdfunding campaign in 2024 by The Smiths drummer Mike Joyce, to create a powerful **mural in memory of beloved bassist, Andy Rourke** who tragically passed away from pancreatic cancer in 2023. Located in Manchester's Northern Quarter, on the side of The Wheatsheaf Pub on Oak Street, the mural was launched on World Pancreatic Cancer Day 2024 as a fitting tribute to Rourkes life and legacy. This generated significant media attention including TV and radio and the mural continues to raise funds and awareness for pancreatic cancer.

Trusts and grants

We are very grateful to the many funders that give so generously towards our initiatives, activities and projects. In 2024 these included £18,000 of restricted grants.

Financial review

The results for the year are summarised in the Statement of Financial Activities on page 16.

The Trustees are pleased to report that the charity's incoming resources for 2024 amounted to £633,973 (2023: £752,504), (2022: £488,089), (2021: £754,217), (2020: £1,256,477; an exceptional year which included a one-off transfer of £607,560 due to the merger with Pancreatic Cancer Scotland and £58,781 through the Coronavirus Job Retention Scheme) (2019: £786,505), (2018: £892,851), (2017: £757,812).

The Trustees would like to thank all those volunteers, fundraisers and donors - corporate, trusts and foundations, as well as individual donors who have supported the charity over the past years and upon whom we are dependent.

Total spending on charitable activities was £492,318 (2023: £465,441), (2022: £450,195), (2021: £513,874), (2020: £437,838) (2019: £609,931) (2018: £669,187), (2017: £669,077).

The charity achieved a net deficit for the year of -£222,418 (2023: -£8,077), (2022: £-241,741), (2021: £-87,740), (2020: £510,025) (2019: £-115,305) (2018: £-24,634) (2017: £-169,315).

Reserves policy

It is the policy of the charity that unrestricted funds which have not been designated for a specific use should be maintained to cover at least 6 months of operating expenditure. The Trustees consider that reserves at this level will ensure that, in the event of a significant drop in funding, they will be able to continue the charity's current activities while consideration is given to ways in which additional funds may be raised.

At 31st December 2024, the charity held reserves of £369,961 of which £103,440 was restricted. Free reserves stood at £193,256 which is in line with the level of the reserves policy established by the board.

Structure, governance and management

The charity is a company limited by guarantee, incorporated in June 2010, and is therefore governed by its Articles of Association. Its company registration number is 07272699 and its charity numbers are 1137689 (England and Wales) and SC049777 (Scotland).

The Trustees, who are also the directors for the purpose of company law, and who served during the year and up to the date of signature of the financial statements were:

H Matthews	(Resigned 17 March 2024)
N Menezes	
N Mumford	(Resigned 18 March 2024)
H Goodfellow	(Resigned 12 June 2024)
L Condron	(Resigned 15 July 2024)
R Legg	
C Carter	
E Cowan	
N Longworth	
L Nylander	
G Codacci Pisanelli	(Appointed 18 March 2024)
D Slater	(Appointed 18 March 2024)
G Lesca	(Appointed 18 March 2024)
T Matthews	(Appointed 20 August 2024)

None of the Trustees has any beneficial interest in the charity. The members of the company guarantee to contribute £10 in the event of liquidation.

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

The Trustees continue to keep the Charity's activities under review, particularly with regard to any major physical or financial risks that may arise from time to time, and to monitor the effectiveness of the system of internal controls and other variable means, including insurance cover where appropriate, by which those risks already identified by the Trustees can be mitigated.

Auditor

In accordance with the company's articles, a resolution proposing that Alliotts LLP be reappointed as auditor of the company will be put at The Annual General Meeting.

Disclosure of information to auditor

Each of the Trustees has confirmed that there is no information of which they are aware which is relevant to the audit, but of which the auditor is unaware. They have further confirmed that they have taken appropriate steps to identify such relevant information and to establish that the auditor is aware of such information.

The Trustees' report was approved by the Board of Trustees.

giulio codacci Pisanelli

Giulio Codacci-Pisanelli (Sep 5, 2025, 2:32pm)

G Codacci Pisanelli
Chair of Trustees

Dated: 05 Sep 2025

PANCREATIC CANCER ACTION

STATEMENT OF TRUSTEES' RESPONSIBILITIES

FOR THE YEAR ENDED 31 DECEMBER 2024

The Trustees, who are also the directors of Pancreatic Cancer Action for the purpose of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that year.

In preparing these financial statements, the Trustees are required to:
- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The Trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

PANCREATIC CANCER ACTION

INDEPENDENT AUDITOR'S REPORT

TO THE MEMBERS AND TRUSTEES OF PANCREATIC CANCER ACTION

Opinion

We have audited the financial statements of Pancreatic Cancer Action (the 'charity') for the year ended 31 December 2024 which comprise the statement of financial activities, the balance sheet, the statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2024 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial statements* section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The Trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

INDEPENDENT AUDITOR'S REPORT (CONTINUED)

TO THE MEMBERS AND TRUSTEES OF PANCREATIC CANCER ACTION

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

- the information given in the Trustees' report for the financial year for which the financial statements are prepared, which includes the directors' report prepared for the purposes of company law, is consistent with the financial statements; and
- the directors' report included within the Trustees' report has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the charity and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report included within the Trustees' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 require us to report to you if, in our opinion:

- adequate and proper accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the Trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemptions in preparing the Trustees' report and from the requirement to prepare a strategic report.

Responsibilities of Trustees

As explained more fully in the statement of Trustees' responsibilities, the Trustees, who are also the directors of the charity for the purpose of company law, are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the Trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with the Acts and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Extent to which the audit was considered capable of detecting irregularities, including fraud
Our approach to identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows:

- the engagement partner ensured that the engagement team collectively had the appropriate competence, capabilities and skills to identify or recognise non-compliance with applicable laws and regulations;
- we identified the laws and regulations applicable to the company through discussions with Trustees and other management, and from our knowledge and experience of the sector;
- we focused on specific laws and regulations which we considered may have a direct material effect on the financial statements or the operations of the charitable company, including the Companies Act 2006, the Charities Act 2011, the Charities SORP, taxation legislation, data protection, anti-bribery, employment, environmental and health and safety legislation;
- we assessed the extent of compliance with the laws and regulations identified above through making enquiries of management and inspecting legal correspondence; and
- identified laws and regulations were communicated within the audit team regularly and the team remained alert to instances of non-compliance throughout the audit.

We assessed the susceptibility of the charitable company's financial statements to material misstatement, including obtaining an understanding of how fraud might occur, by:

- making enquiries of management as to where they considered there was susceptibility to fraud, their knowledge of actual, suspected and alleged fraud; and
- considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations.

Audit response to risks identified
To address the risk of fraud through management bias and override of controls, we:

- performed analytical procedures to identify any unusual or unexpected relationships;
- reviewed all transactions listed;
- assessed whether judgements and assumptions made in determining the accounting estimates were indicative of potential bias; and
- investigated the rationale behind significant or unusual transactions.

In response to the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to:

- agreeing financial statement disclosures to underlying supporting documentation; and
- enquiring of management as to actual and potential litigation and claims.

There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the Trustees and other management and the inspection of regulatory and legal correspondence, if any.

Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealment or collusion.

A further description of our responsibilities is available on the Financial Reporting Council's website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

INDEPENDENT AUDITOR'S REPORT (CONTINUED)

TO THE MEMBERS AND TRUSTEES OF PANCREATIC CANCER ACTION

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charitable company's trustees, as a body, in accordance with Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company's members and trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company, the charitable company's members as a body and the charitable company's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Stephen Meredith

Stephen Meredith (Sep 5, 2025, 3:27pm)

Stephen Meredith BA FCA DChA (Senior Statutory Auditor)
for and on behalf of Alliotts LLP

05 Sep 2025
.....

Chartered Accountants
Statutory Auditor

3 London Square
Cross Lanes
Guildford
GU1 1UJ

PANCREATIC CANCER ACTION

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2024

	Notes	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
Income from:							
Donations and legacies	**3**	594,096	29,264	623,360	571,774	170,357	742,131
Other trading activities	**4**	2,943	-	2,943	3,334	-	3,334
Investments	**5**	7,670	-	7,670	7,039	-	7,039
Total income		604,709	29,264	633,973	582,147	170,357	752,504
Expenditure on:							
Raising funds	**6**	322,757	41,316	364,073	276,495	18,645	295,140
Charitable activities	**7**	317,928	174,390	492,318	288,539	176,902	465,441
Total expenditure		640,685	215,706	856,391	565,034	195,547	760,581
Net expenditure		(35,976)	(186,442)	(222,418)	17,113	(25,190)	(8,077)
Transfers between funds		(6,093)	6,093	-	-	-	-
Net movement in funds		(42,069)	(180,349)	(222,418)	17,113	(25,190)	(8,077)
Reconciliation of funds:							
Fund balances at 1 January 2024		308,590	283,789	592,379	291,477	308,979	600,456
Fund balances at 31 December 2024		266,521	103,440	369,961	308,590	283,789	592,379

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

PANCREATIC CANCER ACTION

BALANCE SHEET

AS AT 31 DECEMBER 2024

	Notes	2024 £	£	2023 £	£
Fixed assets					
Intangible assets	**12**		46,012		-
Tangible assets	**13**		27,253		-
			73,265		-
Current assets					
Stocks	**14**	4,565		3,675	
Debtors falling due after one year	**15**	-		333	
Debtors falling due within one year	**15**	54,375		78,865	
Cash at bank and in hand		331,620		545,716	
		390,560		628,589	
Creditors: amounts falling due within one year	**16**	(93,864)		(36,210)	
Net current assets			296,696		592,379
Total assets less current liabilities			369,961		592,379
The funds of the charity					
Restricted income funds	**18**		103,440		283,789
Unrestricted funds			266,521		308,590
			369,961		592,379

The financial statements were approved by the Trustees on 05 Sep 2025

giulio codacci Pisanelli

Giulio Codacci-Pisanelli (Sep 5, 2025, 2:32pm)

.....

G Codacci Pisanelli

Chair of Trustees

Company registration number 07272699 (England and Wales)

PANCREATIC CANCER ACTION

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 DECEMBER 2024

	Notes	2024 £	2024 £	2023 £	2023 £
Cash flows from operating activities					
Cash absorbed by operations	**21**		(142,026)		(46,052)
Investing activities					
Purchase of intangible assets		(47,140)		-	
Purchase of tangible fixed assets		(32,600)		-	
Investment income received		7,670		7,039	
Net cash (used in)/generated from investing activities			(72,070)		7,039
Net cash generated from financing activities			-		-
Net decrease in cash and cash equivalents			(214,096)		(39,013)
Cash and cash equivalents at beginning of year			545,716		584,729
Cash and cash equivalents at end of year			331,620		545,716

1 Accounting policies

Charity information

Pancreatic Cancer Action is a registered charity and a company incorporated by guarantee with no share capital, exempted under section 5 of the Companies Act 2006 from the requirement to use "Limited" as part of its name. It is incorporated in England and Wales under registration number 07272699 and its registered office is 3 London Square, Cross Lanes, Guildford, England, GU1 1UJ. Correspondence address is Suite 3.10 CoVault, Fullarton Road, Cambuslang, Glasgow, G32 8YL.

1.1 Accounting convention

The financial statements have been prepared in accordance with the charity's Statement of Recommended Practice applicable to charities preparing accounts with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended), FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019). The charity is a Public Benefit Entity as defined by FRS 102.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors or grantors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

Gifts of assets and services are recognised at market value to the charity.

1 Accounting policies **(Continued)**

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset's use.

Expenditure has been allocated between the main headings in the Statement of Financial Activities on the basis of the type of activity to which they relate, including irrecoverable V.A.T.

Income and expenses have not been netted off.

1.6 Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

Intangible assets acquired on internally generated assets are recognised at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Software	33.3% on cost
Website Development Costs	14.3% on cost

1.7 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures, fittings & equipment	25% on cost
Computers	25% on cost
Motor vehicles	25% on cost

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the statement of financial activities.

1.8 Impairment of fixed assets

At each reporting end date, the charity reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

1 Accounting policies **(Continued)**

1.9 Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition. Items held for distribution at no or nominal consideration are measured the lower of replacement cost and cost.

The charity are recognising 80% of the stock as free stock issues to support activities raising funds and awareness. The balance recognised on the balance sheet is the residual value of the stock.

Net realisable value is the estimated selling price less all estimated costs of completion and costs to be incurred in marketing, selling and distribution.

1.10 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.11 Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

1 Accounting policies **(Continued)**

1.12 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.13 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Key sources of estimation uncertainty

Fair value of Gifts in Kind

The trustees have exercised judgement in recognising and valuing gifts in kind, including donated goods and services. Recognition is made when entitlement is established, receipt is probable, and value can be reliably measured.

Fair value is based on estimated market prices or equivalent services rates at the date of donation.

3 Donations and legacies

	Unrestricted funds	Restricted funds	Total	Unrestricted funds	Restricted funds	Total
	2024	2024	2024	2023	2023	2023
	£	£	£	£	£	£
Donations and gifts	581,248	11,264	592,512	544,215	14,539	558,754
Legacies receivable	12,848	-	12,848	22,559	98,558	121,117
Grants receivable for core activities	-	18,000	18,000	5,000	57,260	62,260
	594,096	29,264	623,360	571,774	170,357	742,131

4 Other trading activities

	Unrestricted funds 2024 £	Unrestricted funds 2023 £
Sales of merchandise	2,943	3,334

5 Income from investments

	Unrestricted funds 2024 £	Unrestricted funds 2023 £
Interest receivable	7,670	7,039

6 Expenditure on raising funds

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
Fundraising and publicity						
Fundraising costs	126,436	-	126,436	91,592	-	91,592
Staff costs	159,204	37,701	196,905	152,271	15,934	168,205
Depreciation and impairment	664	-	664	137	-	137
Support costs	21,296	3,615	24,911	26,603	2,711	29,314
	307,600	41,316	348,916	270,603	18,645	289,248
Trading costs						
Other trading activities	15,157	-	15,157	5,893	-	5,893
Total costs	322,757	41,316	364,073	276,495	18,645	295,140

7 Charitable activities

	Raising awareness	Supporting research	Medical education	Patient support/ information	Total 2024	Total 2023
	2024	2024	2024	2024		
	£	£	£	£	£	£
Staff costs	167,421	18,133	36,700	32,435	254,689	254,142
Depreciation and impairment	5,592	45	93	81	5,811	227
Other costs	124,494	12,386	29,387	22,151	188,421	162,195
	297,507	30,564	66,180	54,670	448,921	416,564
Share of support costs (see note 9)	21,264	2,303	4,661	4,124	32,352	40,351
Share of governance costs (see note 9)	7,262	787	1,592	1,407	11,048	8,526
	326,033	33,654	72,433	60,198	492,318	465,441
Analysis by fund						
Unrestricted funds	229,859	13,818	44,878	29,373	317,928	288,539
Restricted funds	96,174	19,836	27,555	30,825	174,390	176,902
	326,033	33,654	72,433	60,198	492,318	465,441

7 Charitable activities **(Continued)**

For the year ended 31 December 2023

	Raising awareness	Supporting research	Medical education	Patient support/ information	Total 2023
	£	£	£	£	£
Staff costs	158,002	17,798	35,354	42,988	254,142
Depreciation and impairment	143	16	32	36	227
Other costs	100,840	11,360	22,564	27,434	162,195
	258,985	29,174	57,950	70,458	416,564
Share of support costs (see note 9)	25,084	2,826	5,613	6,828	40,351
Share of governance costs (see note 9)	5,301	597	1,186	1,442	8,526
	289,370	32,597	64,749	78,725	465,441
Analysis by fund					
Unrestricted funds	205,911	14,364	37,191	31,073	288,539
Restricted funds	83,459	18,233	27,558	47,652	176,902
	289,370	32,597	64,749	78,725	465,441

8 Trustees

None of the Trustees (or any persons connected with them) received any remuneration during the year and none of them were reimbursed travelling expenses (2023- £Nil).

9 Support costs

	Support costs	Governance costs	2024	Support costs	Governance costs	2023
	£	£	£	£	£	£
Rent	18,970	-	18,970	22,268	-	22,268
Office costs	3,724	-	3,724	2,841	-	2,841
Telephone costs	2,857	-	2,857	3,140	-	3,140
Computer costs	18,692	-	18,692	24,718	-	24,718
Insurance	3,327	-	3,327	3,029	-	3,029
Staff welfare	1,909	-	1,909	-	-	-
Training, recruitment and internship costs	4,501	-	4,501	5,196	-	5,196
Book-keeping and Accountancy	3,082	-	3,082	2,885	-	2,885
Bank charges	199	-	199	474	-	474
Audit fees	-	11,650	11,650	-	11,100	- 11,100
Audit fees - prior year under/(over) accrual		2,850	2,850		(700)	(700)
Legal and professional	-	5,056	5,056	-	3,240	3,240
	57,261	19,556	76,817	64,551	13,640	78,191
Analysed between						
Fundraising	24,912	8,508	33,420	24,200	5,114	29,314
Charitable activities	32,349	11,048	43,397	40,351	8,526	48,877
	57,261	19,556	76,817	64,551	13,640	78,191

Governance costs include payments of £8,750 (2023 - £8,500) for audit fees and £2,900 (2023: £2,600) for accounts preparation fees.

10 Employees

The average monthly number of employees during the year was:

	2024 Number	2023 Number
	13	13

Employment costs	2024 £	2023 £
Wages and salaries	406,678	380,476
Social security costs	34,851	32,403
Other pension costs	10,065	9,468
	451,594	422,347

10 Employees **(Continued)**

There were no employees whose annual remuneration was more than £60,000.

Remuneration of key management personnel
The remuneration of key management personnel is as follows.

	2024	2023
	£	£
Aggregate compensation	52,429	53,231

The key management personnel of the Charity is considered to be the CEO.

11 Taxation

The company is a registered charity and is, therefore, exempt from taxation on its charitable activities.

12 Intangible fixed assets

	Software	Website Development Costs	Total
	£	£	£
Cost			
At 1 January 2024	-	-	-
Additions - internally developed	12,140	35,000	47,140
At 31 December 2024	12,140	35,000	47,140
Amortisation and impairment			
At 1 January 2024	-	-	-
Amortisation charged for the year	1,128	-	1,128
At 31 December 2024	1,128	-	1,128
Carrying amount			
At 31 December 2024	11,012	35,000	46,012
At 31 December 2023	-	-	-

13 Tangible fixed assets

	Fixtures, fittings & equipment	Computers	Motor vehicles	Total
	£	£	£	£
Cost				
At 1 January 2024	10,612	12,245	-	22,857
Additions	12,600	-	20,000	32,600
Disposals	(7,180)	(5,486)	-	(12,666)
At 31 December 2024	16,032	6,759	20,000	42,791
Depreciation and impairment				
At 1 January 2024	10,612	12,245	-	22,857
Depreciation charged in the year	347	-	5,000	5,347
Eliminated in respect of disposals	(7,180)	(5,486)	-	(12,666)
At 31 December 2024	3,779	6,759	5,000	15,538
Carrying amount				
At 31 December 2024	12,253	-	15,000	27,253
At 31 December 2023	-	-	-	-

14 Stocks

	2024	2023
	£	£
Finished goods and goods for resale	4,565	3,675

15 Debtors

	2024	2023
Amounts falling due within one year:	£	£
Prepayments and accrued income	54,375	78,865

	2024	2023
Amounts falling due after more than one year:	£	£
Prepayments and accrued income	-	333
Total debtors	54,375	79,198

16 Creditors: amounts falling due within one year

	2024	2023
	£	£
Other taxation and social security	12,171	10,010
Trade creditors	36,322	7,916
Other creditors	19,265	-
Accruals and deferred income	26,106	18,284
	93,864	36,210

17 Retirement benefit schemes

Defined contribution schemes	2024 £	2023 £
Charge to the Statement of Financial Activities in respect of defined contribution schemes	10,065	9,468

The charity operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the charity in an independently administered fund.

18 Restricted funds

The restricted funds of the charity comprise the unexpended balances of donations and grants held on trust subject to specific conditions by donors as to how they may be used.

	At 1 January 2024	Incoming resources	Resources expended	Transfers	At 31 December 2024
	£	£	£	£	£
Pat & Paul	21,189	11,264	(10,446)	-	22,007
POW app	17,200	-	-	-	17,200
Recipe Book	10,645	-	(4,213)	-	6,432
PC Aware Campaign	-	5,500	(5,000)	-	500
HCP Education	-	3,500	(4,320)	820	-
Patient Information Booklets	-	6,000	(6,273)	5,273	5,000
NIPanC	5,845	-	-	-	5,845
Translation of resources	493	-	(493)	-	-
Research	22,500	3,000	(3,500)	-	22,000
Pancreatic Cancer Scotland	175,197	-	(150,741)	-	24,456
PC Aware North East England	20,000	-	(20,000)	-	-
Action on the Ground Glasgow Project	9,760	-	(9,760)	-	-
Community volunteers	960	-	(960)	-	-
	283,789	29,264	(215,706)	6,093	103,440

18 Restricted funds **(Continued)**

Previous year:	At 1 January 2023	Incoming resources	Resources expended	Transfers	At 31 December 2023
	£	£	£	£	£
Pat & Paul	12,605	8,584	-	-	21,189
POW app	17,200	-	-	-	17,200
Recipe Book	14,335	1,000	(4,690)	-	10,645
Patient Information Booklets	8,357	7,955	(16,312)	-	-
NIPanC	5,845	-	-	-	5,845
Translation of resources	-	2,000	(1,507)	-	493
Research	-	22,500	-	-	22,500
Pancreatic Cancer Scotland	247,677	98,558	(171,038)	-	175,197
PC Aware North East England	-	20,000	-	-	20,000
Action on the Ground Glasgow Project	-	9,760	-	-	9,760
Community volunteers	960	-	-	-	960
GP Packs	2,000	-	(2,000)	-	-
	308,979	170,357	(195,547)	-	283,789

Restricted funds relate to grants received for the specific purposes as set out above. Any amount unspent is carried forward to be spent in the next financial year.

A transfer of £6,093 between unrestricted and restricted funds has been made in the year ended 31 December 2024.

19 Analysis of net assets between funds

	Unrestricted funds 2024	Restricted funds 2024	Total 2024
	£	£	£
At 31 December 2024:			
Intangible fixed assets	46,012	-	46,012
Tangible assets	27,253	-	27,253
Current assets/(liabilities)	193,256	103,440	296,696
	266,521	103,440	369,961

19 Analysis of net assets between funds **(Continued)**

	Unrestricted funds 2023	Restricted funds 2023	Total 2023
	£	£	£
At 31 December 2023:			
Current assets/(liabilities)	308,590	283,789	592,379
	308,590	283,789	592,379

20 Financial commitments, guarantees and contingent liabilities

To date, the charity has received £48,235 (2023: £46,897) in donations from solicitors relating to old monies held in client accounts which they have not been able to return. There is a possibility that in the future the clients in question could still return for these monies and, as such, the charity has agreed to refund part of the donation if this occurs. No provision has been made in these financial statements for any possible refund as the likelihood is remote and cannot be quantified.

The charity has committed to sponsor a nursing post within NHS Greater Glasgow & Clyde (GGC) for a three year period which started in January 2023. The total commitment over the next 13 months is expected to be £46,874 (2023: £90,238).

21 Cash absorbed by operations

	2024	2023
	£	£
Deficit for the year	(222,418)	(8,077)
Adjustments for:		
Investment income recognised in statement of financial activities	(7,670)	(7,039)
Depreciation and impairment of tangible fixed assets	6,475	364
Movements in working capital:		
(Increase)/decrease in stocks	(890)	200
Decrease/(increase) in debtors	24,823	(4,590)
Increase/(decrease) in creditors	57,654	(26,910)
Cash absorbed by operations	(142,026)	(46,052)

22 Analysis of changes in net funds

The charity had no material debt during the year.

PANCREATIC CANCER ACTION

England & Wales - Charity number 1137689

Accounts

Charity registration number 1137689 (England and Wales)

Charity registration number SC049777 (Scotland)

Company registration number 07272699 (England and Wales)

PANCREATIC CANCER ACTION

ANNUAL REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2023

PANCREATIC CANCER ACTION

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	N Menezes R Legg C Carter E Cowan N Longworth L Nylander G Codacci Pisanelli (Appointed 18 March 2024) D Slater (Appointed 18 March 2024) G Lesca (Appointed 18 March 2024)
Secretary	G Brown (Resigned 12 January 2023)
Charity number (England and Wales)	1137689
Charity number (Scotland)	SC049777
Company number	07272699
Registered office	BASE Bordon Innovation Centre Broxhead House 60 Barbados Road Bordon GU35 0FX
Auditor	Alliotts LLP 3 London Square Cross Lanes Guildford GU1 1UJ

PANCREATIC CANCER ACTION

CONTENTS

	Page
CEO's report	1
Trustees' report	2 - 8
Independent auditor's report	9 - 11
Statement of financial activities	12
Balance sheet	13
Statement of cash flows	17
Notes to the financial statements	14 - 26

PANCREATIC CANCER ACTION

CEO'S REPORT

FOR THE YEAR ENDED 31 DECEMBER 2023

The year 2023 was one of change and growth for Pancreatic Cancer Action while continuing to champion the voice of patients and families, support individuals in a time of crisis and campaign to improve early diagnosis and save lives.

During the year we welcomed a new Chief Executive for the first time in thirteen years, we delivered our largest-ever digital symptom awareness campaign, we supported a record number of patients and families, we rebuilt relationships with volunteers and our wider community and we delivered major system changes through our lobbying and campaign work.

We are rightly very proud of our achievements; however, we know that there is still a great deal of work remaining to be done if we are to improve pancreatic cancer survival rates and save lives. This means we will have to redouble our efforts in all areas if we are to finally improve the care for patients and get people diagnosed in time for life-saving surgery.

It is worth noting that as an organisation Pancreatic Cancer Action could not operate at the same level without the hard work and dedication of our volunteers. They fulfil such varied roles from campaigners and fundraisers to reviewing our patient information booklets and of course, serving on our Trustee Board or as Ambassadors. Without our volunteers, hardworking staff team, patients and families we could not do what we do.

Looking forward to 2024 we plan to build on that proud record of growth and activity we established in 2023. We shall do this through investing more in research, creating new resources to support patients, recruiting more volunteers, delivering innovative campaigns and promoting our resources for healthcare professionals.

We look forward to fighting for each and every patient and their families.

Joe Kirwin (Sep 6, 2024 11:19 GMT+1)

Joe Kirwin
Chief Executive
Dated: 06/09/2024.....

PANCREATIC CANCER ACTION

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)

FOR THE YEAR ENDED 31 DECEMBER 2023

The Trustees present their annual report and financial statements for the year ended 31 December 2023.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charity's Memorandum and Articles of Association, the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)".

Objectives and activities

Our purpose

Pancreatic Cancer Action works to save lives through promoting earlier diagnosis of pancreatic cancer. We do this through promoting greater awareness of the symptoms of the disease, the funding and development of medical educational programmes, supporting patients through improved information about pancreatic cancer either on our website or in print and by funding research.

Our vision

Our vision is that everyone survives pancreatic cancer.

Our mission

Our mission is to improve survival rates of pancreatic cancer by ensuring more people are diagnosed early and that everyone has access to effective treatments, support, information and care.

Objectives

The charity's objectives are:

A	**Awareness -** increase public awareness and knowledge of pancreatic cancer and its symptoms to achieve early diagnosis
C	**Campaign** and lobby the government and key stakeholders for change to advance the standard of healthcare for individuals affected by pancreatic cancer
T	**Train** and provide pioneering educational resources for our medical and healthcare communities
I	**Innovative** research - we fund it, we support it - to improve early diagnosis and develop effective treatments to improve pancreatic cancer outcomes
O	**Offer** the provision of practical and emotional support and information to all affected by pancreatic cancer
N	**Now –** we are the action charity and action is needed more than ever before!

The Trustees have paid due regard to guidance issued by the Charity Commission in deciding what activities the charity should undertake.

The Trustees' activities

The Trustees meet regularly to develop and support strategies to meet the charitable objectives. The Trustees currently have a range of skills and experience that range from medical/scientific, legal, corporate governance, finance and PR.

Role of volunteers / PCA Action Ambassadors

The Charity receives the very welcome assistance of volunteers. who help support a range of projects to raise awareness of pancreatic cancer, provide support, review literature and fundraise in their communities.

The charity seeks volunteer assistance via the website, social media and by word of mouth.

Public benefit statement

The Trustees confirm that they have complied with the duty in Section 4 of the Charities Act 2011 to have due regard to the Charity Commission's general guidance on public benefit.

Achievements and performance

Using some of our objectives as headings and some other key areas not covered above, we have set out below highlights of activity and work in 2023 in our ongoing mission to improve survival rates of pancreatic cancer by ensuring more people are diagnosed early and that everyone has access to effective treatments, support, information and care.

***1. Awareness* - increase public awareness and knowledge of pancreatic cancer and its symptoms to achieve early diagnosis**

Throughout the year Pancreatic Cancer Action provided individuals, communities and organisations with resources to help raise and improve symptom awareness of Britain's deadliest cancer. We did this through providing posters, leaflets, booklets, online resources, and occupational health talks. In our mission to improve early diagnosis and save lives, symptom awareness is key to ensuring that people approach their GP for support.

As well as providing these resources to individuals and communities free of charge, Pancreatic Cancer Action also took proactive and innovative steps to raise awareness with different communities and target those hard-to-reach groups. This included attending the **Health & Wellbeing at Work Show** on 14-15 March 2023 at the NEC Birmingham. This was an opportunity for us to promote our occupational health resources to organisations and companies both large and small. Cancer is a significant and growing issue in the workplace and it also has a significant impact on the economy. Issues like cancer can be very difficult to discuss in the workplace so through attending the Health & Wellbeing at Work Show we were able to educate employers about the need to properly support their employees who might have suspicions of cancer or are going through cancer treatment and just as importantly we were able to provide them with resources and an offer of occupational health training for their employees.

Following on from our success the previous year in reaching out to communities who do not have English as their first language, we took further steps to update our **translated online and print health education resources**. This meant we could provide quality accredited health information to those who have **Polish, Urdu, Punjabi, Bengali, Arabic or Gujarati** as their first language. These updates included highly trained medical professionals with their own first language experience reviewing the medical advice to ensure it was up to date and accurate.

Not being content with waiting for people with concerns to seek out support, as part of our ongoing **Action on the Ground** project we sought out communities with a low health literacy to provide them with symptom awareness resources. This included partnering with The Women's Integration Network in Glasgow to deliver an education talk and provide copies of a "Quick Guide to Pancreatic Cancer" in both Arabic and Urdu to the large number of non-native English speakers who are part of the Women's Integration Network. We also partnered with the Coalfields Regeneration Trust to specifically target men in former mining communities where health literacy is low. This partnership resulted in the production of symptom-awareness beer mats that were distributed to pubs and working men's clubs in areas of high deprivation.

The chance of developing pancreatic cancer unfortunately increases with age and therefore we must take action to reach out to educate older people on the symptoms of pancreatic cancer. One of the ways we did this in 2023 was sharing 10,000 symptom awareness leaflets at Gardeners World Live. The demographics of those who attend this event skew older and are more likely to need this essential information that could save their lives. We also visited a number of older people's groups to deliver symptom awareness talks and provide leaflets to them.

Pancreatic Cancer Awareness Month or **PCAM** in November is normally our best opportunity to get key health information out there to the public and improve symptom awareness. 2023 was the **biggest digital symptom awareness campaign** ever delivered by Pancreatic Cancer Action. We reached more people than ever before through our innovative and groundbreaking **# missed** campaign. Through the hashtag missed campaign, we sought to highlight all those who passed away from pancreatic cancer because their symptoms were missed. These symptoms were either missed by healthcare professionals or by the individuals themselves.

Collaborative campaigns with **Purple Lights UK** and **The World Pancreatic Cancer Coalition** continue to see locations across the world light up purple to raise awareness during November and in particular on **World Pancreatic Cancer Day.** This is largely a supporter focused campaign and has evolved to include supporters lighting up their towns in support, as well as buildings and landmarks.

Pancreatic Cancer Action had a presence at Glasgow Central Station on World Pancreatic Cancer Day, arranged by one of our amazing supporters and Network Rail. We are grateful to our volunteers and team members that helped make the day a huge success, with music from The Glasgow Rock Choir and various performers throughout the day helping attract lots of attention. Information was shared with commuters and visitors to the station, with a collection of generous donations.

2. Campaign and lobby the government and key stakeholders for change to advance the standard of healthcare for individuals affected by pancreatic cancer.

As a small charity, we punch well above our weight when influencing governments and campaigning to win changes that will improve early diagnosis and save lives. Since launching a new campaigning and influencing strategy in 2021 we have seen significant steps forward in all Four Nations to improve early diagnosis.

Early in 2023, we worked with a number of bodies to submit proposals to the **National Cancer Board** that would take further innovative steps to improve early diagnosis of pancreatic cancer in England. These proposals included:

- Expanding Targeted Lung Health Checks to cover Pancreatic Cancer - At risk cohorts will be offered an extra scan of the area covering the kidney and pancreas and it only adds 10 -15 seconds to the procedure.
- Pancreatic Cancer Surveillance Coordinators to meet NG85 NICE guidance. - 10% of cases are linked to genetic risk factors. Coordinators will implement high-risk surveillance protocol to identify these people and enrol them on annual surveillance
- New case finding protocol for pancreatic cancer in patients with New Onset Diabetes and weight loss. - A new algorithm to identify these patients faster and speed up diagnosis
- Enable direct referrals into urgent cancer pathways and/or testing from a centralised service (such as NHS 111)
- Cutting the strain on Primary Care, this is an additional route to diagnosis for those with a combination of 'vague' and 'non-descript' symptoms.

We were very pleased when the National Cancer Board adopted all of these proposals and at the time of writing these projects are in the process of being piloted. As an organisation, we have continued to be heavily involved in shaping and delivering some of these projects including the new case-finding protocol for pancreatic cancer patients with new onset diabetes and weight loss. We have worked with NHS England and the University of Surrey to develop this project, identify partners, and create a pilot before any further rollout across England. We have met as a group once every four to six weeks so we can manage the progress and ensure there are no delays in getting this up and running.

We've continued to seek to change the key areas of our healthcare system to improve support and care for pancreatic cancer patients. One way we do this is through submitting consultation responses to governments and public bodies. In 2023 this included but was not limited to responses to the **National Cancer Strategy for England** (now the major conditions strategy) the **Scottish Cancer Strategy and Action Plan** and the **NICE suspected cancer consultation**. Our consultation responses resulted in governments adopting new proposals to improve early diagnosis of pancreatic cancer. For example, included in the Scottish Cancer Action Plan published alongside the final strategy it included a commitment to exploring the ways community pharmacists can support the diagnosis of cancer. This has long been an area of work for Pancreatic Cancer Action and was a key part of our submission to the strategy consultation.

In order to advance and promote our policy proposals in Scotland that had already been adopted in England, we attended the **Scottish Conservative Party conference** and the **Scottish Labour Party conference** in the spring. (There was no spring SNP Conference). Members of the team met with MSPs, MPs and councillors to explain the priorities of Pancreatic Cancer Action and why we needed to take action to improve the survival rate of pancreatic cancer. During the conferences, we also asked politicians to help us raise awareness of pancreatic cancer symptoms within their communities.

Throughout the year we networked and promoted our policy proposals to politicians and health leaders across the UK. In the run-up to the **annual Pancreatic Cancer Awareness Month debate at the Scottish Parliament,** we provided briefings to all MSPs on the key issues patients and their families face in Scotland and our proposals to improve early diagnosis and save lives. We also offered MSPs the opportunity to meet with a member of the team and our supporters.

As a charity, we attended the annual **Scottish Cancer Conference**. The conference allows us an opportunity to speak directly with health leaders and promote our accredited education and training for healthcare professionals as well as sharing our priorities for patients. Coming out of the conference it was clear that there is growing support within the wider healthcare community for some of the proposals we're putting forward to improve early diagnosis and save lives.

We continue to **work in partnership** with the Scottish Cancer Coalition, the Less Survivable Cancers Taskforce, the North Cancer Alliance (Scotland), CanCern (North East England), Cancer 52, One Cancer Voice and a number of other coalitions of cancer charities. This partnership working strengthens our voice and makes sure that patients' voices are put at the heart of decision-making by politicians and governments.

We continue to be a key partner in the delivery of The **SHPBN Pathway Improvement Project** (now called SCOT-HPB). This is delivered by the Scottish Government, NHS Scotland, and cancer charities and partners such as ourselves. Pancreatic Cancer Action have been leading on the patient and public involvement aspect of the project that is already seeing results and reducing the time from suspicion to treatment and care for pancreatic cancer patients.

3. Train and provide pioneering educational resources for our medical and healthcare communities.

Pancreatic Cancer Action provides **accredited e-learning for GPs, Pharmacists and Pharmacy** Teams. Our GP e-learning, hosted by The Royal College of General Practitioners (RCGP) was updated during the year. Various webinars were hosted with networks including members of RCGP Wales and The Wessex Cancer Alliance. We continue to provide GP and Pharmacy packs across the UK and thank our community of volunteers who help disseminate information on our resources in their local communities.

4. Innovative research - we fund it, we support it - to improve early diagnosis and develop effective treatments to improve pancreatic cancer outcomes.

As a small charity with limited funds, we are not able to invest millions into research, the same as larger organisations. However, by also being a small charity we are able to be more innovative and invest, kickstart, pump prime and support research that has the potential to save lives that might have been looked over by other organisations and much larger funders.

In anticipation of relaunching our **Early Diagnostic Challenge Award** in 2024, Pancreatic Cancer Action rejoined The Association of Medical Research Charities also known as The AMRC. The association provides support and advice to charities such as our own when making research grant awards. Since rejoining the association, staff members have partaken in AMRC hosted training to prepare us for the relaunch of the early diagnostic challenge award in 2024.

We continued to be an active partner in the research project we previously funded with a **University of Surrey** research team led by Dr Agnieszka Lemanska. The aims of the study were to confirm the link between diabetes and pancreatic cancer and to examine the differences in diabetes management and primary care presentation between patients who go on to develop pancreatic cancer and those who do not. The project was a retrospective case-control study, interrogating the RCGP database to provide a large sample size of cases and controls. Multiple variables can be examined from demographics to diagnostics, number of presentations at primary care to disease management. The project involves examining the GP records of patients with diabetes who went on to develop pancreatic cancer and those who did not develop the disease. Records will be taken from the RCGP database where approximately 9.5 million patients' data are stored. This allows a large sample of patients to be investigated. We have now supported the next stages of the research as we take its findings and implement the new case-finding protocol mentioned above. Pancreatic Cancer Action have been key in leading the patient and public involvement aspect of this work and making sure patients' voices are at the heart of the decision-making process. In order to continue to support this research the team at Pancreatic Cancer Action has supported **continuing funding applications** from the University of Surrey to ensure our seed-funded research has an even bigger impact.

Members of the team attended the **Prevention Research Conference** in Edinburgh and were able to speak to academics, scientists, health leaders and politicians about our research and the impact it has had so far. It was also an opportunity to inform partners about the plans to relaunch the Early Diagnostic Challenge Award.

5. Offer the provision of practical and emotional support and information to all affected by pancreatic cancer.

One of the key ways we offer support to patients and their families is through our **patient and health information booklets**. Our booklets cover a wide range of topics to ensure that patients and their families are getting the support and advice they need. These booklets are provided free of charge and are regularly ordered by both individuals and organisations such as hospitals and cancer centres. 2023 saw a 33% increase in the demand for our patient and health information booklets. This meant we were reaching more people than ever before with our accredited high-quality support information. Each one of the booklets is independently assessed and accredited by the Patient Information Forum and reviewed by highly trained medical professionals. The booklets are also complemented by our groundbreaking **recipe book**, which continues to be in high demand amongst patients and also continues to be provided free of charge thanks to the generous support of our donors.

We continue to look at how we can expand our offer and range of support for patients and their families going through an incredibly difficult time. One way in which we are looking to ensure comprehensive coverage of support information is through the creation of new patient and health information booklets. As a result, 2023 saw a **new genetics booklet** and a **new booklet for patients and carers** begin production. Creating new world-class accredited health information is a long process due to the need to involve and consult medical professionals peer reviewers, lay reviewers, patients and their families, health leaders and other charitable organisations. However, this process is necessary to ensure we can provide the best possible support to the people who need us most.

One of the key and most practical ways we can offer support to patients is through the funding we provide for a **Clinical Nurse Specialist** based at Glasgow Royal Infirmary. Our supporters' fundraising has enabled this post since 2019 and since then they have supported hundreds of individuals, patients, family members, colleagues and members of the public through their work. 2023 began with a new person being appointed to the role and as part of the Pancreatic Clinical Nurse Specialist team at Glasgow Royal Infirmary, they help to support over 230 patients per year. This workload includes interactions with patients in environments such as outpatient clinics, endoscopy, ward inpatient areas and telephone clinics. The Pancreatic Clinical Nurse Specialist team at Glasgow Royal Infirmary has over 2,500 interactions with patients every year across their work at return clinics, weekly consultant clinics, and weekly nurse-led clinics.

In 2023 we hosted our first “Purple Hearts Gathering” in Glasgow, providing a relaxed afternoon for our wonderful community of supporters, volunteers and staff to engage and connect during November’s Pancreatic Cancer Awareness Month.

Fundraising

In 2023, income was generated through a wide range of fundraising activities and donations, including our amazing supporters taking part in challenge events, hosting fundraising activities in their communities and incredible support from corporates.

A significant event in the year was the Just Employment Law Summer Ball raising over £120,000 in June 2023. We are forever grateful for their ongoing support and charity partnership with Pancreatic Cancer Action.

Substantial legacies were bequeathed to our charity in 2023 and we value the kind generosity of people affected by pancreatic cancer.

We are continually inspired by the energy, enthusiasm and commitment of our supporters who are determined to change the pancreatic cancer story and save more lives through early diagnosis.

From dress down days in schools and workplaces, cake stalls, coffee mornings, bingo nights, charity dances, golf days, to distance challenges running, walking, swimming and climbing, our supporters continually put the fun into fundraising and embracing the colour purple, to help raise awareness and funds for pancreatic cancer. THANK YOU – we are so grateful for all you do.

Trusts and grants

We are very grateful to the many funders that give so generously towards our initiatives, activities and projects. In 2023 these included £5,000 of unrestricted grants and £57,260 of restricted grants.

Financial review

The results for the year are summarised in the Statement of Financial Activities on page 15.

The Trustees are pleased to report that the charity's incoming resources for 2023 amounted to £752,504 (2022: £488,089), (2021: £754,217), (2020: £1,256,477; an exceptional year which included a one-off transfer of £607,560 due to the merger with Pancreatic Cancer Scotland and £58,781 through the Coronavirus Job Retention Scheme) (2019: £786,505), (2018: £892,851), (2017: £757,812).

The Trustees would like to thank all those volunteers, fundraisers and donors - corporate, trusts and foundations, as well as individual donors who have supported the charity over the past years and upon whom we are dependent.

Total spending on charitable activities was £465,441 (2022: £450,195), (2021: £513,874), (2020: £437,838) (2019: £609,931) (2018: £669,187), (2017: £669,077).

The charity achieved a net loss for the year of -£8,077 (2022: £-241,741), (2021: £-87,740), (2020: £510,025) (2019: £-115,305) (2018: £-24,634) (2017: £-169,315).

Reserves policy

It is the policy of the charity that unrestricted funds which have not been designated for a specific use should be maintained to cover at least 6 months of operating expenditure. The Trustees consider that reserves at this level will ensure that, in the event of a significant drop in funding, they will be able to continue the charity's current activities while consideration is given to ways in which additional funds may be raised.

At 31st December 2023, the charity held reserves of £592,379 of which £283,789 was restricted. Free reserves stood at £308,590 which is in line with the level of the reserves policy established by the board.

Structure, governance and management

The charity is a company limited by guarantee, incorporated in June 2010, and is therefore governed by its Memorandum and Articles of Association. Its company registration number is 07272699 and its charity numbers are 1137689 (England and Wales) and SC049777 (Scotland).

The Trustees, who are also the directors for the purpose of company law, and who served during the year and up to the date of signature of the financial statements were:

H Matthews	(Resigned 17 March 2024)
N Menezes	
N Mumford	(Resigned 18 March 2024)
S Krag	(Resigned 23 May 2023)
H Goodfellow	(Resigned 12 June 2024)
L Condron	(Resigned 15 July 2024)
D Georgiou	(Resigned 2 July 2023)
R Legg	
C Carter	
E Cowan	
N Longworth	
L Nylander	
G Codacci Pisanelli	(Appointed 18 March 2024)
D Slater	(Appointed 18 March 2024)
G Lesca	(Appointed 18 March 2024)

None of the Trustees has any beneficial interest in the charity. The members of the company guarantee to contribute £10 in the event of liquidation.

The Trustees continue to keep the Charity's activities under review, particularly with regard to any major physical or financial risks that may arise from time to time, and to monitor the effectiveness of the system of internal controls and other variable means, including insurance cover where appropriate, by which those risks already identified by the Trustees can be mitigated.

Statement of Trustees' responsibilities

The Trustees, who are also the directors of Pancreatic Cancer Action for the purpose of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company Law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that year.

In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;

- observe the methods and principles in the Charities SORP;

- make judgements and estimates that are reasonable and prudent;

- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and

- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The Trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 (as amended). They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Auditor

In accordance with the company's articles, a resolution proposing that Alliotts LLP be reappointed as auditor of the company will be put at a General Meeting.

The Trustees' report was approved by the Board of Trustees.

giulio codacci-pisanelli
giulio codacci-pisanelli (Sep 23, 2024 17:02 GMT+1)

.....

G Codacci Pisanelli
Chair of Trustees
Dated: 23/09/2024.....

PANCREATIC CANCER ACTION

INDEPENDENT AUDITOR'S REPORT

TO THE TRUSTEES OF PANCREATIC CANCER ACTION

Opinion

We have audited the financial statements of Pancreatic Cancer Action (the 'charity') for the year ended 31 December 2023 which comprise the statement of financial activities, the balance sheet, the statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2023 and of its incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended).

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial statements* section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The Trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 and the Charities Accounts (Scotland) Regulations 2006 (as amended) require us to report to you if, in our opinion:

- the information given in the financial statements is inconsistent in any material respect with the Trustees' report; or
- sufficient and proper accounting records have not been kept; or
- the financial statements are not in agreement with the accounting records; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of Trustees

As explained more fully in the statement of Trustees' responsibilities, the Trustees, who are also the directors of the charity for the purpose of company law, are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the Trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and report in accordance with the Acts and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Extent to which the audit was considered capable of detecting irregularities, including fraud

Our approach to identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows:

- the engagement partner ensured that the engagement team collectively had the appropriate competence, capabilities and skills to identify or recognise non-compliance with applicable laws and regulations;
- we identified the laws and regulations applicable to the company through discussions with Trustees and other management, and from our knowledge and experience of the sector;
- we focused on specific laws and regulations which we considered may have a direct material effect on the financial statements or the operations of the charitable company, including the Companies Act 2006, the Charities Act 2011, the Charities SORP, taxation legislation, data protection, anti-bribery, employment, environmental and health and safety legislation;
- we assessed the extent of compliance with the laws and regulations identified above through making enquiries of management and inspecting legal correspondence; and
- identified laws and regulations were communicated within the audit team regularly and the team remained alert to instances of non-compliance throughout the audit.

INDEPENDENT AUDITOR'S REPORT (CONTINUED)

TO THE TRUSTEES OF PANCREATIC CANCER ACTION

We assessed the susceptibility of the charitable company's financial statements to material misstatement, including obtaining an understanding of how fraud might occur, by:

- making enquiries of management as to where they considered there was susceptibility to fraud, their knowledge of actual, suspected and alleged fraud; and
- considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations.

Audit response to risks identified

To address the risk of fraud through management bias and override of controls, we:

- performed analytical procedures to identify any unusual or unexpected relationships;
- reviewed all transactions listed;
- assessed whether judgements and assumptions made in determining the accounting estimates were indicative of potential bias; and
- investigated the rationale behind significant or unusual transactions.

In response to the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to:

- agreeing financial statement disclosures to underlying supporting documentation; and
- enquiring of management as to actual and potential litigation and claims.

There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the Trustees and other management and the inspection of regulatory and legal correspondence, if any.

Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealment or collusion.

A further description of our responsibilities is available on the Financial Reporting Council's website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Other matters which we are required to address

In the previous accounting period, the trustees took advantage of audit exemption under s477 of the Companies Act. Therefore, the comparative figures in respect of the prior period to 31 December 2022 were not subject to audit.

This report is made solely to the company's members, as a body, in accordance with section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Stephen Meredith

Stephen Meredith BA FCA DChA (Senior Statutory Auditor)
for and on behalf of Alliotts LLP

23/09/2024

Chartered Accountants
Statutory Auditor

3 London Square
Cross Lanes
Guildford
GU1 1UJ

Alliotts LLP is eligible for appointment as auditor of the charity by virtue of its eligibility for appointment as auditor of a company under section 1212 of the Companies Act 2006.

PANCREATIC CANCER ACTION

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2023

	Notes	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £
Income from:							
Donations and legacies	**3**	571,774	170,357	742,131	463,769	18,474	482,243
Other trading activities	**4**	3,334	-	3,334	4,691	-	4,691
Investments	**5**	7,039	-	7,039	1,155	-	1,155
Total income		582,147	170,357	752,504	469,615	18,474	488,089
Expenditure on:							
Raising funds	**6**	276,495	18,645	295,140	279,635	-	279,635
Charitable activities	**7**	288,539	176,902	465,441	322,026	128,169	450,195
Total expenditure		565,034	195,547	760,581	601,661	128,169	729,830
Gross transfers between funds	**17**	-	-	-	56,213	(56,213)	-
Net income/(expenditure) for the year/ Net movement in funds		17,113	(25,190)	(8,077)	(75,833)	(165,908)	(241,741)
Fund balances at 1 January 2023		291,477	308,979	600,456	367,310	474,887	842,197
Fund balances at 31 December 2023		308,590	283,789	592,379	291,477	308,979	600,456

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

PANCREATIC CANCER ACTION

BALANCE SHEET

AS AT 31 DECEMBER 2023

	Notes	2023 £	£	2022 £	£
Fixed assets					
Tangible assets	**12**		-		364
Current assets					
Stocks	**13**	3,675		3,875	
Debtors falling due after one year	**14**	333		2,333	
Debtors falling due within one year	**14**	78,865		72,275	
Cash at bank and in hand		545,716		584,729	
		628,589		663,212	
Creditors: amounts falling due within one year	**15**	(36,210)		(63,120)	
Net current assets			592,379		600,092
Total assets less current liabilities			592,379		600,456
The funds of the charity					
Restricted income funds	**17**		283,789		308,979
Unrestricted funds			308,590		291,477
			592,379		600,456

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Trustees on 23/09/2024

giulio codacci-pisanelli
giulio codacci-pisanelli (Sep 23, 2024 17:02 GMT+1)

G Codacci Pisanelli
Chair of Trustees

Company registration number 07272699 (England and Wales)

1 Accounting policies

Charity information

Pancreatic Cancer Action is a registered charity and a company incorporated by guarentee with no share capital, exempted under section 5 of the Companies Act 2006 from the requirement to use "Limited" as part of its name. It is incorporated in England and Wales under registration number 07272699 and its registered office is Suite 3.10 Covault, Fullarton Road, Cambuslang, Glasgow, G32 8YL.

1.1 Accounting convention

The financial statements have been prepared in accordance with the charity's Statement of Recommended Practice applicable to charities preparing accounts with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended), FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019). The charity is a Public Benefit Entity as defined by FRS 102.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors or grantors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

Gifts of assets and services are recognised at market value to the charity.

1 Accounting policies **(Continued)**

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset's use.

Expenditure has been allocated between the main headings in the Statement of Financial Activities on the basis of the type of activity to which they relate, including irrecoverable V.A.T.

Income and expenses have not been netted off.

1.6 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures, fittings & equipment	25% on cost
Computers	25% on cost

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the statement of financial activities.

1.7 Impairment of fixed assets

At each reporting end date, the charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

1.8 Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition. Items held for distribution at no or nominal consideration are measured the lower of replacement cost and cost.

The charity are recognising 80% of the stock as free stock issues to support activities raising funds and awareness. The balance recognised on the balance sheet is the residual value of the stock.

Net realisable value is the estimated selling price less all estimated costs of completion and costs to be incurred in marketing, selling and distribution.

1.9 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1 Accounting policies **(Continued)**

1.10 Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

1.11 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.12 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

PANCREATIC CANCER ACTION

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 DECEMBER 2023

	Notes	2023 £	2023 £	2022 £	2022 £
Cash flows from operating activities					
Cash absorbed by operations	**22**		(46,052)		(239,155)
Investing activities					
Investment income received		7,039		1,155	
Net cash generated from investing activities			7,039		1,155
Net cash used in financing activities			-		-
Net decrease in cash and cash equivalents			(39,013)		(238,000)
Cash and cash equivalents at beginning of year			584,729		822,729
Cash and cash equivalents at end of year			545,716		584,729

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3 Donations and legacies

	Unrestricted funds	Restricted funds	Total	Unrestricted funds	Restricted funds	Total
	2023	2023	2023	2022	2022	2022
	£	£	£	£	£	£
Donations and gifts	544,215	14,539	558,754	463,769	18,474	482,243
Legacies receivable	22,559	98,558	121,117	-	-	-
Grants receivable for core activities	5,000	57,260	62,260	-	-	-
	571,774	170,357	742,131	463,769	18,474	482,243

4 Other trading activities

	Unrestricted funds	Unrestricted funds
	2023	2022
	£	£
Sales of merchandise	3,334	4,691

5 Income from investments

	Unrestricted funds 2023	Unrestricted funds 2022
	£	£
Interest receivable	7,039	1,155

6 Raising funds

	Unrestricted funds	Restricted funds	Total	Total
	2023	2023	2023	2022
	£	£	£	£
Fundraising and publicity				
Fundraising costs	91,592	-	91,592	84,797
Staff costs	152,271	15,934	168,205	139,222
Depreciation and impairment	137	-	137	1,042
Support costs	26,603	2,711	29,314	34,427
Fundraising and publicity	270,603	18,645	289,448	259,488
Trading costs				
Other trading activities	5,893	-	5,893	20,147
	276,495	18,645	295,140	279,635

7 Charitable activities

	Raising awareness	Supporting research	Medical education	Patient support/ information	Total 2023	Total 2022
	2023	2023	2023	2023		
	£	£	£	£	£	£
Staff costs	158,002	17,798	35,354	42,988	254,142	240,105
Depreciation and impairment	143	16	32	36	227	1,711
Other costs	100,840	11,360	22,564	27,431	162,195	151,855
	258,985	29,174	57,950	70,458	416,567	393,671
Share of support costs (see note 9)	25,084	2,826	5,613	6,828	40,351	50,932
Share of governance costs (see note 9)	5,301	597	1,186	1,442	8,526	5,592
	289,370	32,597	64,749	78,725	465,441	450,195
Analysis by fund						
Unrestricted funds	205,911	14,364	37,191	31,073	288,539	322,026
Restricted funds	83,459	18,233	27,558	47,652	176,902	128,169
	289,370	32,597	64,749	78,725	465,441	450,195

7 Charitable activities **(Continued)**

For the year ended 31 December 2022

	Raising awareness	Supporting research	Medical education	Patient support/ information	Total 2022
	£	£	£	£	£
Staff costs	188,938	3,839	18,338	28,990	240,105
Depreciation and impairment	1,346	27	131	207	1,711
Other costs	119,338	2,391	12,070	18,056	151,855
	309,622	6,257	30,539	47,253	393,671
Share of support costs (see note 9)	40,079	814	3,890	6,149	50,932
Share of governance costs (see note 9)	4,401	89	427	675	5,592
	354,102	7,160	34,856	54,077	450,195
Analysis by fund					
Unrestricted funds	253,382	4,620	32,316	31,708	322,026
Restricted funds	100,720	2,540	2,540	22,369	128,169
	354,102	7,160	34,856	54,077	450,195

8 Trustees

None of the Trustees (or any persons connected with them) received any remuneration during the year and none of them were reimbursed travelling expenses (2022- £Nil).

9 Support costs

	Support costs	Governance costs	2023	Support costs	Governance costs	2022
	£	£	£	£	£	£
Rent	22,268	-	22,268	18,941	-	18,941
Office costs	2,841	-	2,841	6,378	-	6,378
Telephone costs	3,140	-	3,140	2,272	-	2,272
Computer costs	24,718	-	24,718	17,303	-	17,303
Insurance	3,029	-	3,029	2,496	-	2,496
Training, recruitment and internship costs	5,196	-	5,196	31,400	-	31,400
Book-keeping and Accountancy	2,885	-	2,885	2,587	-	2,587
Bank charges	474	-	474	572	-	575
Audit fees	-	10,400	10,400	-	5,760	5,760
Legal and professional	-	3,240	3,240	-	3,240	3,240
	64,551	13,640	78,191	81,952	9,000	90,952
Analysed between						
Fundraising	24,200	5,114	29,314	31,020	3,408	34,428
Charitable activities	40,351	8,526	48,877	50,932	5,592	56,524
	64,551	13,640	78,191	81,952	9,000	90,952

Governance costs include payments of £7,800 (2022 - £5,760 for independent examination fees) for audit fees and £2,600 for accounts preparation fees.

10 Employees

The average monthly number of employees during the year was:

	2023 Number	2022 Number
	13	11

Employment costs	2023 £	2022 £
Wages and salaries	380,476	339,477
Social security costs	32,403	29,650
Other pension costs	9,468	10,200
	422,347	379,327

There were no employees whose annual remuneration was more than £60,000.

11 Taxation

The company is a registered charity and is, therefore, exempt from taxation on its charitable activities.

12 Tangible fixed assets

	Fixtures, fittings & equipment	Computers	Total
	£	£	£
Cost			
At 1 January 2023	10,612	12,245	22,857
At 31 December 2023	10,612	12,245	22,857
Depreciation and impairment			
At 1 January 2023	10,329	12,164	22,493
Depreciation charged in the year	283	81	364
At 31 December 2023	10,612	12,245	22,857
Carrying amount			
At 31 December 2023	-	-	-
At 31 December 2022	283	81	364

13 Stocks

	2023	2022
	£	£
Finished goods and goods for resale	3,675	3,875

14 Debtors

	2023	2022
Amounts falling due within one year:	£	£
Other debtors	-	12,076
Prepayments and accrued income	78,865	60,199
	78,865	72,275

	2023	2022
Amounts falling due after more than one year:	£	£
Prepayments and accrued income	333	2,333
Total debtors	79,198	74,608

15 Creditors: amounts falling due within one year

	2023	2022
	£	£
Other taxation and social security	10,010	8,528
Trade creditors	7,916	29,399
Accruals and deferred income	18,284	25,193
	36,210	63,120

16 Retirement benefit schemes

	2023	2022
Defined contribution schemes	£	£
Charge to profit or loss in respect of defined contribution schemes	9,468	10,200

The charity operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the charity in an independently administered fund.

17 Restricted funds

The restricted funds of the charity comprise the unexpended balances of donations and grants held on trust subject to specific conditions by donors as to how they may be used.

	At 1 January 2023	Incoming resources	Resources expended	Transfers	At 31 December 2023
	£	£	£	£	£
Pat & Paul	12,605	8,584	-	-	21,189
POW app	17,200	-	-	-	17,200
Recipe Book	14,335	1,000	(4,690)	-	10,645
Patient Information Booklets	8,357	7,955	(16,312)	-	-
NIPanC	5,845	-	-	-	5,845
Translation of resources	-	2,000	(1,507)	-	493
Research	-	22,500	-	-	22,500
Pancreatic Cancer Scotland	247,677	98,558	(171,039)	-	175,196
PC Aware North East England	-	20,000	-	-	20,000
Action on the Ground Glasgow Project	-	9,760	-	-	9,760
Community volunteers	960	-	-	-	960
GP Packs	2,000	-	(2,000)	-	-
	308,979	170,357	(195,548)	-	283,788

17 Restricted funds **(Continued)**

Previous year:	At 1 January 2022	Incoming resources	Resources expended	Transfers	At 31 December 2022
	£	£	£	£	£
Pat & Paul	2,506	10,099	-	-	12,605
POW app	17,200	-	-	-	17,200
Recipe Book	18,174	-	(3,839)	-	14,335
Patient Information Booklets	15,972	8,375	(15,990)	-	8,357
Hope is Contagious	156	-	(156)	-	-
NIPanC	6,456	-	(611)	-	5,845
Pancreatic Cancer Scotland	411,463	-	(107,573)	(56,213)	247,677
Community volunteers	960	-	-	-	960
GP Packs	2,000	-	-	-	2,000
	474,887	18,474	(128,169)	(56,213)	308,979

Restricted funds relate to grants received for the specific purposes as set out above. Any amount unspent is carried forward to be spent in the next financial year.

No transfer between unrestricted and restricted funds has been made in the year ended 31 December 2023.

18 Analysis of net assets between funds

	Unrestricted funds 2023	Restricted funds 2023	Total 2023
	£	£	£
At 31 December 2023:			
Current assets/(liabilities)	308,590	283,789	592,379
	308,590	283,789	592,379

	Unrestricted funds 2022	Restricted funds 2022	Total 2022
	£	£	£
At 31 December 2022:			
Tangible assets	364	-	364
Current assets/(liabilities)	291,113	308,979	600,092
	291,477	308,979	600,456

19 Financial commitments, guarantees and contingent liabilities

To date, the charity has received £46,897 in donations from solicitors relating to old monies held in client accounts which they have not been able to return. There is a possibility that in the future the clients in question could still return for these monies and, as such, the charity has agreed to refund part of the donation if this occurs. No provision has been made in these financial statements for any possible refund as the likelihood is remote and cannot be quantified.

The charity has committed to sponsor a nursing post within NHS Greater Glasgow & Clyde (GGC) for a three year period which started in January 2023. The total commitment over the next two years is expected to be £90,238

20 Operating lease commitments

Lessee
Operating lease payments in the prior year related to office lease rental. The charity moved to new premises in the current year using licence agreements which provide shorter, more flexible terms.

At the reporting end date the charity had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

	2023	2022
	£	£
Within one year	-	4,320

21 Related party transactions

Remuneration of key management personnel
The remuneration of key management personnel is as follows.

	2023	2022
	£	£
Aggregate compensation	58,599	56,393

The key management personnel of the Charity is considered to be the CEO.

There were no other related party transactions.

STATEMENT OF CASH FLOWS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

22	Cash generated from operations	2023 £	2022 £
	Deficit for the year	(8,077)	(241,741)
	Adjustments for:		
	Investment income recognised in statement of financial activities	(7,039)	(1,155)
	Depreciation and impairment of tangible fixed assets	364	2,753
	Movements in working capital:		
	Decrease in stocks	200	14,536
	(Increase) in debtors	(4,590)	(24,031)
	(Decrease)/increase in creditors	(26,910)	10,483
	Cash absorbed by operations	(46,052)	(239,155)

23 Analysis of changes in net funds

The charity had no material debt during the year.

PANCREATIC CANCER ACTION

England & Wales - Charity number 1137689

Accounts

Charity registration number 1137689 (England and Wales)

Charity registration number SC049777 (Scotland)

Company registration number 07272699 (England and Wales)

PANCREATIC CANCER ACTION

ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2022

PANCREATIC CANCER ACTION

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	H Matthews N Menezes N Mumford H Goodfellow L Condron D Georgiou R Legg C Carter E Cowan N Longworth L Nylander
Secretary	G Brown (Resigned 12 January 2023)
Charity number (England and Wales)	1137689
Charity number (Scotland)	SC049777
Company number	07272699
Registered office	BASE Bordon Innovation Centre Broxhead House Louisburg Barracks 60 Barbados Road Bordon GU35 0FX
Independent examiner	Alliotts LLP Friary Court 13-21 High Street Guildford Surrey GU1 3DL

PANCREATIC CANCER ACTION

CONTENTS

	Page
CEO's report	1
Trustees' report	2 - 10
Statement of Trustees' responsibilities	11
Independent examiner's report	12
Statement of financial activities	13
Balance sheet	14
Statement of cash flows	18
Notes to the financial statements	15 - 27

PANCREATIC CANCER ACTION

CEO'S REPORT

FOR THE YEAR ENDED 31 DECEMBER 2022

We will continue to be a voice for patients and families to ensure pancreatic cancer is a focused priority.

We are very proud of our achievements to date and we will continue to have a primary focus of improving early diagnosis of pancreatic cancer as well as ensuring all those affected by pancreatic cancer have access to the care, information and support they need. Going forward, 2023 will be a year of significant change for Pancreatic Cancer Action, including a new CEO and the closure and relocation of our head office. Our founder Ali Stunt built an internationally recognised organisation with a proud record of campaigning for change, supporting patients and investing in innovative research. I'm very pleased that Ali shall be remaining a member of PCA and along with the whole of the PCA team I look forward to building on the legacy she has left behind.

We are so very grateful to our wonderful supporters, donors and fundraisers for their generous donations, taking on challenge events and organising events in their communities.

We are so fortunate to have so many Community Representatives, Action Ambassadors and other volunteers who help in a variety of ways including providing us with lay reviews for our patient information. We rely heavily on their generosity of time as well as their efforts to raise awareness and funds in their localities.

Some of our key volunteers are our Trustees, who have supported our team so very well over the past year.

I am also grateful to our wonderful Patrons and Ambassadors who help us with our activities and support our campaigns and of course to our marvellous fundraisers and donors, without whom, we couldn't do what we do.

Joe Kirwin

Joe Kirwin (Sep 18, 2023 12:07 GMT+1)

.....

Joe Kirwin

Chief Executive

Dated: 18/09/2023.....

PANCREATIC CANCER ACTION

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)

FOR THE YEAR ENDED 31 DECEMBER 2022

The Trustees present their annual report and financial statements for the year ended 31 December 2022.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charity's Memorandum and Articles of Association, the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)".

Objectives and activities

Our purpose

Pancreatic Cancer Action works to save lives through promoting earlier diagnosis of pancreatic cancer. We do this through promoting greater awareness of the symptoms of the disease, the funding and development of medical educational programmes, supporting patients through improved information about pancreatic cancer either on our website or in print and by funding research.

Our vision

Our vision is that everyone survives pancreatic cancer.

Our mission

Our mission is to improve survival rates of pancreatic cancer by ensuring more people are diagnosed early and that everyone has access to effective treatments, support, information and care.

Objectives

The charity's objectives are:

A **Awareness** - increase public awareness and knowledge of pancreatic cancer and its symptoms to achieve early diagnosis

C **Campaign** and lobby the government and key stakeholders for change to advance the standard of healthcare for individuals affected by pancreatic cancer

T **Train** and provide pioneering educational resources for our medical and healthcare communities

I **Innovative** research - we fund it, we support it - to improve early diagnosis and develop effective treatments to improve pancreatic cancer outcomes

O **Offer** the provision of practical and emotional support and information to all affected by pancreatic cancer

N **Now** – we are the action charity and action is needed more than ever before!

The Trustees have paid due regard to guidance issued by the Charity Commission in deciding what activities the charity should undertake.

The Trustees' activities

The Trustees meet annually to develop a strategy to meet the charitable objectives. Once the overall strategy has been agreed by the Trustees a series of operational meetings attended by a selection of the Trustees and volunteers, who the Trustees believe have relevant skills and experience in the specific area look at the operational implementation.

The Trustees currently have a range of skills and experience that range from medical/scientific, Legal corporate governance, finance and PR.

Role of volunteers / PCA Action Ambassadors
The Charity receives the very welcome assistance of volunteers. To date this has usually been for specific projects or fund-raising initiatives. In 2022 our network of Regional Representatives across the UK was made up of 50 volunteers. The aim is that these volunteers represent Pancreatic Cancer Action, raise awareness of pancreatic cancer and fundraise in their communities.

The pandemic impacted how volunteers can assist in our office, at events or within their communities, but we continue to evolve ways to enable people to show their support. The charity seeks volunteer assistance via the website, social media and by word of mouth.

We will continue to recruit further patients or carers who have had experience of pancreatic cancer as regional representatives in areas where we currently do not have representation.

Public benefit statement
The Trustees confirm that they have complied with the duty in Section 4 of the Charities Act 2011 to have due regard to the Charity Commission's general guidance on public benefit.

Achievements and performance

***1. Awareness* - increase public awareness and knowledge of pancreatic cancer and its symptoms to achieve early diagnosis**

Action on the Ground
Action on the Ground (AoG) is a project committed to working with those that have low health literacy and groups that are hard to reach with the worst outcomes in relation to diagnosis and survival of pancreatic cancer.

In 2022 AoG expanded on its work reaching out into new locations and working with new communities as well as strengthening our existing partnerships. In the first 3 months of 2022 we had 112 one to one conversations with service users of the Scottish Pantry Network about the signs and symptoms of pancreatic cancer and what to do if they have any concerns. To support these conversations 500 easy to read leaflets were sent out with food parcels during this same period.

In the second half of the year, we began delivering awareness talks to groups support those over the age of 50 in areas of higher depravation. This included lunch clubs, knit and natter groups and Men’s clubs. During this period of time we were able to speak to over 200 individuals, hand out symptoms diaries to those who were concerned and wished to track their symptoms and in a small number of cases refer people to their GP.

Prevention In Action
2022 saw us launch a new project known as Prevention In Action (PiA) to raise **awareness** of the risk factors associated with pancreatic cancer with the public and lobby governments for the necessary policy changes to mitigate these risk factors.

Since its launch the campaign has mainly focused on the relationship between smoking and pancreatic cancer, the signs and symptoms to look out for and to signpost smokers to cessation support. Working in partnership with anti-smoking charity ASH, we created specialist information and resources to encourage and support smokers to quit. Over 1,000 copies of our smoking and pancreatic cancer leaflet have been handed out to community groups and health centres. Work has begun on a digital toolkit for partners to share information on their socials, websites and digital billboards.

The public awareness aspect of the project has been supported by ongoing lobbying efforts that include becoming a member of the Scottish Coalition on Tobacco and publishing an open letter calling on Government Ministers to fully implement the recommendations of the Khan Review on creating a ‘Smoke Free’ England.

Translating Assets / Action for All
Building on the success of 2021 when we began the process of translating our resources and support for patients into the 6 most common languages spoken in the UK other than English, we wanted to ensure we were expanding our reach and supporting new and diverse communities.

To achieve this goal, we now have additional resources converted into braille and large print versions.

The Health & Wellbeing Show
It is estimated that by 2030, there will be more than a million people of working age living with cancer in the UK. It has never been more vital to raise awareness of cancer in the workplace amongst workers and employers. We once again attended the Health & Wellbeing Show in 2022 to meet with major employers, promote the importance of cancer awareness in the workplace and offer our occupational health talks to companies free of charge.

Pancreatic Cancer Awareness Month (PCAM)
This year our focus was off the back of the research we funded at the Universities of Surrey and Oxford. The study discovered it may be possible to diagnose people up to three years earlier than is currently possible via an elevation in their blood glucose levels usually followed with a misdiagnosis of Type 2 diabetes, when it is in fact, Type 3c.

A range of both offline and online channels were used across the month to ensure as large a reach as possible, including paid ads across social media and Google, press releases, e-marketing and TV/Radio Interviews with Ali and other PCA Ambassadors.

Key highlights:

PCAM Assets
A series of striking assets were created to promote our messaging. We commissioned both photography and video which we used for our digital channels, in our ads, across our social media channels, and also on our e-signatures in our emails.

Broadcast Media
A specialist broadcast PR agency was hired to maximise our broadcast coverage on the first day of PCAM. The investment achieved incredible results, including:

- 9 TV hits with an audience reach of 8,200,000 and included ITV National News, BBC Scotland, BBC West Midlands, ITV Meridian and STV to name a few.
- 38 radio hits, over 47 stations with a total audience reach of 21,910,000 and included BBC Solent, Hits Radio, BBC, Signal and Lincs FM.

Press
During PCAM 2022 we sent out 14 Press Releases (two topics). The first press release targeted a national response using the University of Surrey study's results, and the second one later in the month targeted regional press off the back of our survey of 2,002 respondents nationwide.

As a result, 74 articles were written. Highlights of these include BBC Online, ITV Online, The Times Online, MailOnline, Express.co.uk, The Sun, Daily Mirror, Daily Record and many more.

All of the above activity meant that we saw a spike in total web page views throughout November - an 83% increase on 2021, and a 139% increase on 2020.

Digital Advertising
Throughout November, a digital PCAM awareness campaign ran through Google, Meta and LinkedIn Ads. This investment helped our campaign reach over 10 million people digitally.

Purple Lights UK and World Pancreatic Cancer Day
The collaborative campaign Purple Lights UK continues to see locations across the country light up purple to raise awareness during November and in particular on World Pancreatic Cancer Day. This is largely a supporter focused campaign and has evolved to include supporters lighting up their own homes in support, as well as buildings and landmarks.

We had a presence at Glasgow Central Station on World Pancreatic Cancer Day, arranged by one of our amazing supporters and Network Rail. Information was shared with commuters and visitors to the station, with a collection of generous donations. We are grateful to our volunteers and team members that helped make the day a huge success. A flashmob dance, singing and music from The Theatre School of Scotland students and Marty Bryon also helped attract lots of attention.

***2. Campaign* and lobby the government and key stakeholders for change to advance the standard of healthcare for individuals affected by pancreatic cancer.**

Policy Changes
The year of 2022 saw the team at Pancreatic Cancer Action make a number of consultation responses and submissions to 'call for evidence' from all four Governments in the UK and other public bodies such as Cancer Alliances or the NHS. This work has resulted in a number of significant changes that could have a real impact on survival rate for pancreatic cancer patients.

Changes to NICE guidelines
All those in England, Wales and Northern Ireland over the age of 60 who present with weight loss and new-onset diabetes will now be automatically referred for a CT-Scan to check for pancreatic cancer.

In January 2022 the NHS Cancer Programme Team began the process of carrying out a series of 'tumour site reviews'. As part of the review, we had a series of meetings with members of the NHS Cancer Programme Team where we put forward a number of proposals to improve early diagnosis. Each were dismissed as they 'cost too much money'. Using the early findings from the research we funded at the University of Surrey we pulled together evidence-based proposals for identifying those with a high risk of pc and how they could be caught. These changes have now been fully implemented.

GPs are now able to make direct referrals for CT scans
At the start of 2022, only 21% of GPs in England could make direct referrals for a CT scan. However, thanks to PCA campaigning, every GP team in England is now able to directly order CT scans and ultrasounds and the Scottish Government have indicated they will also be adopting our proposals.

PCA first called for this back in 2015 as part of our Manifesto for the General Election. It has been something we have lobbied on since then and had multiple MP's ask questions in the House of Commons about. Australia's PC 5 year survival rate is over 14% and the key difference between our systems is the ability for GP's to make direct referrals. In February 2022, these proposals formed the main feature of our submission to the Department of Health & Social Care's Cancer Strategy Consultation. Our campaign was given a major boost when Jeremy Hunt came out in support of our proposal and it was soon adopted.

Pharmacists empowered to make direct cancer referrals to secondary care
We have been lobbying to empower pharmacists to be able to make direct referrals for those with red-flag cancer symptoms. In a huge win for PCA and patients, the UK Government has committed to rolling out these powers.

The pandemic changed the way we interacted with our health system with more folk going to their local pharmacy first. Giving the Pharmacists the ability to make direct cancer referrals to Secondary Care was the main plank of our Westminster Health & Social Care Select Committee inquiry into cancer in 2021. Community Pharmacy referrals also formed part of our submission to the Welsh cancer recovery plan as well as lobbying the Welsh Health Minister. In late 2021 we partnered with the Royal Pharmaceutical Society to once again put forward the proposal and create a 'decision tree' on how this would work in practice to the NHS Transformation Lead. In June 2022 it was announced that this would be piloted. PCA Pharmacy Ambassador Ade Williams is on the advisory committee for the project.

Political Engagement / Parliamentary Debates
We continue to engage with politicians across the UK to raise awareness of the statistics around pancreatic cancer and the importance of early diagnosis

During Pancreatic Cancer Awareness Month we were vital in securing debates on pancreatic cancer in both Westminster and Holyrood. Ahead of both debates we provided specialist briefings for MPs and MSPs on the issues in their constituencies relating to cancer care and the policy changes we were lobbying for.

***3. Train* and provide pioneering educational resources for our medical and healthcare communities.**

Updating our accredited E-Learning
Pancreatic Cancer Action provides accredited e-learning for GPs, Pharmacists and Pharmacy Teams. As part of our commitment to providing health care professionals with the most up to date and top-quality information, our e-learning underwent a full review and update supported by medical professionals. Updates included changes to NICE Guidelines, changes to practice relating to referrals for CT scans and the role of pharmacy in detecting cancer.

The Pharmacy Show
Many of those feeling unwell with non-specific symptoms associated with pancreatic cancer may visit the pharmacy to self-medicate. A pharmacist with a regular customer base is also well placed to spot escalating symptoms, refer patients and save lives. At the 2022 Pharmacy Show we met with Pharmacists and their support teams from all over the UK to promote our Pharmacy e-learning and provide resources directly to pharmacists to detect cancer early.

Surrey & Sussex Cancer Alliance Webinar
In December, working in partnership with the Surrey and Sussex Cancer Alliance, we delivered a tailor-made webinar for those working in primary care in in Surrey and Sussex on the topic of new research on the relationship with pancreatic cancer and diabetes. The webinar was attended by over 80 primary care professionals and was also recorded so it could be shared with those who could not attend on the day.

***4. Innovative research* - we fund it, we support it - to improve early diagnosis and develop effective treatments to improve pancreatic cancer outcomes.**

Research Strategy
Following meetings last year with the Scientific Sub-committee of the Trustee Board and the Association of Medical Research Charities it was agreed that we develop a new ‘Research strategy’ for the organisation. The new strategy sets out our priorities, processes for making awards and be a key part of how we make the decade of change a reality.

University of Surrey - Diabetes and pancreatic cancer
Pancreatic Cancer Action funded a research project in partnership with the University of Surrey which published its findings in autumn 2022. The University of Surrey research project explored the relationship between diabetes, BMI and glycated haemoglobin (HbA1c) as markers for pancreatic cancer. The study found that in some cases pancreatic cancer develops up to 3 years before they eventual diagnosis.

Our past early diagnosis challenge award gave funding to researchers primarily working with biomarkers that has led to further investment from Pancreatic Cancer Research Fund (PCRF) and Cancer Research UK. Throughout 2021 and beyond we are funding projects examining the link between diabetes and pancreatic cancer. Research is emerging in this area that suggests there may be an opportunity for early diagnosis of pancreatic cancer in patients with new diabetes.

5. Offer **the provision of practical and emotional support and information to all affected by pancreatic cancer.**

Pancreatic Cancer Clinical Nurse Specialist
We are proud to fund an innovative dedicated pancreatic cancer nurse specialist role with NHS Greater Glasgow and Clyde, to support the West of Scotland Pancreatic Unit.

Based at Glasgow Royal Infirmary the post-holder provides supplementary direct clinical support for patients and carers, ensuring that there is a point of contact for information and advice, before, during and after treatment. A large part of this includes signposting individuals to appropriate support services and guiding them through a complex pathway. This is key in facilitating holistic treatment throughout a patient's journey, recognising that every individual is different.

While this is not a research nurse post, the unique combined research aspect of this role supports patients and families understanding of clinical trials and has contributed to enhancing participation and recruitment of patients to clinical trials, which are key to improving survival in the future.

During 2022, the original post-holder changed jobs but we are looking forward to a new post-holder being appointed in 2023.

Patient and Health Information
We remain the only pancreatic cancer charity providing fully accredited and reviewed health and patient information especially for patients and the public. We currently offer ten information booklets on a range of topics. Our booklets are shipped free of charge to hospitals, GP practices and patients. Last year saw us begin the process of expanding this offer by beginning development on two new booklets for patients. One on Genetic Variants and another booklet just for families and carers.

Support
Our help and support section of our website is designed to help everyone that is affected by pancreatic cancer to help answer any questions people may have. Our website contains helpful information and links to support, from the moment symptoms first appear, treatment, coping and bereavement.

We continue to develop relationships with stakeholders to ensure that there is support available throughout the UK as we listen to the needs of patients and families.

Fundraising

Jog Jan for Pan Can continued in January 2022 but was less popular than the original flagship virtual event in 2021 during the pandemic.

Pyjama’s for Pan Can in April was well supported by various companies, care homes, and schools organising dress down days, holding cake stalls and fun activities in aid of PCA

A new Fundraising Toolkit was created with digital giving ideas, like celebration, in memory and tribute giving.

Turn it Purple - This year we had three specific calls to action over Pancreatic Cancer Awareness month - Wear it Purple, Bake it Purple and Walk it Purple. Our fundraising assets were developed to inspire and help supporters with their activities.

Our new Bake it Purple pack was created as an all year round PCA product for workplace, schools and community fundraising. This was very well received by our supporters.

Challenge events
We had twenty-one runners taking part in The London Marathon in October 2022, raising more than £66,000.

Other challenge events included The Great North Run, Coast to Coast cycle, Double Ironman, Isle of Wight Challenge, Cotswold Way Challenge, Lake District Challenge, skydives, The Edinburgh Marathon and Kiltwalk events (which included a very generous 50% top up on income raise by Sir Tom Hunter and The Hunter Foundation).

We also had supporters take part in some of the more niche challenge events, including The Dalai Lama Himalayan Trek and a 10 Day Triathlon Style Challenge.

Community Fundraising
The support from our community fundraisers is, as ever, invaluable. We have seen supporters dye or shave their hair, hold concerts, quizzes, raffles, coffee mornings, ladies lunches, golf days, charity nights and school fun-runs to help us with our work. Thank you – we are so very grateful for all you do.

Action funds:

At the end of 2022, we had the following action funds: ·

- Action for Pat and Paul (Scotland)
- Hope is Contagious
- The Shaun Wright Foundation (NE England)

Corporate partnerships and support
Some significant leads and relationships have been developed with businesses throughout 2022 both large and small. We will continue to steward and cultivate these relationships into 2023. Our corporate partners play a vital role in allowing us to raise more awareness and funds for pancreatic cancer and we can't thank them enough for their support.

They work with us in various capacities and for various lengths of time and in 2022 we were supported by:

- Pen Underwriting
- Sheila Fleet Jewellery
- Just Employment Law
- Partick Thistle Football Club
- Tunnocks
- Arnold Clark Car & Van Rental
- Better Placed
- Walters Plant Hire

Trusts and Grants
We are very grateful to the many funders that give so generously towards our initiatives, activities and projects.

In 2022 these included grants from:

Restricted: None

Unrestricted: Tyl by Natwest £5,000

Financial review

The results for the year are summarised in the Statement of Financial Activities on page 13.

The Trustees are pleased to report that the charity's incoming resources for 2022 amounted to £488,089 (2021: £754,217), (2020: £1,256,477; an exceptional year which included a one-off transfer of £607,560 due to the merger with Pancreatic Cancer Scotland and £58,781 through the Coronavirus Job Retention Scheme) (2019: £786,505), (2018: £892,851), (2017: £757,812).

The Trustees would like to thank all those volunteers, fundraisers and donors - corporate, trusts and foundations, as well as individual donors who have supported the charity over the past years and upon whom we are dependent.

Total spending on charitable activities was £450,195, (2021: £513,874), (2020: £437,838) (2019: £609,931) (2018: £669,187), (2017: £669,077).

Primarily as a result of these activities, the charity achieved a net loss for the year of £-241,741 (2021: £-87,740), (2020: £510,025) (2019: £-115,305) (2018: £-24,634) (2017: £-169,315).

Reserves policy

It is the policy of the charity that unrestricted funds which have not been designated for a specific use should be maintained to cover at least 6 months of operating expenditure. The Trustees consider that reserves at this level will ensure that, in the event of a significant drop in funding, they will be able to continue the charity's current activities while consideration is given to ways in which additional funds may be raised.

At 31st December 2022, the charity held reserves of £600,456 of which £308,979 was restricted. Free reserves stood at £291,113 which is in line with the level of the reserves policy established by the board.

Structure, governance and management

The charity is a company limited by guarantee, incorporated in June 2010, and is therefore governed by its Memorandum and Articles of Association. Its company registration number is 07272699 and its charity numbers are 1137689 (England and Wales) and SC049777 (Scotland).

The Trustees, who are also the directors for the purpose of company law, and who served during the year and up to the date of signature of the financial statements were:

H Matthews
N Menezes
N Mumford
S Krag (Resigned 23 May 2023)
H Goodfellow
L Condron
D Georgiou
R Legg
C Carter
E Cowan
N Longworth
L Nylander

None of the Trustees has any beneficial interest in the charity. The members of the company guarantee to contribute £10 in the event of liquidation.

The Trustees continue to keep the Charity's activities under review, particularly with regard to any major physical or financial risks that may arise from time to time, and to monitor the effectiveness of the system of internal controls and other variable means, including insurance cover where appropriate, by which those risks already identified by the Trustees can be mitigated.

The Trustees' report was approved by the Board of Trustees.

Nicola Rees Mumford

Nicola Rees Mumford (Sep 20, 2023 11:04 GMT+1)

N Mumford
Chair of Trustees
Dated: 20/09/2023

PANCREATIC CANCER ACTION

STATEMENT OF TRUSTEES' RESPONSIBILITIES

FOR THE YEAR ENDED 31 DECEMBER 2022

The Trustees, who are also the directors of Pancreatic Cancer Action for the purpose of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company Law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that year.

In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;

- observe the methods and principles in the Charities SORP;

- make judgements and estimates that are reasonable and prudent;

- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and

- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The Trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 (as amended). They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

PANCREATIC CANCER ACTION

INDEPENDENT EXAMINER'S REPORT

TO THE TRUSTEES OF PANCREATIC CANCER ACTION

I report to the Trustees on my examination of the financial statements of Pancreatic Cancer Action (the charity) for the year ended 31 December 2022.

Responsibilities and basis of report

As the Trustees of the charity (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Charities and Trustee Investment (Scotland) Act 2005 (the 2005 Act), the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Companies Act 2006 (the 2006 Act). You are satisfied that the financial statements of the charity are not required by charity or company law to be audited and have chosen instead to have an independent examination.

Having satisfied myself that the financial statements of the charity are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the charity's financial statements carried out under section 44 (1) (c) of the 2005 Act and section 145 of the Charities Act 2011 (the 2011 Act). In carrying out my examination I have followed the requirements of Regulation 11 of the Charities Accounts (Scotland) Regulations 2006 (as amended) and all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

Since the charity is required by company law to prepare its accounts on an accruals basis and is registered as a charity in Scotland your examiner must be a member of a body listed in Regulation 11(2) of the Charities Accounts (Scotland) Regulations 2006 (as amended). I confirm that I am qualified to undertake the examination because I am a member of Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1 accounting records were not kept in respect of the charity as required by section 386 of the 2006 Act and Regulation 4 of the 2006 Accounts Regulations; or

2 the financial statements do not accord with those records; or

3 the financial statements do not comply with the accounting requirements of Regulation 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended) and do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or

4 the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Stephen Meredith

Stephen Meredith FCA DChA
Alliotts LLP

Friary Court
13-21 High Street
Guildford
Surrey
GU1 3DL

Dated: 20/09/2023

PANCREATIC CANCER ACTION

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2022

	Notes	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £	Unrestricted funds 2021 £	Restricted funds 2021 £	Total 2021 £
Income from:							
Donations and legacies	**3**	463,769	18,474	482,243	725,410	21,790	747,200
Other trading activities	**4**	4,691	-	4,691	6,963	-	6,963
Investments	**5**	1,155	-	1,155	54	-	54
Total income		469,615	18,474	488,089	732,427	21,790	754,217
Expenditure on:							
Raising funds	**6**	279,635	-	279,635	328,083	-	328,083
Charitable activities	**7**	322,026	128,169	450,195	346,437	167,437	513,874
Total expenditure		601,661	128,169	729,830	674,520	167,437	841,957
Net outgoing resources before transfers		(132,046)	(109,695)	(241,741)	57,907	(145,647)	(87,740)
Gross transfers between funds	**17**	56,213	(56,213)	-	-	-	-
Net expenditure for the year/ Net movement in funds		(75,833)	(165,908)	(241,741)	57,907	(145,647)	(87,740)
Fund balances at 1 January 2022		367,310	474,887	842,197	309,403	620,534	929,937
Fund balances at 31 December 2022		291,477	308,979	600,456	367,310	474,887	842,197

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

PANCREATIC CANCER ACTION

BALANCE SHEET

AS AT 31 DECEMBER 2022

	Notes	2022 £	2022 £	2021 £	2021 £
Fixed assets					
Tangible assets	**12**		364		3,117
Current assets					
Stocks	**13**	3,875		18,411	
Debtors falling due after one year	**14**	2,333		-	
Debtors falling due within one year	**14**	72,275		50,577	
Cash at bank and in hand		584,729		822,729	
		663,212		891,717	
Creditors: amounts falling due within one year	**15**	(63,120)		(52,637)	
Net current assets			600,092		839,080
Total assets less current liabilities			600,456		842,197
Income funds					
Restricted funds	**17**		308,979		474,887
Unrestricted funds					
Designated funds	**19**	-		2,075	
General unrestricted funds		291,477		365,235	
			291,477		367,310
			600,456		842,197

The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 December 2022.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Trustees on 20/09/2023

Nicola Rees Mumford

Nicola Rees Mumford (Sep 20, 2023 11:04 GMT+1)

N Mumford
Trustee

Company registration number 07272699

1 Accounting policies

Charity information

Pancreatic Cancer Action is a private company limited by guarantee incorporated in England and Wales. The registered office is BASE Bordon Innovation Centre, Broxhead House, Louisburg Barracks, 60 Barbados Road, Bordon, GU35 0FX.

1.1 Accounting convention

The financial statements have been prepared in accordance with the charity's [governing document], the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended), FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019). The charity is a Public Benefit Entity as defined by FRS 102.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

Gifts of assets and services are recognised at market value to the charity.

1 Accounting policies **(Continued)**

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset's use.

Expenditure has been allocated between the main headings in the Statement of Financial Activities on the basis of the type of activity to which they relate, including irrecoverable V.A.T.

Income and expenses have not been netted off.

1.6 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures, fittings & equipment	25% on cost
Computers	25% on cost

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the statement of financial activities.

1.7 Impairment of fixed assets

At each reporting end date, the charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

1.8 Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition. Items held for distribution at no or nominal consideration are measured the lower of replacement cost and cost.

Net realisable value is the estimated selling price less all estimated costs of completion and costs to be incurred in marketing, selling and distribution.

1.9 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1 Accounting policies **(Continued)**

1.10 Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

1.11 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.12 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

PANCREATIC CANCER ACTION

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 DECEMBER 2022

	Notes	2022 £	2022 £	2021 £	2021 £
Cash flows from operating activities					
Cash absorbed by operations	**23**		(239,155)		(17,975)
Investing activities					
Investment income received		1,155		53	
Net cash generated from investing activities			1,155		53
Net cash used in financing activities			-		-
Net decrease in cash and cash equivalents			(238,000)		(17,922)
Cash and cash equivalents at beginning of year			822,729		840,651
Cash and cash equivalents at end of year			584,729		822,729

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3 Donations and legacies

	Unrestricted funds	**Restricted funds**	**Total**	Unrestricted funds	Restricted funds	Total
	2022	**2022**	**2022**	2021	2021	2021
	£	**£**	**£**	£	£	£
Donations and gifts	463,769	18,474	482,243	725,410	21,790	747,200

4 Other trading activities

	Unrestricted funds	Unrestricted funds
	2022	2021
	£	£
Sales of merchandise	4,691	6,963

5 Investments

	Unrestricted funds	**Unrestricted funds**
	2022	**2021**
	£	**£**
Interest receivable	1,155	54

6 Raising funds

	Unrestricted funds	Unrestricted funds
	2022	2021
	£	£
Fundraising and publicity		
Fundraising costs	86,444	123,185
Staff costs	139,222	146,382
Depreciation and impairment	1,042	5,725
Support costs	34,427	38,308
Fundraising and publicity	259,488	313,600
Trading costs		
Other trading activities	20,147	14,483
	279,635	328,083

7 Charitable activities

	Raising awareness	**Supporting research**	**Medical education**	**Patient support/ information**	**Total 2022**	**Total 2021**
	2022	**2022**	**2022**	**2022**		
	£	**£**	**£**	**£**	**£**	**£**
Staff costs	188,938	3,839	18,338	28,990	240,105	204,039
Depreciation and impairment	1,346	27	131	207	1,711	9,731
Other costs	119,338	2,391	12,070	18,056	151,855	234,998
	309,622	6,257	30,539	47,253	393,671	448,768
Share of support costs (see note 8)	40,079	814	3,890	6,149	50,932	54,981
Share of governance costs (see note 8)	4,401	89	427	675	5,592	10,125
	354,102	7,160	34,856	54,077	450,195	513,874
Analysis by fund						
Unrestricted funds	253,382	4,620	32,316	31,708	322,026	346,437
Restricted funds	100,720	2,540	2,540	22,369	128,169	167,437
	354,102	7,160	34,856	54,077	450,195	513,874

7 Charitable activities **(Continued)**

For the year ended 31 December 2021

	Raising awareness	Supporting research	Medical education	Patient support/ information	Total 2021
	£	£	£	£	£
Staff costs	141,581	30,469	16,453	15,536	204,039
Depreciation and impairment	6,752	1,453	785	741	9,731
Other costs	163,389	34,933	18,863	17,813	234,998
	311,722	66,855	36,101	34,090	448,768
Share of support costs (see note 8)	38,151	8,210	4,433	4,187	54,981
Share of governance costs (see note 8)	7,026	1,512	816	770	10,125
	356,899	76,577	41,350	39,047	513,874
Analysis by fund					
Unrestricted funds	237,611	55,390	32,377	21,059	346,437
Restricted funds	119,288	21,188	8,973	17,988	167,437
	356,899	76,578	41,350	39,047	513,874

8 Support costs

	Support costs	Governance costs	2022	Support costs	Governance costs	2021
	£	£	£	£	£	£
Rent	18,941	-	18,941	26,878	-	26,878
Office costs	6,378	-	6,378	9,672	-	9,672
Telephone costs	2,272	-	2,272	2,862	-	2,862
Computer costs	17,303	-	17,303	20,312	-	20,312
Insurance	2,496	-	2,496	3,199	-	3,199
Training, recruitment and internship costs	31,400	-	31,400	22,005	-	22,005
Book-keeping and Accountancy	2,587	-	2,587	2,016	-	2,016
Bank charges	575	-	575	392	-	392
Audit or Independent Examination fees	-	5,760	5,760	-	10,680	10,680
Legal and professional	-	3,240	3,240	-	5,398	5,398
	81,952	9,000	90,952	87,336	16,078	103,414
Analysed between						
Fundraising	31,020	3,408	34,428	32,355	5,953	38,308
Charitable activities	50,932	5,592	56,524	54,981	10,125	65,106
	81,952	9,000	90,952	87,336	16,078	103,414

Governance costs include payments to the independent examiner of £3,120 (2021 - £8,520 for audit) for independent examination fees and £2,640 (2021 - £2,160) for accounts preparation fees.

9 Trustees

None of the Trustees (or any persons connected with them) received any remuneration during the year and none of them were reimbursed travelling expenses (2021- £Nil).

10 Employees

The average monthly number of employees during the year was:

2022	2021
Number	Number
11	11

10 Employees **(Continued)**

Employment costs	2022	2021
	£	£
Wages and salaries	339,477	314,528
Social security costs	29,650	26,329
Other pension costs	10,200	9,564
	379,327	350,421

There were no employees whose annual remuneration was more than £60,000.

11 Taxation

The company is a registered charity and is, therefore, exempt from taxation on its charitable activities.

12 Tangible fixed assets

	Fixtures, fittings & equipment	Computers	Total
	£	£	£
Cost			
At 1 January 2022	10,612	12,244	22,856
At 31 December 2022	10,612	12,244	22,856
Depreciation and impairment			
At 1 January 2022	9,362	10,377	19,739
Depreciation charged in the year	967	1,786	2,753
At 31 December 2022	10,329	12,163	22,492
Carrying amount			
At 31 December 2022	283	81	364
At 31 December 2021	1,250	1,867	3,117

13 Stocks

	2022	2021
	£	£
Finished goods and goods for resale	3,875	18,411

14 Debtors

	2022	2021
Amounts falling due within one year:	**£**	**£**
Trade debtors	-	250
Other debtors	12,076	258
Prepayments and accrued income	60,199	50,069
	72,275	50,577

	2022	2021
Amounts falling due after more than one year:	**£**	**£**
Prepayments and accrued income	2,333	-
Total debtors	74,608	50,577

15 Creditors: amounts falling due within one year

	2022	2021
	£	**£**
Other taxation and social security	8,528	11,028
Trade creditors	29,399	13,846
Accruals and deferred income	25,193	27,763
	63,120	52,637

16 Retirement benefit schemes

Defined contribution schemes
The charity operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the charity in an independently administered fund.

The charge to the SOFA in respect of defined contribution schemes was £10,200 (2021 - £9,564).

17 Restricted funds

The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

	Movement in funds				Movement in funds			
	Balance at 1 January 2021	Incoming resources	Resources expended1	Balance at January 2022	Incoming resources	Resources expended	Transfers	Balance at 31 December 2022
	£	£	£	£	£	£	£	£
Pat & Paul	1,366	1,140	-	2,506	10,099	-	-	12,605
POW app	17,200	-	-	17,200	-	-	-	17,200
Recipe Book	20,110	-	(1,936)	18,174	-	(3,839)	-	14,335
Patient Information Booklets	17,987	-	(2,015)	15,972	8,375	(15,990)	-	8,357
Hope is Contagious	6	150	-	156	-	(156)	-	-
NIPanC	6,456	-	-	6,456	-	(611)	-	5,845
PC Aware Wales	27,745	-	(27,745)	-	-	-	-	-
Hard to reach groups	6,000	-	(6,000)	-	-	-	-	-
Pancreatic Cancer Scotland	520,454	18,500	(127,491)	411,463	-	(107,573)	(56,213)	247,677
Health information officer	2,250	-	(2,250)	-	-	-	-	-
Community volunteers	960	-	-	960	-	-	-	960
GP Packs	-	2,000	-	2,000	-	-	-	2,000
	620,534	21,790	(167,437)	474,887	18,474	(128,169)	(56,213)	308,979

Restricted funds relate to grants received for the specific purposes as set out above. Any amount unspent is carried forward to be spent in the next financial year.

A transfer between unrestricted and restricted funds has been made to reflect the allocation of support costs attributable to the PCS Legacy Fund the for the year ended 2021.

18 Analysis of net assets between funds

	Unrestricted 2022	Restricted 2022	Total 2022	Unrestricted 2021	Restricted 2021	Total 2021
	£	£	£	£	£	£
Fund balances at 31 December 2022 are represented by:						
Tangible assets	364	-	364	3,117	-	3,117
Current assets/(liabilities)	291,113	308,979	600,092	364,193	474,887	839,080
	291,477	308,979	600,456	367,310	474,887	842,197

19 Designated funds

The income funds of the charity include the following designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes:

	Balance at 1 January 2021	Resources expended1	Balance at January 2022	Resources expended	Balance at 31 December 2022
	£	£	£	£	£
Early diagnosis challenge award (research)	15,485	(13,410)	2,075	(2,075)	-
	15,485	(13,410)	2,075	(2,075)	-

20 Financial commitments, guarantees and contingent liabilities

To date, the charity has received £46,897 in donations from solicitors relating to old monies held in client accounts which they have not been able to return. There is a possibility that in the future the clients in question could still return for these monies and, as such, the charity has agreed to refund part of the donation if this occurs. No provision has been made in these financial statements for any possible refund as the likelihood is remote and cannot be quantified.

The charity has committed to sponsor a nursing post within NHS Greater Glasgow & Clyde (GGC) for a three year period starting in January 2023. The total commitment over the three years is expected to be £135,357.

21 Operating lease commitments

At the reporting end date the charity had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

	2022	2021
	£	£
Within one year	4,320	4,320

22 Related party transactions

Remuneration of key management personnel
The remuneration of key management personnel is as follows.

	2022	2021
	£	£
Aggregate compensation	56,393	44,921

The key management personnel of the Charity is considered to be the CEO.

There were no other related party transactions.

23 Cash generated from operations	2022	2021
	£	£
Deficit for the year	(241,741)	(87,740)
Adjustments for:		
Investment income recognised in statement of financial activities	(1,155)	(54)
Depreciation and impairment of tangible fixed assets	2,753	15,455
Movements in working capital:		
Decrease/(increase) in stocks	14,536	(3,519)
(Increase)/decrease in debtors	(24,031)	62,748
Increase/(decrease) in creditors	10,483	(4,865)
Cash absorbed by operations	(239,155)	(17,975)

24 Analysis of changes in net funds
The charity had no debt during the year.

PANCREATIC CANCER ACTION

England & Wales - Charity number 1137689

Accounts

Charity registration number 1137689 (England and Wales)

Charity registration number SC049777 (Scotland)

Company registration number 07272699 (England and Wales)

PANCREATIC CANCER ACTION

ANNUAL REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2021

PANCREATIC CANCER ACTION

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	H Matthews	
	N Menezes	
	N Mumford	
	S Krag	
	H Goodfellow	
	L Condron	
	D Georgiou	
	R Legg	
	C Carter	
	E Cowan	(Appointed 24 August 2021)
	N Longworth	(Appointed 27 August 2021)
	L Nylander	(Appointed 24 August 2021)
Secretary	G Brown	
Charity number (England and Wales)	1137689	
Charity number (Scotland)	SC049777	
Company number	07272699	
Registered office	Unit 9 Oakhanger Farm Business Park Oakhanger Road Oakhanger Hampshire GU35 9JA	
Auditor	Alliotts LLP Friary Court 13-21 High Street Guildford Surrey GU1 3DL	

PANCREATIC CANCER ACTION

CONTENTS

	Page
CEO's report	1 - 2
Trustees' report	3 - 14
Statement of Trustees' responsibilities	15
Independent auditor's report	16 - 19
Statement of financial activities	20
Balance sheet	21
Statement of cash flows	22
Notes to the financial statements	23 - 35

PANCREATIC CANCER ACTION

CEO'S REPORT

FOR THE YEAR ENDED 31 DECEMBER 2021

2021 was also a year of uncertainty as the pandemic was very much still with us. However, as a small and nimble organisation, we were able to flex our activities to take account of restrictions that were happening across the UK.

We started with a new concept – Jog Jan for Pan Can – allowing people to give themselves their own running or walking target for the month whilst getting friends and relatives to sponsor them. This raised an incredible £140,000.

We were hoping to do a PC Aware Wales campaign in 2020, but it was not only postponed to 2021, but due to the pandemic we had to flex it to accommodate the lockdowns. All assets were developed in Welsh and English and the campaign involved raising awareness to the public, GPs and Pharmacists.

We ran two TV awareness campaigns which resulting in increased visits to the symptoms pages of our website and we were heavily involved in the development of the ITV Tonight documentary on pancreatic cancer.

We further developed our Action on the Ground pilot in Glasgow and in Pancreatic Cancer Awareness Month, we translated many of our awareness assets into the 6 key foreign languages spoken in the UK.

We have also been extremely active in the policy arena with a debate in the Scottish Parliament and submitting evidence to the Health & Social Care Select Committee. We have also been attending many NHS England and Scotland meetings to assess the impact the pandemic has been having on our patient cohort and teaming up with other coalitions such as One Cancer Voice and Cancer 52 to spread our messages further.

We continued with our research project at the University of Surrey looking at patient records of people with diabetes who went on to get pancreatic cancer and those who did not. The aim is to identify a group of new-onset diabetes patients who could potentially be at risk of pancreatic cancer and to help GPs know when to refer a patient with new-onset diabetes for pancreatic cancer testing in the hope they can be diagnosed early.

We continued to provide advice and information relating to COVID-19, cancer services, but we at Pancreatic Cancer Action (PCA) kept on top of it by attending many (virtual) meetings with NHS, Governments and collaborating with other charities and organisations to share information.

Using these channels, we continued to update our website and social media channels daily to give our patients and their families the most up-to date information we could.

The long-term impact of reduced public presentation to primary care and reduced urgent referrals at the height of the pandemic has not yet been fully realised. The missed and delayed cohort of cancer patients not yet recorded will have come through alongside incident cancer cases, adding to diagnostic and treatment demand. These people will naturally be presenting at a later stage and so are more likely to be, or become, inoperable, due to diagnostic delays and reduced investigative capacity. The impact of revised treatment pathways during the first wave of the pandemic is just coming through with one specialist centre reporting a doubling of mortality.

We will continue to be a voice for patients and families to ensure pancreatic cancer is a focused priority in NHS Recovery Plans.

We are so very grateful to our wonderful supporters and fundraisers who have not only stuck with us but helped us increase income to near normal levels.

PANCREATIC CANCER ACTION

CEO'S REPORT

FOR THE YEAR ENDED 31 DECEMBER 2021

In 2020 we started the development of a project to look at the underserved groups in the UK who have a poorer prognosis when diagnosed with pancreatic cancer. We not only want to understand why, but we want to ensure all our information is communicated effectively and that we reach these groups to ensure they take action when presenting with symptoms.

We had great plans to celebrate our 10th anniversary in 2020 by launching our new vision for the future in what we hope will be the 'Decade of Change' for pancreatic cancer.

We are very proud of our achievements to date and we will continue to have a primary focus of improving early diagnosis of pancreatic cancer as well as ensuring all those affected by pancreatic cancer have access to the care, information and support they need.

However, we can't do all this alone and we are so fortunate to have so many Community Representatives, Action Ambassadors and other volunteers who help in a variety of ways including providing us with lay reviews for our patient information. We rely heavily on their generosity of time as well as their efforts to raise awareness and fundraise in their localities.

Some of our key volunteers are our Trustees, who have supported me and my team so very well over the past year.

I am also grateful to our wonderful Patrons and Ambassadors who help us with our activities and support our campaigns and of course to our marvellous fundraisers and donors, without whom, we couldn't do what we do.

Ali Stunt (Sep 9, 2022 16:12 GMT+1)

.....

Ali Stunt

Founder & Chief Executive

Dated: 09/09/2022

PANCREATIC CANCER ACTION

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)

FOR THE YEAR ENDED 31 DECEMBER 2021

The Trustees present their annual report and financial statements for the year ended 31 December 2021.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charity's Memorandum and Articles of Association, the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)".

Objectives and activities

Our purpose

Pancreatic Cancer Action works to save lives through promoting earlier diagnosis of pancreatic cancer. We do this through promoting greater awareness of the symptoms of the disease, the funding and development of medical educational programmes, supporting patients through improved information about pancreatic cancer either on our website or in print and by funding research.

Our vision

Our vision is that everyone survives pancreatic cancer.

Our mission

Our mission is to improve survival rates of pancreatic cancer by ensuring more people are diagnosed early and that everyone has access to effective treatments, support, information and care.

Objectives

The charity's objectives are:

A **Awareness** - increase public awareness and knowledge of pancreatic cancer and its symptoms to achieve early diagnosis

C **Campaign** and lobby the government and key stakeholders for change to advance the standard of healthcare for individuals affected by pancreatic cancer

T **Train** and provide pioneering educational resources for our medical and healthcare communities

I **Innovative** research - we fund it, we support it - to improve early diagnosis and develop effective treatments to improve pancreatic cancer outcomes

O **Offer** the provision of practical and emotional support and information to all affected by pancreatic cancer

N **Now** – we are the action charity and action is needed more than ever before!

The Trustees have paid due regard to guidance issued by the Charity Commission in deciding what activities the charity should undertake.

The Trustees' activities

The Trustees meet annually to develop a strategy to meet the charitable objectives. Once the overall strategy has been agreed by the Trustees a series of operational meetings attended by a selection of the Trustees and employees, who the Trustees believe have relevant skills and experience in the specific area look at the operational implementation.

The Trustees currently have a range of skills and experience that range from medical/scientific, Legal, corporate governance, finance and PR.

Role of volunteers
The Charity receives the very welcome assistance of volunteers. To date this has usually been for specific projects or fund-raising initiatives. In 2021 our network of Regional Representatives across the UK was made up of 50 volunteers. The aim is that these volunteers represent Pancreatic Cancer Action, raise awareness of pancreatic cancer and fundraise in their communities.

The pandemic and ever-changing restrictions has impacted how volunteers can assist in our office, at events or within their communities, but we continue to evolve ways to enable people show their support. The charity seeks volunteer assistance via the website, social media and by word of mouth.

Public benefit statement
The Trustees confirm that they have complied with the duty in Section 4 of the Charities Act 2011 to have due regard to the Charity Commission's general guidance on public benefit.

Achievements and performance
***1. Awareness* - increase public awareness and knowledge of pancreatic cancer and its symptoms to achieve early diagnosis**

STV Advert
In April 2021 we re-ran the TV awareness advert featuring one of our amazing supporters, Gavin Oattes talking about the symptoms of pancreatic cancer and how he sadly lost his dad to the disease. This advert was due to scheduled for January 2021, but because of the sensitivities surrounding the pandemic and the winter pressures on the NHS, we delayed until April.
During the month we saw a 60% increase in visits to our symptoms pages on our website versus the previous month, despite the advert only being shown in Scotland.

PC Aware Wales
Due to launch in June 2020, this public and healthcare professional awareness campaign had to be put on hold until June 2021 due to Covid-19 lockdown restrictions.

Pancreatic cancer is the 16th most common cancer in Wales, affecting around 500 annually. It is the 6th biggest cancer killer, with 505 deaths. Incidence and mortality can be examined by health board. However, these results may mislead, as the size of health board, and demographic varies widely across the country. Many areas in Wales have a five-year survival rate of only three per cent (versus 7.3% UK wide).

We conducted a pre-campaign survey which found that 75% of the 1,000 Welsh people surveyed, reported that they know “nothing” (21.6%) or “almost nothing” (53.4%) about pancreatic cancer.

We delivered GP resource packs to 297 GP surgeries and Pharmacy packs to 256 community pharmacies and dropped 110,000 symptom awareness leaflets into people’s homes in Denbighshire, Wrexham, Caerphilly, Newport, Merthyr Tydfil and Rhondda Cyon Taf.

By targeting all key stakeholders in the same region within the same time frame we hoped to significantly increase awareness of pancreatic cancer and save lives through early diagnosis.

ITV Tonight Documentary

In October 2021, Daniel Kennedy, a well-known documentary film maker turned his lens to something close to his heart; his father, Paul, passed away from pancreatic cancer just three months after he was diagnosed. Whilst being treated at the height of the pandemic, Daniel captured Paul's most precious moments though the course of his final journey.

Daniel came to become familiar with Pancreatic Cancer Action in June last year after receiving support from Pancreatic Cancer Action's Founder & CEO, Ali Stunt. For many years charities like ours, have tried to cut through the noise to increase awareness of the 5th biggest cancer killer in the UK.

With this documentary for the ITV Tonight current affairs programme, Daniel focused a spotlight on the deadliest common cancer. He investigated whether enough is being done to get patients diagnosed early. During the documentary we saw interviews with professors, doctors, charity CEOs and our very own 14-year survivor and Founding CEO of Pancreatic Cancer Action, Ali Stunt. Speaking on the program, Ali opened up about how "Pancreatic cancer survivors over ten years can't remain in the 1% statistic. This is a very lonely place to be,".

Islets of Silence – The C Word

A play written and directed by Isobel Barrett of Tram Direct Theatre Company was set to tour around theatres in Scotland in 2020 to help raise awareness of pancreatic cancer through the arts.

Originally funded by PCS alongside Culture & Business Fund Scotland match funding by Arts & Business Scotland, the project launch in 2020 attracted fantastic media coverage including STV News.

The tour was postponed due to the pandemic, but Isobel and the production team continued to create innovative ways to use the arts to raise awareness, with excerpts of the play filmed and shared via social media.

In September/October 2021 the Islets of Silence play was able to tour again to great acclaim.

Pancreatic Cancer Awareness Month
Throughout the month of November we had an extra push on raising awareness of the symptoms of pancreatic cancer to reach more people than we ever have before. This started at the beginning of the month and we saw an incredible amount of social media shares of our symptoms posts.

Key highlights:

Translation of assets:
In 2021 we embarked on a project to provide digital access to our Symptoms poster, Fact's poster, Risks poster. Symptom's diary, the poster for our Patient Information Booklets and About us leaflet. Translated into 6 languages: Polish, Punjabi, Urdu, Bengali, Gujarati, Arabic. These assets are hosted on their own translated landing pages on our website.
We want to use this initiative to make our resources more accessible to ethnic minorities in the UK and individuals who have the symptoms or are at risk of pancreatic cancer and to develop it further in 2022.

Leaflet drop in Burnley
We conducted a PC aware style leaflet drop across 31,000 households in Burnley on 15th November 2021.
Burnley is recognised as an area of high deprivation, making it important for us to target communities in this area.
We used the leaflet to promote awareness of who we are and the signs and symptoms of pancreatic cancer.

National TV Campaign
We developed a 20 second commercial across some of the ITV portfolio including, STV, ITV Borders, ITV2 and ITV3 for maximum reach of our core demographic (men and women over the age of 45).

Turn it Purple campaign.
We continued our Turn it Purple campaign and in 2021 sent out over 150 packs to supporters.

Purple Lights UK
The collaborative campaign Purple Lights UK saw locations across the country light up purple to raise awareness during November and in particular on World Pancreatic Cancer Day. This is largely a supporter focused campaign and this year we saw lots of supporters light up their own homes in support as well as buildings and landmarks.

Broadcast Media
Press coverage in ‘The Sun’, ‘Daily Express’, ‘Daily Mirror’, ‘Daily Record’, local news outlets for the campaign such as ‘Northern Daily Echo’, Farnham Herald, The Exeter Daily’ and more. And STV news coverage in Scotland with Survivor Debra Grindall & PCA Team member Nicky McManus.

Action on the Ground (AoG)
During 2019 PCA started to research and define its approach to communicating with groups that have low health literacy, groups that are hard to reach with the worst outcomes in relation to diagnosis and survival of pancreatic cancer.
AoG kicked off its work in east end of Glasgow, one of the highest areas of deprivation in not only Scotland but the whole of the UK. Research suggests this community has some of the lowest health literacy, an increase in barriers to presentation and are exposed to a higher rate of the risk factors associated with pancreatic cancer that other communities.

In 2021 we have taken a proactive approach to reach this community and provide them the education and support relating to catching pancreatic cancer early. AoG has developed a number of relationships with trusted partners to carry out this work. This includes the Scottish Pantry Network where we conducted a survey of service users’ knowledge of pancreatic cancer, followed by us distributing a specialist easy-to-read leaflet with symptoms with every food parcel that went out and the Scottish Pantry Network promoting our health information booklets including our recipe book. We are currently waiting on the results of a second survey with service users to see if this has increased their understanding of the signs and symptoms of pancreatic cancer.

2. Campaign **and lobby the government and key stakeholders for change to advance the standard of healthcare for individuals affected by pancreatic cancer.**

Scottish Parliament Engagement
We engaged with politicians across the UK to raise awareness of the statistics around pancreatic cancer and the importance of early diagnosis.
As part of our ongoing plan to engage, lobby and influence decisions makers we wrote to all MSPs to re/introduce ourselves and explain our operations in Scotland.
We supported Clare Adamson MSP in securing a debate in the Scottish Parliament in Pancreatic Cancer Awareness Month. The motion achieved cross-party support from over 40 MPs/MSPs.

On World Pancreatic Cancer Day, our Scottish team parked the Pan Can Van outside Scottish Parliament and 29 parliamentarians came to the van to discuss issues surrounding pancreatic cancer.

In Scotland, we continued to engage with key stakeholders, including representation at meetings and discussions with The Scottish Cancer Coalition, Cross Party Group on Cancer, The Scottish HPB Network and various other networks and contacts.

Westminster Engagement
We had hoped to have an in-person meeting at the Palace Of Westminster on 29th November but unfortunately, due to covid restrictions, members of the public were not allowed onto the Parliamentary estate, so we had to cancel our plans. Hopefully we can reschedule this for 2022.

Furthermore, we wrote to every MP across the UK, asking them to support PCA in November's awareness month and use our resources to raise awareness of pancreatic cancer.

Health & Social Care Select Committee
The House of Commons Health & Social Care Select Committee conducted an investigation into why cancer outcomes in England continued to lag behind comparable countries internationally and examined evidence submitted relating to the underlying causes of these differences. They also collated evidence on the impact and disruption to cancer services during the covid-19 pandemic, the efforts to catch up, and ask whether the ambitions set out in the NHS Long Term Plan would help close the gap with the best performing countries worldwide.
PCA submitted written evidence highlighting the key challenges to improving pancreatic cancer survival rates and made clear recommendations on changes required. These recommendations focused on workforce planning, equipment, education and empowering health care professionals. The full report can be found here:
https://committees.parliament.uk/work/1377/cancer-services/publications/written-evidence/?page=2

We continue to lobby members of the select committee to take oral evidence sessions from third sector organisations and patient groups.

All Party Parliamentary Group on Pancreatic Cancer
Unfortunately, due to the pandemic, the APPG PC was unable to function as usual. However, we did put into motion an inquiry into the impact that Covid-19 has had on pancreatic cancer diagnosis and treatments. This report was published in 2021.
In 2022, Pancreatic Cancer Action will be taking over as secretariat for the APPG PC.

Local Government Engagement
All local authorities have responsibilities concerning public health and the promotion of health and wellbeing. Their powers and responsibilities vary depending on whether they are a county council, district council, unitary authority, metropolitan borough, London boroughs, Welsh unitary, Scottish unitary.
We are working with local authorities across the UK to pass motions in Council Chambers relating to pancreatic cancer. A standard motion would include requirements for the Council to host our occupational health e-learning, host information relating to pancreatic cancer on their website, display symptoms posters in their public buildings such as libraries, support care staff in commissioned services with training for staff to recognise the symptoms of pancreatic cancer amongst their residents, light up local landmarks purple for PCAM. Outside of the motions are working with Councillors who are part of their local Health scrutiny committee to request reports into local cancer services.
The first motion went to East Hampshire Council on November 11th.

Cancer Alliances
We have worked more closely than ever before with cancer alliances and those running cancer services across the UK. We collaborated with Surrey and Sussex Cancer Alliance to raise awareness and promote our services among GPs and pharmacists. Alongside this, we worked with the Lancashire and South Cumbria Cancer Alliance to raise awareness with GPs, hospitals and the public. As a result of this, we were able to promote our E-learning modules to help health care professionals diagnose pancreatic cancer early as well as raising awareness in local communities.

***3. Train* and provide pioneering educational resources for our medical and healthcare communities.**

Health Care Professional Engagement
Ongoing work is taking place to provide resources and educate health care professionals on pancreatic cancer and how to support their patients. Current work includes:
GP Link letter – Around 400 letters were hand-delivered to GP practices across Scotland. The letter included information about our GP e-learning as well as symptom awareness posters.
Pharmacy Bags – Following their success in our PC Aware Wales campaign, 100,000 pharmacy bags were given to pharmacies in the Early Cancer Diagnostic Centre pilot areas designated by the Scottish Government. These are in Ayrshire & Arran, Dumfries & Galloway and Fife. Pharmacy bags also went out in the east end of Glasgow to support the Action on the Ground project.

New e-learning
Work has been undertaken to develop new e-learning for allied health care professionals. A key area of focus has been about what happened to those who are misdiagnosed and where are they referred. As a result, work had begun on new e-learning for physiotherapists. The Chartered Society of Physiotherapy have agreed to accredit, host and promote the new e-learning. Discussions are also taking place to see if this e-learning can be tweaked for chiropractors and if there is a professional body interested in partnering with us.

GP Advisory Committee
Recruitment is currently taking place for a PCA GP Advisory Committee. We are committed to ensuring it provides the highest quality possible support and resources for both healthcare professionals and patients. The value and importance of involving GPs in the development, delivery, and promotion of our services and support to patients, through an Advisory Committee sitting under the Trustee Board**.**

***4.Innovative research* - we fund it, we support it - to improve early diagnosis and develop effective treatments to improve pancreatic cancer outcomes.**

Research Strategy
Following meetings with the Scientific Sub-committee of the Trustee Board and the Association of Medical Research Charities it has been agreed that we develop a new 'Research strategy' for the organisation. This new strategy will set out our priorities, processes for making awards and be a key part of how we make the decade of change a reality.

Diabetes and pancreatic cancer
Pancreatic Cancer Action is committed to funding early diagnosis research projects. Our past early diagnosis challenge award gave funding to researchers primarily working with biomarkers that has led to further investment from Pancreatic Cancer Research Fund (PCRF) and Cancer Research UK. Throughout 2021 and beyond we are funding projects examining the link between diabetes and pancreatic cancer. Research is emerging in this area that suggests there may be an opportunity for early diagnosis of pancreatic cancer in patients with new diabetes. The University of Surrey research project exploring is BMI and glycated haemoglobin (HbA1c) are markers for pancreatic cancer is making good progress. The project is due to come to an end late 2022.

Precision-Panc

We continue to engage and support the ground-breaking Precision-Panc project led from The University of Glasgow.

Majority funded by Cancer Research UK, the Precision-Panc platform was founded in 2017, bringing together expertise in pancreatic cancer from universities, research institutes and the NHS.

Precision medicine is about tailoring treatments to an individual's cancer and the overall aim is to make this a reality for more people with pancreatic cancer – through building knowledge that will ultimately allow clinicians to match patients with the most suitable treatment.

There is now a UK wide network of over 30 hospitals that can offer precision medicine clinical trials as a vital treatment option for people with pancreatic cancer. As part of the wider Precision-Panc programme tissue samples are also collected from participants for molecular profiling, which could lead to vital new insights into the development of the disease in the future.

In Precision-Panc all registered patients have their genome testing using Glasgow Precision Oncology Laboratories bespoke panel. Networked clinical trials with researchers across the country share expertise and knowledge, as well as
creating and sharing infrastructure, leading to trials which are quicker to set up and recruit.

This ambitious programme of research could transform how pancreatic cancer is treated and as we learn more about the disease, pave the way for patients entering clinical trials in a way that matches their tumour biology to the type of treatment.

PCA are proud to work closely with the Precision-Panc team with our Founder and CEO Ali Stunt currently sitting on the Precision Panc Steering Committee. We share and contribute knowledge and experiences and work collaboratively to improve access to clinical trials. We provide additional resource by fully funding a dedicated pancreatic cancer clinical nurse specialist within the West of Scotland Cancer Network.

***5. Offer* the provision of practical and emotional support and information to all affected by pancreatic cancer**

PCS Precision-Panc, Pancreatic Cancer Clinical Nurse Specialist

Sine our merger with Pancreatic Cancer Scotland in March 2020, we have taken over fully funding an innovative new dedicated pancreatic cancer nurse specialist role with NHS Greater Glasgow and Clyde to support the West of Scotland Pancreatic Team, Precision-Panc and our charity.

Based at Glasgow Royal Infirmary the post-holder provides supplementary direct clinical support for patients and carers, ensuring there is a point of contact for information and advice, before, during and after treatment. A large part of this
includes signposting individuals to appropriate support services and guiding them through a complex pathway. This is key in facilitating holistic treatment throughout a patient's journey, recognising every individual is different.

While this is not a research nurse post, the unique combined research aspect of this role supports patients and families understanding of clinical trials and has contributed to enhancing participation and recruitment of patients to the Precision-Panc study and other trials, which are key to improving survival in the future.

We are delighted with how the role has adapted and evolved – joining everything together with the patient at the heart of it. The success of this role demonstrates how a collaborative approach with the third sector, healthcare professionals and
research programmes can make a real difference - especially in ensuring patients and families are provided with support and information.

We are currently exploring the opportunity of a second CNS post for NOSCAN/NHS Grampian/Highland. Further discussions have taken place with Ross Carter, Elspeth Cowan, Fiona Brown and Chrissie Lane, Consultant Nurse for Cancer Care within NHS Highland to understand the geographical differences, complexities and needs for The North. A post within NHS Highland is being scoped which could potentially be part time.

Patient Information Booklets

Our booklets contain the most up to date information available to help patients to understand pancreatic cancer, treatment options and the experience of the disease.

We are very grateful to our peer and lay reviewers who have given their time to ensure our information is evidence based, accurate and understandable.

The booklets are easy to understand at any stage of the patients journey and are available to order or view online.

Patient Information Forum (PIF) Audit

PIF TICK on our leaflets, websites or videos shows and our health information has been through a professional and robust production process. Due to recent recruitment, a review took place in November where we were issued a certificate of certification for six months before a full audit in Summer 2022. The team are using this as an opportunity to update all our processes relating to the production of health information to ensure they are both as streamlined and robust as possible.

Support

Our help and support section of our website is designed to help everyone that is affected by pancreatic cancer to help answer any questions people may have.

Our website contains helpful information and links to support, from the moment symptoms first appear, treatment, coping and bereavement.

Our sources of support includes an interactive option to engage with our partners at Grief Chat.
GriefChat is a safe space for grieving or bereaved people to be able to share their story, explore their feelings and be supported by a qualified bereavement counsellor.

We are proud to continue our partnership with Cancer Support Scotland (CSS), funding support services for anyone affected by pancreatic cancer in Scotland. This includes the person diagnosed, their family, friends, carers and those who have lost a loved one.

We will continue to develop relationships with stakeholders to ensure that there is support available throughout the UK as we listen to the needs of patients and families.

Wider activities and engagement:

Conferences and Exhibitions
Due to the pandemic, we were only able to attend the Pharmacy Show in October 2021

PCA Action Ambassadors
We will continue to recruit further patients or carers who have had experience of pancreatic cancer as regional representatives in areas where we currently do not have representation.

Fundraising

Actions were taken to review fundraising activities that could be pivoted to virtual events and products which meant income continued to be received.

Increasing supporter engagement was top of the agenda during 2021 and we have worked hard as a team to make sure that all supporters have been communicated with accordingly throughout. We have hosted Zoom calls, made personal phones calls and have sent newsletters and the Action Post to keep them updated.

With the lens of the pandemic in mind, we were fairly conservative in our targets for fundraising

Challenge events

We continued to focus on virtual events and in January launched Jog Jan for Pan Can. This was particularly well received and raised over an incredible £140,000 for us which was an excellent start of the year.

Challenge events were more challenging as lock downs meant we weren't sure any would take place. However, the London Marathon did take place. Other challenge events included the London Landmarks Half Marathon, the Manchester Marathon, The Kiltwalk (which included a very generous 50% top up on income raise by Sir Tom Hunter).

We would like to say a big thank you to all our fantastic supporters, without whom we would not be able to carry out our vital work. This year they have adapted to run, walk, and cycle locally and take on new challenges, with virtual activities and online fundraising taking place across the country and taking on in-person events when the country opened up again.

Community Fundraising

Notable community fundraising included £40,000 raised by the Freemasons of Glasgow over a five year period.

Lord Margadale and his family opened their gardens at Fontill House and ran a silent auction in memory of his dear friends' Charlie Barton and Louise Eadie's mother who sadly passed away from pancreatic cancer. The event raised a huge £53,000

Luzija Dance raised an incredible £3,000 in July at her family fun day despite being just 16 years old. Luzija has lost an uncle and Grandad to PC and her Grandma was undergoing treatment at the time. Luzija set out to plan this event with her parents however quickly showed she had the determination to plan the whole event. Over 100 people from around her local community attended. From bouncy castles to local stall holders, Luzija was able to source all at very little cost meaning she was able to raise such a fantastic amount.

Charlie Creagh- Barry has raised over £9,000 for PCA after losing his mum in May. We were privileged to meet Charlie and his sister Millie at Fonthill after they found a flyer for the event when sorting through his mum's possessions. Charlie took on a gruelling army style challenge for 30 days across the summer raising over £7,000 and a further £1500 being donated following his mums funeral. Charlie has since got his workplace involved (Sav UK) and is hoping to raise even more for PCA in the future.

The support from our community fundraisers is, as ever, invaluable and we have seen supporters dye their hair, hold online concerts and quizzes to help us with our work. Thank you – we are so very grateful for all you do, then, now and in the future.

Action funds:
At the end of 2021, we had the following action funds:

- Action for Pat and Paul (Scotland)
- Hope is Contagious
- The Shaun Wright Foundation (NE England)

Corporate partnerships and support
We have invested in developing relationships with businesses both large and small and are delighted to have been able to partner and receive support from such passionate people in 2021. Our corporate partners play a vital role in allowing us to raise more awareness and funds for pancreatic cancer and we can't thank them enough for their support.

They work with us in various capacities and for various lengths of time and in 2021 we were supported by:

- Pen Underwriting
- Sheila Fleet Jewellery
- Just Employment Law
- Partick Thistle Football Club
- Tunnocks
- Arnold Clark Car & Van Rental

Just Employment Law has continued to give us phenomenal support. In Pancreatic Cancer Awareness Month their online auction raised a whopping £73,000!

Trusts and Grants
We are very grateful to the many funders that give so generously towards our initiatives, activities and projects. In 2021 these included grants from:

Restricted
Pavers Foundation £2,000

Unrestricted:

None

Financial review
The results for the year are summarised in the Statement of Financial Activities on page 19.

The Trustees are pleased to report that the charity's incoming resources for 2021 amounted to £754,217 (2020: £1,256,477; an exceptional year which included a one-off transfer of £607,560 due to the merger with Pancreatic Cancer Scotland and £58,781 through the Coronavirus Job Retention Scheme) (2019: £786,505), (2018: £892,851), (2017: £757,812).

The Trustees would like to thank all those volunteers, fundraisers and donors - corporate, trusts and foundations, as well as individual donors who have supported the charity over the past years and upon whom we are dependent.

Total spending on charitable activities was £513,874 (2020: £437,838) (2019: £609,931) (2018: £669,187), (2017: £669,077).

Primarily as a result of these activities, the charity achieved a net loss for the year of -£87,740 (2020: £510,025) (2019: £-115,305) (2018: £-24,634) (2017: £-169,315).

Reserves policy
It is the policy of the charity that unrestricted funds which have not been designated for a specific use should be maintained to cover at least 6 months of operating expenditure. The Trustees consider that reserves at this level will ensure that, in the event of a significant drop in funding, they will be able to continue the charity's current activities while consideration is given to ways in which additional funds may be raised.

At 31st December 2021, the charity held reserves of £842,197 of which £474,887 was restricted. Free reserves stood at £362,118, which is in line with the level of the reserves policy established by the board.

Structure, governance and management
The charity is a company limited by guarantee, incorporated in June 2010, and is therefore governed by its Memorandum and Articles of Association. Its company registration number is 07272699 and its charity numbers are 1137689 (England and Wales) and SC049777 (Scotland).

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2021

The Trustees, who are also the directors for the purpose of company law, and who served during the year and up to the date of signature of the financial statements were:

H Matthews	
N Menezes	
N Mumford	
S Krag	
H Goodfellow	
L Condron	
D Georgiou	
R Legg	
A Clancy	(Resigned 14 April 2021)
C Carter	
E Cowan	(Appointed 24 August 2021)
N Longworth	(Appointed 27 August 2021)
L Nylander	(Appointed 24 August 2021)

None of the Trustees has any beneficial interest in the charity. There are five members of the company who guarantee to contribute £10 in the event of liquidation. The following trustees are members: H Matthews, N Menezes and C Carter.

The Trustees continue to keep the Charity's activities under review, particularly with regard to any major physical or financial risks that may arise from time to time, and to monitor the effectiveness of the system of internal controls and other variable means, including insurance cover where appropriate, by which those risks already identified by the Trustees can be mitigated.

Auditor

In accordance with the company's articles, a resolution proposing that Alliotts LLP be reappointed as auditor of the company will be put at a General Meeting.

Disclosure of information to auditor

Each of the Trustees has confirmed that there is no information of which they are aware which is relevant to the audit, but of which the auditor is unaware. They have further confirmed that they have taken appropriate steps to identify such relevant information and to establish that the auditor is aware of such information.

The Trustees' report was approved by the Board of Trustees.

Nicola Mumford
Nicola Mumford (Sep 9, 2022 16:11 GMT+1)

.....

N Mumford
Chair of Trustees
Dated: 09/09/2022

PANCREATIC CANCER ACTION

STATEMENT OF TRUSTEES' RESPONSIBILITIES

FOR THE YEAR ENDED 31 DECEMBER 2021

The Trustees, who are also the directors of Pancreatic Cancer Action for the purpose of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company Law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that year.

In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;

- observe the methods and principles in the Charities SORP;

- make judgements and estimates that are reasonable and prudent;

- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and

- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The Trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 (as amended). They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

PANCREATIC CANCER ACTION

INDEPENDENT AUDITOR'S REPORT

TO THE MEMBERS AND TRUSTEES OF PANCREATIC CANCER ACTION

Opinion

We have audited the financial statements of Pancreatic Cancer Action (the 'charity') for the year ended 31 December 2021 which comprise the statement of financial activities, the balance sheet, the statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2021 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended).

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial statements* section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The Trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

- the information given in the Trustees' report for the financial year for which the financial statements are prepared, which includes the directors' report prepared for the purposes of company law, is consistent with the financial statements; and
- the directors' report included within the Trustees' report has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the charity and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report included within the Trustees' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 (as amended) require us to report to you if, in our opinion:

- adequate and proper accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the Trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemptions in preparing the Trustees' report and from the requirement to prepare a strategic report.

Responsibilities of Trustees

As explained more fully in the statement of Trustees' responsibilities, the Trustees, who are also the directors of the charity for the purpose of company law, are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the Trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with the Acts and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Extent to which the audit was considered capable of detecting irregularities, including fraud
Our approach to identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows:

- the engagement partner ensured that the engagement team collectively had the appropriate competence, capabilities and skills to identify or recognise non-compliance with applicable laws and regulations;
- we identified the laws and regulations applicable to the company through discussions with Trustees and other management, and from our knowledge and experience of the sector;
- we focused on specific laws and regulations which we considered may have a direct material effect on the financial statements or the operations of the charitable company, including the Companies Act 2006, the Charities Act 2011, the Charities SORP, taxation legislation, data protection, anti-bribery, employment, environmental and health and safety legislation;
- we assessed the extent of compliance with the laws and regulations identified above through making enquiries of management and inspecting legal correspondence; and
- identified laws and regulations were communicated within the audit team regularly and the team remained alert to instances of non-compliance throughout the audit.

We assessed the susceptibility of the charitable company's financial statements to material misstatement, including obtaining an understanding of how fraud might occur, by:

- making enquiries of management as to where they considered there was susceptibility to fraud, their knowledge of actual, suspected and alleged fraud; and
- considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations.

Audit response to risks identified
To address the risk of fraud through management bias and override of controls, we:

- performed analytical procedures to identify any unusual or unexpected relationships;
- reviewed all transactions listed;
- assessed whether judgements and assumptions made in determining the accounting estimates were indicative of potential bias; and
- investigated the rationale behind significant or unusual transactions.

In response to the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to:

- agreeing financial statement disclosures to underlying supporting documentation; and
- enquiring of management as to actual and potential litigation and claims.

There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the Trustees and other management and the inspection of regulatory and legal correspondence, if any.

Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealment or collusion.

A further description of our responsibilities is available on the Financial Reporting Council's website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

INDEPENDENT AUDITOR'S REPORT (CONTINUED)

TO THE MEMBERS AND TRUSTEES OF PANCREATIC CANCER ACTION

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and to the regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company's members and trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company, the charitable company's members as a body,and the charitable company's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Stephen Meredith BA FCA DChA (Senior Statutory Auditor)
for and on behalf of Alliotts LLP

09/09/2022
.....

Chartered Accountants
Statutory Auditor

Friary Court
13-21 High Street
Guildford
Surrey
GU1 3DL

PANCREATIC CANCER ACTION

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2021

	Notes	Unrestricted funds 2021 £	Restricted funds 2021 £	Total 2021 £	Unrestricted funds 2020 £	Restricted funds 2020 £	Total 2020 £
Income from:							
Donations and legacies	**3**	725,410	21,790	747,200	532,104	623,639	1,155,743
Charitable activities	**4**	-	-	-	-	92,236	92,236
Other trading activities	**6**	6,963	-	6,963	7,697	-	7,697
Investments	**5**	54	-	54	801	-	801
Total income		732,427	21,790	754,217	540,602	715,875	1,256,477
Expenditure on:							
Raising funds	**7**	328,083	-	328,083	270,766	37,849	308,615
Charitable activities	**8**	346,437	167,437	513,874	312,399	125,439	437,838
Total expenditure		674,520	167,437	841,957	583,165	163,288	746,453
Net income/(expenditure) for the year/ Net movement in funds		57,907	(145,647)	(87,740)	(42,563)	552,587	510,024
Fund balances at 1 January 2021		309,403	620,534	929,937	351,966	67,947	419,913
Fund balances at 31 December 2021		367,310	474,887	842,197	309,403	620,534	929,937

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

PANCREATIC CANCER ACTION

BALANCE SHEET

AS AT 31 DECEMBER 2021

	Notes	2021 £	£	2020 £	£
Fixed assets					
Tangible assets	**13**		3,117		18,571
Current assets					
Stocks	**14**	18,411		14,892	
Debtors	**15**	50,577		113,325	
Cash at bank and in hand		822,729		840,651	
		891,717		968,868	
Creditors: amounts falling due within one year	**16**	(52,637)		(57,502)	
Net current assets			839,080		911,366
Total assets less current liabilities			842,197		929,937
Income funds					
Restricted funds	**18**		474,887		620,534
Unrestricted funds					
Designated funds	**20**	2,075		15,485	
General unrestricted funds		365,235		293,918	
			367,310		309,403
			842,197		929,937

The financial statements were approved by the Trustees on 09/09/2022

Nicola Mumford
Nicola Mumford (Sep 9, 2022 16:11 GMT+1)

.....

N Mumford
Trustee

Company Registration No. 07272699

PANCREATIC CANCER ACTION

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 DECEMBER 2021

	Notes	2021		2020	
		£	£	£	£
Cash flows from operating activities					
Cash (absorbed by)/generated from operations	**24**		(17,975)		532,890
Investing activities					
Investment income received		53		801	
Net cash generated from investing activities			53		801
Net cash used in financing activities			-		-
Net (decrease)/increase in cash and cash equivalents			(17,922)		533,691
Cash and cash equivalents at beginning of year			840,651		306,960
Cash and cash equivalents at end of year			822,729		840,651

1 Accounting policies

Charity information

Pancreatic Cancer Action is a private company limited by guarantee incorporated in England and Wales. The registered office is Unit 9, Oakhanger Farm Business Park, Oakhanger Road, Oakhanger, Hampshire, GU35 9JA.

1.1 Accounting convention

The financial statements have been prepared in accordance with the charity's [governing document], the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended), FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019). The charity is a Public Benefit Entity as defined by FRS 102.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

Gifts of assets and services are recognised at market value to the charity.

1 Accounting policies **(Continued)**

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset's use.

Expenditure has been allocated between the main headings in the Statement of Financial Activities on the basis of the type of activity to which they relate, including irrecoverable V.A.T.

Income and expenses have not been netted off.

1.6 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures, fittings & equipment	25% on cost
Computers	25% on cost

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the statement of financial activities.

1.7 Impairment of fixed assets

At each reporting end date, the charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

1.8 Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition. Items held for distribution at no or nominal consideration are measured the lower of replacement cost and cost.

Net realisable value is the estimated selling price less all estimated costs of completion and costs to be incurred in marketing, selling and distribution.

1.9 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1 Accounting policies **(Continued)**

1.10 Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

1.11 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.12 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Key sources of estimation uncertainty

Covid-19

The full impact following the recent emergence of the global coronavirus pandemic is still unknown. It is therefore not currently possible to evaluate all the potential implications for the charity's activities, suppliers, beneficiaries and the wider economy at the date of approval of these financial statements. However, the trustees are closely monitoring the impact of COVID-19 on the charity.

3 Donations and legacies

	Unrestricted funds	**Restricted funds**	**Total**	Unrestricted funds	Restricted funds	Total
	2021	**2021**	**2021**	2020	2020	2020
	£	**£**	**£**	£	£	£
Donations and gifts	725,410	21,790	747,200	501,104	623,639	1,124,743
Grants receivable for core activities	-	-	-	31,000	-	31,000
	725,410	21,790	747,200	532,104	623,639	1,155,743

4 Charitable activities

	Grants 2021	**Grants 2020**
	£	**£**
Performance related grants	-	33,455
Government Grant	-	58,781
	-	92,236

5 Investments

	Unrestricted funds	Unrestricted funds
	2021	2020
	£	£
Interest receivable	54	801

6 Other trading activities

	Unrestricted funds	Unrestricted funds
	2021	2020
	£	£
Sales of merchandise	6,963	7,697

7 Raising funds

	Unrestricted funds	Unrestricted funds	Restricted funds	Total
	2021	2020	2020	2020
	£	£	£	£
Fundraising and publicity				
Fundraising costs	123,185	46,773	-	46,773
Staff costs	146,382	165,990	37,849	203,839
Depreciation and impairment	5,725	5,096	-	5,096
Support costs	38,308	37,103	-	37,103
Fundraising and publicity	313,600	254,962	37,849	292,811
Trading costs				
Other trading activities	14,483	15,804	-	15,804
	328,083	270,766	37,849	308,615

8 Charitable activities

	Raising awareness	Supporting research	Medical education	Patient support/ information	Total 2021	Total 2020
	2021	2021	2021	2021		
	£	£	£	£	£	£
Staff costs	141,581	30,469	16,453	15,536	204,039	231,294
Depreciation and impairment	6,752	1,453	785	741	9,731	10,419
Other costs	163,389	34,933	18,863	17,813	234,998	120,279
	311,722	66,855	36,101	34,090	448,768	361,992
Share of support costs (see note 9)	38,151	8,210	4,433	4,187	54,981	59,963
Share of governance costs (see note 9)	7,026	1,512	816	770	10,125	15,883
	356,899	76,577	41,350	39,047	513,874	437,838
Analysis by fund						
Unrestricted funds	237,611	55,390	32,377	21,059	346,437	312,399
Restricted funds	119,288	21,188	8,973	17,988	167,437	125,439
	356,899	76,578	41,350	39,047	513,874	437,838

8 Charitable activities **(Continued)**

For the year ended 31 December 2020

	Raising awareness	Supporting research	Medical education	Patient support/ information	Total 2020
	£	£	£	£	£
Staff costs	133,330	39,581	18,624	39,759	231,294
Depreciation and impairment	5,982	1,817	836	1,784	10,419
Other costs	67,989	21,418	9,848	21,024	120,279
	207,301	62,816	29,308	62,567	361,992
Share of support costs (see note 9)	34,428	10,459	4,809	10,267	59,963
Share of governance costs (see note 9)	9,119	2,770	1,274	2,720	15,883
	250,848	76,045	35,391	75,554	437,838
Analysis by fund					
Unrestricted funds	181,974	52,981	26,558	50,886	312,399
Restricted funds	68,874	23,064	8,833	24,668	125,439
	250,848	76,045	35,391	75,554	437,838

9 Support costs

	Support costs	Governance costs	2021	Support costs	Governance costs	2020
	£	£	£	£	£	£
Rent	26,878	-	26,878	48,062	-	48,062
Office costs	9,672	-	9,672	3,076	-	3,076
Telephone costs	2,862	-	2,862	6,589	-	6,589
Computer costs	20,312	-	20,312	21,609	-	21,609
Insurance	3,199	-	3,199	3,758	-	3,758
Training, recruitment and internship costs	22,005	-	22,005	1,988	-	1,988
Book-keeping and Accountancy	2,016	-	2,016	1,747	-	1,747
Bank charges	392	-	392	2,468	-	2,468
Audit fees	-	10,680	10,680	-	6,960	6,960
Legal and professional	-	5,398	5,398	-	16,692	16,692
	87,336	16,078	103,414	89,297	23,652	112,949
Analysed between						
Fundraising	32,355	5,953	38,308	29,334	7,769	37,103
Charitable activities	54,981	10,125	65,106	59,963	15,883	75,846
	87,336	16,078	103,414	89,297	23,652	112,949

Governance costs include payments to the auditor of £8,520 (2020 - £4,920) for audit fees and £2,160 (2020 - £2,040 for accounts preparation fees)

10 Trustees

None of the Trustees (or any persons connected with them) received any remuneration during the year and none of them were reimbursed travelling expenses (2020- £Nil).

11 Employees

The average monthly number of employees during the year was:

2021 Number	2020 Number
11	13

11 Employees **(Continued)**

Employment costs	2021	2020
	£	£
Wages and salaries	314,528	392,647
Social security costs	26,329	31,655
Other pension costs	9,564	10,831
	350,421	435,133

From April 2021 to 16th September 2021, the CEO salary was reduced by 50%.

The number of employees whose annual remuneration was £60,000 or more were:

	2021	2020
	Number	Number
£60,000 - £70,000	0	0

12 Taxation

The company is a registered charity and is, therefore, exempt from taxation on its charitable activities.

13 Tangible fixed assets

	Fixtures, fittings & equipment	Computers	Total
	£	£	£
Cost			
At 1 January 2021	31,237	41,911	73,148
Disposals	(20,625)	(29,667)	(50,292)
At 31 December 2021	10,612	12,244	22,856
Depreciation and impairment			
At 1 January 2021	22,378	32,199	54,577
Depreciation charged in the year	7,609	7,845	15,454
Eliminated in respect of disposals	(20,625)	(29,667)	(50,292)
At 31 December 2021	9,362	10,377	19,739
Carrying amount			
At 31 December 2021	1,250	1,867	3,117
At 31 December 2020	8,859	9,712	18,571

14 Stocks

	2021	2020
	£	£
Finished goods and goods for resale	18,411	14,892

15 Debtors

	2021	2020
Amounts falling due within one year:	£	£
Trade debtors	250	-
Other debtors	258	278
Prepayments and accrued income	50,069	113,047
	50,577	113,325

16 Creditors: amounts falling due within one year

	2021	2020
	£	£
Other taxation and social security	11,028	30,432
Trade creditors	13,846	(6)
Accruals and deferred income	27,763	27,076
	52,637	57,502

17 Retirement benefit schemes

Defined contribution schemes

The charity operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the charity in an independently administered fund.

The charge to the SOFA in respect of defined contribution schemes was £9,564 (2020 - £10,831).

18 Restricted funds

The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

	Movement in funds				Movement in funds		
	Balance at 1 January 2020	Incoming resources	Resources expended	Balance at 1 January 2021	Incoming resources	Resources expended	Balance at 31 December 2021
	£	£	£	£	£	£	£
Pat & Paul	-	1,366	-	1,366	1,140	-	2,506
POW app	17,200	-	-	17,200	-	-	17,200
Recipe Book	20,110	-	-	20,110	-	(1,936)	18,174
Patient Information Booklets	27,137	-	(9,150)	17,987	-	(2,015)	15,972
Hope is Contagious	-	6	-	6	150	-	156
NIPanC	-	14,706	(8,250)	6,456	-	-	6,456
PC Aware Wales	3,500	24,245	-	27,745	-	(27,745)	-
Hard to reach groups	-	6,000	-	6,000	-	(6,000)	-
Pancreatic Cancer Scotland	-	607,560	(87,106)	520,454	18,500	(127,491)	411,463
HMRC JRS Grant	-	58,782	(58,782)	-	-	-	-
Health information officer	-	2,250	-	2,250	-	(2,250)	-
Community volunteers	-	960	-	960	-	-	960
GP Packs	-	-	-	-	2,000	-	2,000
	67,947	715,875	(163,288)	620,534	21,790	(167,437)	474,887

Restricted funds relate to grants received for the specific purposes as set out above. Any amount unspent is carried forward to be spent in the next financial year.

19 Analysis of net assets between funds

	Unrestricted 2021	Restricted 2021	Total 2021	Unrestricted 2020	Restricted 2020	Total 2020
	£	£	£	£	£	£
Fund balances at 31 December 2021 are represented by:						
Tangible assets	3,117	-	3,117	18,571	-	18,571
Current assets/(liabilities)	364,193	474,887	839,080	290,832	620,534	911,366
	367,310	474,887	842,197	309,403	620,534	929,937

20 Designated funds

The income funds of the charity include the following designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes:

	Balance at 1 January 2020	Resources expended	Balance at 1 January 2021	Resources expended	Balance at 31 December 2021
	£	£	£	£	£
Early diagnosis challenge award (research)	17,107	(1,622)	15,485	(13,410)	2,075
	17,107	(1,622)	15,485	(13,410)	2,075

21 Financial commitments, guarantees and contingent liabilities

To date, the charity has received £46,897 in donations from solicitors relating to old monies held in client accounts which they have not been able to return. There is a possibility that in the future the clients in question could still return for these monies and, as such, the charity has agreed to refund part of the donation if this occurs. No provision has been made in these financial statements for any possible refund as the likelihood is remote and cannot be quantified.

22 Operating lease commitments

At the reporting end date the charity had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

	2021	2020
	£	£
Within one year	4,320	23,423

23 Related party transactions

Remuneration of key management personnel

The remuneration of key management personnel is as follows.

	2021	2020
	£	£
Aggregate compensation	44,921	42,512

The key management personnel of the Charity is considered to be the CEO.

There were no other related party transactions.

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2021

24	Cash generated from operations	2021 £	2020 £
	(Deficit)/surpus for the year	(87,740)	510,024
	Adjustments for:		
	Investment income recognised in statement of financial activities	(54)	(801)
	Depreciation and impairment of tangible fixed assets	15,455	15,515
	Movements in working capital:		
	(Increase)/decrease in stocks	(3,519)	14,564
	Decrease/(increase) in debtors	62,748	(28,986)
	(Decrease)/increase in creditors	(4,865)	22,574
	Cash (absorbed by)/generated from operations	(17,975)	532,890

25 Analysis of changes in net funds

The charity had no debt during the year.

PANCREATIC CANCER ACTION

England & Wales - Charity number 1137689

Accounts

Charity Registration No. 1137689 (England and Wales)

Charity Registration No. SC049777 (Scotland)

Company Registration No. 07272699 (England and Wales)

PANCREATIC CANCER ACTION

ANNUAL REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2020

PANCREATIC CANCER ACTION

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	H Matthews	
	N Menezes	
	N Mumford	
	S Krag	
	H Goodfellow	
	L Condron	
	D Georgiou	
	R Legg	(Appointed 16 March 2020)
	C Carter	(Appointed 1 April 2020)
	E Cowan	(Appointed 24 August 2021)
	N Longworth	(Appointed 27 August 2021)
	L Nylander	(Appointed 24 August 2021)
Secretary	G Brown	
Charity number (England and Wales)	1137689	
Charity number (Scotland)	SC049777	
Company number	07272699	
Registered office	Unit 9 Oakhanger Farm Business Park Oakhanger Road Oakhanger Hampshire GU35 9JA	
Auditor	Alliotts LLP Friary Court 13-21 High Street Guildford Surrey GU1 3DL	

PANCREATIC CANCER ACTION

CONTENTS

	Page
CEO's Report	1 - 2
Trustees' report	3 - 15
Statement of Trustees' responsibilities	16
Independent auditor's report	17 - 20
Statement of financial activities	21
Balance sheet	22
Statement of cash flows	23
Notes to the financial statements	24 - 37

PANCREATIC CANCER ACTION

CEO'S REPORT

FOR THE YEAR ENDED 31 DECEMBER 2020

2020 was a year of highs and lows which found us transitioning into Brexit followed by a global pandemic which almost literally stopped us in our tracks.

In the midst of the first lockdown, on March 31st 2020, we successfully completed our merger with Pancreatic Cancer Scotland (PCS), the transition to which was made even more difficult due to having to do everything virtually.

Excluding the transfer of £607,560 from PCS and funding of £58,781 through the Coronavirus Job Retention Scheme, our income for the year was down by £196,369, vs 2019 due to the cancellation and postponement of all mass participation events and even small face to face events such as coffee mornings and cake sales.

We were fortunate (and prudent) to have a very robust reserves policy and that, along with very tight financial management of the charity, has meant that we finished 2020 with a net surplus despite income being down 25% overall. In April 2020, I decided to cut my salary by 50% which I have continued to do well into 2021.

We took full advantage of the furlough scheme and in order to ensure that our charitable objectives were still being met as far as we could, we rotated staff on and off furlough and then took advantage of the part-time furlough scheme to bring some team members back.

In late 2020, we unfortunately took the difficult decision to offer redundancy to five members of the team (out of 15).

Despite our internal pressures due to pandemic, we were ever mindful about the effect the pandemic was having on pancreatic cancer patients and their families with many healthcare professionals working in the cancer field being deployed to frontline covid services resulting in delayed diagnoses, and many pancreatic cancer treatments such as surgery and chemotherapy were either postponed or cancelled.

Advice and information relating to COVID-19, cancer services and shielding changed almost on a daily basis, but we at Pancreatic Cancer Action (PCA) kept on top of it by attending many (virtual) meetings with NHS, Governments and collaborating with other charities and organisations to share information.

Using these channels, we continued to update our website and social media channels daily to give our patients and their families the most up-to date information we could.

During a really difficult time for everyone, our first priority was still early diagnosis and to look after pancreatic cancer patients and their families.

We continued with our research project at the University of Surrey looking at patient records of people with diabetes who went on to get pancreatic cancer and those who did not. The aim is to identify a group of new-onset diabetes patients who could potentially be at risk of pancreatic cancer and to help GPs know when to refer a patient with new-onset diabetes for pancreatic cancer testing in the hope they can be diagnosed early.

The long-term impact of reduced public presentation to primary care and reduced urgent referrals at the height of the pandemic has not yet been fully realised. The missed and delayed cohort of cancer patients not yet in the system will have to come through in the subsequent months alongside incident cancer cases, adding to diagnostic and treatment demand. These people will naturally be presenting at a later stage and so are more likely to be, or become, inoperable, due to diagnostic delays and reduced investigative capacity. The impact of revised treatment pathways during the first wave has also yet to be realised, with people who were bridged on neo-adjuvant chemotherapy and who need surgery potentially increasing pressure on services further down the line.

We will continue to be a voice for patients and families to ensure pancreatic cancer is a focused priority in NHS Recovery Plans.

PANCREATIC CANCER ACTION

CEO'S REPORT

FOR THE YEAR ENDED 31 DECEMBER 2020

In 2020 we started the development of a project to look at the underserved groups in the UK who have a poorer prognosis when diagnosed with pancreatic cancer. We not only want to understand why, but we want to ensure all our information is communicated effectively and that we reach these groups to ensure they take action when presenting with symptoms.

We had great plans to celebrate our 10th anniversary in 2020 by launching our new vision for the future in what we hope will be the 'Decade of Change' for pancreatic cancer.

We are very proud of our achievements to date and we will continue to have a primary focus of improving early diagnosis of pancreatic cancer as well as ensuring all those affected by pancreatic cancer have access to the care, information and support they need.

However, we can't do all this alone and we are so fortunate to have so many Community Representatives, Action Ambassadors and other volunteers who help in a variety of ways including providing us with lay reviews for our patient information. We rely heavily on their generosity of time as well as their efforts to raise awareness and fundraise in their localities.

Some of our key volunteers are our Trustees, who have supported me and my team so very well over the past year.

I am also grateful to our wonderful Patrons and Ambassadors who help us with our activities and support our campaigns and of course to our marvellous fundraisers and donors, without whom, we couldn't do what we do.

Ali Stunt
Founder & Chief Executive

Ali Stunt (Sep 23, 2021 13:21 GMT+1)

.....

Ali Stunt
Founder & Chief Executive
Dated: 23/09/2021

PANCREATIC CANCER ACTION

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)

FOR THE YEAR ENDED 31 DECEMBER 2020

The Trustees present their report and financial statements for the year ended 31 December 2020.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charity's Memorandum and Articles of Association, the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)".

Objectives and activities

Our purpose

Pancreatic Cancer Action works to save lives through promoting earlier diagnosis of pancreatic cancer. We do this through promoting greater awareness of the symptoms of the disease, the funding and development of medical educational programmes, supporting patients through improved information about pancreatic cancer either on our website or in print and by funding research.

Our vision

Our vision is that everyone survives pancreatic cancer.

Our mission

Our mission is to improve survival rates of pancreatic cancer by ensuring more people are diagnosed early and that everyone has access to effective treatments, support, information and care.

Objectives

The charity's objectives are:

A **Awareness** - increase public awareness and knowledge of pancreatic cancer and its symptoms to achieve early diagnosis

C **Campaign** and lobby the government and key stakeholders for change to advance the standard of healthcare for individuals affected by pancreatic cancer

T **Train** and provide pioneering educational resources for our medical and healthcare communities

I **Innovative** research - we fund it, we support it - to improve early diagnosis and develop effective treatments to improve pancreatic cancer outcomes

O **Offer** the provision of practical and emotional support and information to all affected by pancreatic cancer

N **Now –** we are the action charity and action is needed more than ever before!

The Trustees have paid due regard to guidance issued by the Charity Commission in deciding what activities the charity should undertake.

The Trustees' activities

The Trustees meet annually to develop a strategy to meet the charitable objectives. Once the overall strategy has been agreed by the Trustees a series of operational meetings attended by a selection of the Trustees and volunteers, who the Trustees believe have relevant skills and experience in the specific area look at the operational implementation.

The Trustees currently have a range of skills and experience that range from medical/scientific, Legal corporate governance, finance and PR.

Role of volunteers

The Charity receives the very welcome assistance of volunteers. To date this has usually been for specific projects or fund-raising initiatives. In 2020 our network of Regional Representatives across the UK was made up of 200 volunteers. The aim is that these volunteers represent Pancreatic Cancer Action, raise awareness of pancreatic cancer and fundraise in their communities.

The pandemic and ever-changing restrictions has impacted how volunteers can assist in our office, at events or within their communities, but we continue to evolve ways to enable people show their support. The charity seeks volunteer assistance via the website, social media and by word of mouth.

Public benefit statement

The Trustees confirm that they have complied with the duty in Section 4 of the Charities Act 2011 to have due regard to the Charity Commission's general guidance on public benefit.

Achievements and performance

Merger between Pancreatic Cancer Action and Pancreatic Cancer Scotland

On March 31st 2020, despite the challenges of the pandemic, Pancreatic Cancer Action (PCA) and Pancreatic Cancer Scotland (PCS), merged to become one organisation.

This merger brings together two charities both of which formed in 2010, out of a need for a pancreatic cancer charity focussing on improving symptom awareness, early diagnosis and patient care in Scotland and the rest of UK.

PCS and PCA have always enjoyed a positive collaborative working relationship. Addressing the urgent need to take more action and to achieve more together and faster, will enable considerable progress towards our shared vision of making the 2020's the Decade of Change for pancreatic cancer.

Driven by a need to increase pancreatic cancer survival rates, the merger is a commitment to the people of Scotland, and the rest of UK, of a stronger united force, pulling together to take determined action to change the numbers, to improve the outcomes for patients and families.

By coming together, we know we can make greater strides in making our vision, a day when everyone is diagnosed early and survives pancreatic cancer, a reality. Consolidating effort makes perfect sense at this time, especially when there are external challenges on organisations within the charity sector.

PCS and PCA have extensively collaborated for over a decade on many projects. This merger provides a symbiotic platform whereby both charities can benefit. We can minimise overheads, maximise innovation, optimise patient and carer benefit. Taking this action is an ideal fit for our concept of the 'Decade of Change'.

Due to the differences in size and legal structure of PCS, a Scottish Charitable Incorporated Organisation (SCIO) and PCA, (a company Ltd by Guarantee), the most cost effective way of achieving the merger was for all of PCS assets, undertakings and employees to be transferred to PCA and PCS wind up its affairs and be dissolved.

Income of £607,560 to PCA in 2020 represents the transfer of PCS net assets of £25,965 and bank balance of £581,595.

Legacy funds from PCS and all future funds raised in Scotland shall continue to benefit the people of Scotland through PCA's initiatives, projects and activities, operating as Pancreatic Cancer Action Scotland.

We have developed the combined organisation's branding, future vision, strategy and action plans within the spirit of the merger.

PCS was mainly volunteer led until as recently as 2017 and continuing the original ethos of volunteer involvement in Scotland, a new Scottish Development Committee (SDC) of PCA has been created. With all funds raised in Scotland continuing to benefit Scotland, the SDC will bring together trustees, volunteers, and employees, to provide an advisory role to support the direction and development of activities and projects.

Activities aligned to our objectives:

1. *Awareness* - increase public awareness and knowledge of pancreatic cancer and its symptoms to achieve early diagnosis

PC Aware Wales
Due to launch in June 2020, this public and healthcare professional awareness campaign had to be put on hold until 2021 due to Covid-19 lockdown restrictions.

By targeting all key stakeholders in the same region within the same time frame we hope to significantly increase awareness of pancreatic cancer and save lives through early diagnosis.

Islets of Silence – The C Word
A play written and directed by Isobel Barrett of Tram Direct Theatre Company was set to tour around theatres in Scotland in 2020 to help raise awareness of pancreatic cancer through the arts.

Originally funded by PCS alongside Culture & Business Fund Scotland match funding by Arts & Business Scotland, the project launch in 2020 attracted fantastic media coverage including STV News.

The tour was postponed due to the pandemic, but Isobel and the production team continued to create innovative ways to use the arts to raise awareness, with excerpts of the play filmed and shared via social media.

We look forward to the tour recommencing in 2021.

Pancreatic Cancer Awareness Month
Throughout the month of November we had an extra push on raising awareness of the symptoms of pancreatic cancer to reach more people than we ever have before. This started at the beginning of the month and we saw an incredible amount of social media shares of our symptoms posts.

STV Advert
We also launched the first ever symptoms awareness TV advert in Scotland that featured on STV for two weeks. We were thrilled with how successful this was and how many people saw it and engaged with us because of it. The advert featured one of our amazing supporters talking about the symptoms of pancreatic cancer and how he sadly lost his dad to the disease. This was complimented with online and billboard advertising to make an even bigger impact.
Through raising awareness of the symptoms and directing people to our symptoms page on our website, we saw a huge spike in website and page visits up by 114%.

Turn it Purple campaign.
We were delighted to see some brilliant fundraising activities “go virtual” from raffles, quizzes and running challenges and had some fantastic support from all our corporate partners across the whole of the UK. Not only have our supporters raised a significant amount of funds, but so much awareness for pancreatic cancer has resulted through the sharing our Purple Heart Poster and information about the symptoms across social media.
Together we definitely turned the month purple, and we are extremely proud and grateful for all the support we received. We smashed our original £5,000 target on our JustGiving page so increased it to £10,000 (which we finished just shy of) which will go towards our vital work to make the 2020’s the Decade of Change for pancreatic cancer.

Light it Purple
The collaborative campaign Purple Lights UK saw locations across the country light up purple to raise awareness during November and in particular on World Pancreatic Cancer Day. This is largely a supporter focused campaign and this year we saw lots of supporters light up their own homes in support as well as buildings and landmarks.

Broadcast Media
We secured 61 pieces of press coverage in November including a feature on BBC South Today on World Pancreatic Cancer Day and an article in The Express. We also had 16 radio interviews throughout the month.

Occupational Health
The Pancreatic Cancer Action Occupational Health and Wellbeing campaign primarily aims to make people aware of the symptoms of pancreatic cancer to ensure that more people are diagnosed early.

Targeting people in the workplace is a perfect opportunity for PCA to raise awareness in large numbers as well as increase brand awareness and encourage corporate fundraising.

During 2020 it was impossible to have any face-to-face meetings, so instead, our patron, Dr Hilary Jones (GP and TV Medic) presented a video version of the presentation. This is to be rolled out in 2021 and we will use this in addition to face-to-face presentations once lockdowns have ended.

Underserved Groups
During 2019 PCA started to research and define its approach to communicating with groups that have low health literacy, groups that are hard to reach with the worst outcomes in relation to diagnosis and survival of pancreatic cancer.

Phase one of the project will define PCA's key target groups, investigate approaches that have been reported successful, identify the barriers to diagnosis, barriers in access to care and aims to identify networks and agents that PCA could engage with to pilot our approach.

In 2020 we engaged with community groups and food banks in East Glasgow, one of the country's most deprived areas. This is with a view to piloting an awareness campaign in this area.

Likely to be a four-year project we expect that this initial research will inform the definition of the long-term strategic project aimed at improving diagnosis in underserved groups and will improve outcomes through information and support for these groups.

We look forward to reporting on our results over the next few years.

***2. Campaign* and lobby the government and key stakeholders for change to advance the standard of healthcare for individuals affected by pancreatic cancer.**

We engaged with politicians across the UK to raise awareness of the statistics around pancreatic cancer and the importance of early diagnosis.

In the lead up to a Scottish parliament debate on pancreatic cancer, we sent personalised briefings and letters to every MSP, discussing pancreatic cancer in their area and the inequalities surrounding the disease. We reminded MSPs that the statistics for pancreatic cancer have not changed in decades but with early diagnosis longer term survival is possible.

We highlighted the issue of socioeconomic deprivation and how those in more deprived areas are diagnosed with cancer more often, at a late stage and with worse outcomes and survival. We offered our support to MSPs in changing the statistics around pancreatic cancer and requested their support in attending the debate and raising awareness in their constituencies.

We have had a great response and there was an excellent debate where MSPs were able to discuss local challenges to early diagnosis of pancreatic cancer in their area.

In Scotland, we continued to engage with key stakeholders, including representation at meetings and discussions with The Scottish Cancer Coalition, Cross Party Group on Cancer, The Scottish HPB Network and various other networks and contacts.

Furthermore, we wrote to every MP across the UK, asking them to support PCA in November's awareness month and use our resources to raise awareness of pancreatic cancer.

All Party Parliamentary Group on Pancreatic Cancer
Unfortunately, due to the pandemic, the APPG PC was unable to function as usual. However, we did put into motion an inquiry into the impact that Covid-19 has had on pancreatic cancer diagnosis and treatments. This report was published in 2021.

Cancer Alliances
We have worked more closely than ever before with cancer alliances and those running cancer services across the UK. We collaborated with Surrey and Sussex Cancer Alliance to raise awareness and promote our services among GPs and pharmacists. Alongside this, we worked with the Lancashire and South Cumbria Cancer Alliance to raise awareness with GPs, hospitals and the public. As a result of this, we were able to promote our E-learning modules to help health care professionals diagnose pancreatic cancer early as well as raising awareness in local communities.

***3. Train* and provide pioneering educational resources for our medical and healthcare communities.**

HealthCare Professional Awareness
We continue to provide free resources and e-learning modules to help GPs and pharmacy teams.

GP Aware
As an organisation we understand how difficult it can be for GP's to diagnose pancreatic cancer in the early stages because the symptoms can be non-specific. As a result, 80% of patients are diagnosed at an advanced stage with over half being diagnosed in A&E as an emergency presentation.
With the Covid-19 pandemic and the resulting strain on the health service, we decided not to run our GP Aware campaign in 2020.

Pharmacy Aware
Pharmacy teams are becoming the first point of contact for many people who have health concerns. They are well placed to identify key signs and symptoms of pancreatic cancer by engaging with patients and by the medications prescribed and bought over the counter.

"Pharmacy plays a crucial role in aiding early diagnosis, which can significantly improve a patient's chance of survival"

- Ade Williams, Pharmacist and PCA's Pharmacy Ambassador

With the Covid-19 pandemic and the resulting strain on the health service, we decided not to run our Pharmacy Aware campaign in 2020.

***4. Innovative research* - we fund it, we support it - to improve early diagnosis and develop effective treatments to improve pancreatic cancer outcomes.**

Currently, 80% of patients face a terrible prognosis as they have had their disease diagnosed at a late stage, which is why survival rates are so low. We need to change this and get people diagnosed in time for resectional surgery - currently the only potential for a cure.

Diabetes and pancreatic cancer
Pancreatic Cancer Action is committed to funding early diagnosis research projects. Our past early diagnosis challenge award gave funding to researchers primarily working with biomarkers that has led to further investment from Pancreatic Cancer Research Fund (PCRF) and Cancer Research UK. Throughout 2019 and beyond we are funding projects examining the link between diabetes and pancreatic cancer. Research is emerging in this area that suggests there may be an opportunity for early diagnosis of pancreatic cancer in patients with new diabetes.

Pancreatic cancer and diabetes are linked in multiple ways. Type 1 diabetes is associated with an increased lifetime risk of pancreatic cancer. Adult onset, type 2 diabetes is also a risk factor for pancreatic cancer. However, type 2 diabetes in a patient without metabolic disorder or raised BMI (therefore of “normal” weight) is increasingly described as an important early symptom of pancreatic cancer. Type 2 diabetes in these patients is often a misdiagnosis of type 3c diabetes, associated with damage to the pancreas and loss of function. These patients may present with diabetes months or years before other symptoms develop and this link could present an opportunity for early diagnosis imaging and diagnosis of pancreatic cancer.

At the end of 2019 PCA had partnered with the University of Surrey, to conduct a retrospective case control study (looking back at existing patients with and without a condition). The project involves examining the GP records of patients with diabetes who went onto develop pancreatic cancer and those who did not develop the disease. Records will be taken from the RCGP database where approximately 9.5 million patients’ data is stored. This allows a large sample of patients to investigate.
Despite the pandemic, we were able to continue with this project in 2020, and the first paper is due to be published in 2021.

Co-funded Research

We have continued PCS co-funding, with The Scottish Government Chief Scientist Office, a PhD studentship based at the world-leading Cancer Research UK Beatson Institute in Glasgow, as part of Pancreatic Cancer UK's Future Leaders Academy.

The Academy give PhD student’s access to state-of-the art facilities with leading experts providing them with mentorship and training to develop the essential skills and expertise needed to pursue a career as a leading scientist in pancreatic cancer.

The 4 year project commenced in September 2017 with a focus on improving understanding of the biology of pancreatic cancer – how it grows, how it spreads and how it defends itself against current treatments.

Our co-funding supports PhD student Rachael Smith whose project is titled ‘Targeting protein synthesis in pancreatic cancer.’ Working with pioneer researcher Professor Owen Sansom, she is investigating how targeting the production of specific proteins within cells may affect tumour growth, invasion and survival.

Precision-Panc

We continue to engage and support the ground-breaking Precision-Panc project led from The University of Glasgow.

Majority funded by Cancer Research UK, the Precision-Panc platform was founded in 2017, bringing together expertise in pancreatic cancer from universities, research institutes and the NHS.

Precision medicine is about tailoring treatments to an individual’s cancer and the overall aim is to make this a reality for more people with pancreatic cancer – through building knowledge that will ultimately allow clinicians to match patients with the most suitable treatment.

There is now a UK wide network of over 20 hospitals that can offer precision medicine clinical trials as a vital treatment option for people with pancreatic cancer. As part of the wider Precision-Panc programme tissue samples are also collected from participants for molecular profiling, which could lead to vital new insights into the development of the disease in the future.

In Precision-Panc all registered patients have their genome testing using Glasgow Precision Oncology Laboratories bespoke panel. Networked clinical trials with researchers across the country share expertise and knowledge, as well as creating and sharing infrastructure, leading to trials which are quicker to set up and recruit.

This ambitious programme of research could transform how pancreatic cancer is treated and as we learn more about the disease, pave the way for patients entering clinical trials in a way that matches their tumour biology to the type of treatment.

PCA are proud to work closely with the Precision-Panc team. We share and contribute knowledge and experiences and work collaboratively to improve access to clinical trials. We provide additional resource by fully funding a dedicated pancreatic cancer clinical nurse specialist within the West of Scotland Cancer Network.

5. Offer **the provision of practical and emotional support and information to all affected by pancreatic cancer**

PCS Precision-Panc, Pancreatic Cancer Clinical Nurse Specialist

From August 2018, PCS began fully funding an innovative new dedicated pancreatic cancer nurse specialist role with NHS Greater Glasgow and Clyde to support the West of Scotland Pancreatic Team, Precision-Panc and our charity.

Based at Glasgow Royal Infirmary the post-holder provides supplementary direct clinical support for patients and carers, ensuring there is a point of contact for information and advice, before, during and after treatment. A large part of this includes signposting individuals to appropriate support services and guiding them through a complex pathway. This is key in facilitating holistic treatment throughout a patient's journey, recognising every individual is different.

While this is not a research nurse post, the unique combined research aspect of this role supports patients and families understanding of clinical trials and has contributed to enhancing participation and recruitment of patients to the Precision-Panc study and other trials, which are key to improving survival in the future.

The post-holder will regularly engage with our team to share insights on where support and focus is needed and represent the charity at meetings and events, providing the opportunity to engage with supporters and networks.

We are delighted with how the role has adapted and evolved – joining everything together with the patient at the heart of it. The success of this role demonstrates how a collaborative approach with the third sector, healthcare professionals and research programmes can make a real difference - especially in ensuring patients and families are provided with support and information.

Our aim is to expand this project to fund similar posts in the other pancreatic centres.

Patient Information Booklets

In mid-2020 we relaunched our patient information booklets including a new booklet on palliative and end of life care.

We know that a diagnosis of pancreatic cancer can be a frightening and uncertain time that throws up many questions and concerns.

Our booklets contain the most up to date information available to help patients to understand pancreatic cancer, treatment options and the experience of the disease.

We are very grateful to our peer and lay reviewers who have given their time to ensure our information is evidence based, accurate and understandable.

The booklets are easy to understand at any stage of the patients journey and are available to order or view online.

Our information is accredited by The Patient Information Forum, a mark that demonstrates high quality information that you can trust.

Support

Our help and support section of our website is designed to help everyone affected by pancreatic cancer to help answer any questions people may have.

Our website contains helpful information and links to support people, from the moment symptoms first appear, to treatment, coping and bereavement.

Our sources of support include an interactive option to engage with our partners at Grief Chat.
GriefChat is a safe space for grieving or bereaved people to be able to share their story, explore their feelings and be supported by a qualified bereavement counsellor.

We are proud to continue our partnership with Cancer Support Scotland (CSS), funding support services for anyone affected by pancreatic cancer in Scotland. This includes the person diagnosed, their family, friends, carers and those who have lost a loved one.

We will continue to develop relationships with stakeholders to ensure that there is support available throughout the UK as we listen to the needs of patients and families.

Wider activities and engagement:

Conferences and Exhibitions
Due to the pandemic, we were only able to attend the Wellbeing at Work conference in early March before lockdown.

PCA Action Ambassadors
We will continue to recruit further patients or carers who have had experience of pancreatic cancer as regional representatives in areas where we currently do not have representation.

Fundraising
Covid 19 has impacted fundraising significantly for PCA in 2020. Overall year end income excluding exceptional funding, was down 25% from 2019 and we saw a significant drop in fundraisers from 2019 too.
Actions were taken to review fundraising activities that could be pivoted to virtual events and products which meant income continued to be received. Interestingly, income has started to steadily increase from October and we ended the year on three strong months.

Increasing supporter engagement was top of the agenda during 2020 and we have worked hard as a team to make sure that all supporters have been communicated with accordingly throughout. We have hosted Zoom calls, made personal phones calls and have sent newsletters and the Action Post to keep them updated.

Relationships with corporates has excelled this year. In Scotland Just Employment Law continued with their support and raised over £30,000 with an online Auction in November and we secured Pen Underwriting as charity partners for another year (2021).

We finished the year with the In Memory Tribute Pages, which raised 41% more than in 2019 and the launch of a new fundraising product for 2021, Jog Jan for Pan Can.

We would like to say a big thank you to all our fantastic supporters, without whom we would not be able to carry out our vital work. This year they have adapted to run, walk, and cycle locally and take on new challenges, with virtual activities and online fundraising taking place across the country.

The support from our community fundraisers is, as ever, invaluable and we have seen supporters, dye their hair, hold online concerts and quizzes to help us with our work. Thank you – we are so very grateful for all you do, then, now and in the future.

Action funds:
At the end of 2020, we had the following action funds:

- Action for Pat and Paul (Scotland)
- Hope is Contagious
- The Shaun Wright Foundation (NE England)Corporate partnerships and support

Corporate partnerships and support
We have invested in developing relationships with businesses both large and small and are delighted to have been able to partner and receive support from such passionate people in 2020. Our corporate partners play a vital role in allowing us to raise more awareness and funds for pancreatic cancer and we can't thank them enough for their support.

They work with us in various capacities and for various lengths of time and in 2020 we were supported by:

- Better Placed
- Pen Underwriting
- Be Fresh
- Sheila Fleet Jewellery
- Just Employment Law
- Partick Thistle Football Club
- Tunnocks
- Arnold Clark Car & Van Rental
- DHL
- The Gin Box Shop

Please get in touch if you would like to find out more about becoming a corporate partner – we'd love to hear from you!

Trusts and Grants
We are very grateful to the many funders that give so generously towards our initiatives, activities and projects. In 2020 these included grants from:

Restricted
The Lord Faringdon Charitable Trust - £1,000
The James Tudor Foundation - £9245
Stella Symons Charitable Trust - £250
The Grocers Charitable Trust - £5,000
The Waterloo Foundation - £15,000
Celebrate National Lottery 25 - £960

Unrestricted:
The Ian Maidens Charitable Trust - £4,000
The Adrian Swire Charitable Trust - £2,500
EIG Ecclesiastical - £1,000
The Lyn Foundation - £500

Financial review
The results for the year are summarised in the Statement of Financial Activities on page 21.

The Trustees are pleased to report that the charity's incoming resources for 2020 amounted to £1,256,477, including a one-off transfer of £607,560 from Pancreatic Cancer Scotland (PCS). Excluding the merger transfer transaction from PCS and funding of £58,781 through the Coronavirus Job Retention Scheme, income of £590,136 represented a decrease of 25 per cent vs 2019 (2019: £786,505), (2018: £892,851), (2017: £757,812).

The Trustees would like to thank all those volunteers, fundraisers and donors - corporate, trusts and foundations, as well as individual donors who have supported the charity over the past years and upon whom we are dependent.

Total spending on charitable activities was £437,838 – significantly lower than previous years due to the pandemic (2019: £608,931) (2018: £669,187), (2017: £669,077).

Primarily as a result of these activities, the charity achieved net surplus for the year of £510,024 (2019: deficit £115,305) (2018: deficit £24,634) (2017: deficit £169,315).

Reserves policy
It is the policy of the charity that unrestricted funds which have not been designated for a specific use should be maintained to cover at least 6 months of operating expenditure. The Trustees consider that reserves at this level will ensure that, in the event of a significant drop in funding, they will be able to continue the charity's current activities while consideration is given to ways in which additional funds may be raised.

At 31st December 2020, the charity held reserves of £929,937, of which £620,534 were restricted. Free reserves stood at £275,347 which is in line with the level of the reserves policy established by the board.

The impact of COVID-19

Like many other charities the impact of COVID-19 has been significant, during lockdown the demand on our health service has grown exponentially with the rise of new cases and, sadly the number for deaths from COVID-19.

During the pandemic we heard that many doctors and nurses who work in cancer services were re-deployed to the front line to tackle the virus and that in some cases treatments for pancreatic cancer such as surgery and chemotherapy were postponed or cancelled.

Advice and information relating to COVID-19, cancer services and shielding changed almost on a daily basis, but we at Pancreatic Cancer Action (PCA) kept on top of it by attending many (virtual) meetings with NHS, Governments and collaborating with other charities and organisations to share information.

Using these channels, we continued to update our website and social media channels daily to give our patients and their families the most up-to date information we could.

We advised patients to stay in close contact with their medical teams to ensure that decisions around their treatment were properly communicated. We advised that if patients had symptoms of pancreatic cancer, that they still needed to contact their GP and we continued to post regular updates for patients.

During a really difficult time for everyone, our first priority was still early diagnosis and to look after pancreatic cancer patients and their families.

We continued with our research project at the University of Surrey looking at patient records of people with diabetes who went on to get pancreatic cancer and those who did not. The aim is to identify a group of new-onset diabetes patients who could potentially be at risk of pancreatic cancer and to help GPs know when to refer a patient with new-onset diabetes for pancreatic cancer testing in the hope they can be diagnosed early.

Because we are so reliant on voluntary donations, the lockdown meant that fundraising events have been cancelled or postponed and our income virtually dried up overnight. We therefore made the difficult but prudent decision to utilise the government's Job Retention Scheme and 60 per cent of the team were furloughed.

Our main priority was to cut unnecessary costs, so that when everything was over, we could hit the ground running and pick up where we left off.

We left a core team in place and despite the challenges we turned the focus of our fundraising events into the virtual arena by encouraging our supporters to take part in out PJ's for Pan Can campaign from the comfort of their own home and as the restrictions were slowly lifted we also encouraged our supporters to take part in a socially distanced Stride for Survival.

During this period, the financial forecasting and stability of the organisation was of paramount importance. Going into 2020 PCA had a strong cash balance and unrestricted reserves which were utilised to keep the charity operating throughout 2020. The financial forecasting of the organisation was closely monitored by the finance sub-committee and additional trustee board meetings were held in order to support the management decisions.

Structure, governance and management

The charity is a company limited by guarantee, incorporated in June 2010, and is therefore governed by its Memorandum and Articles of Association. Its company registration number is 07272699 and its charity numbers are 1137689 (England and Wales) and SC049777 (Scotland).

The Trustees, who are also the directors for the purpose of company law, and who served during the year and up to the date of signature of the financial statements were:

H Matthews

N Menezes

N Mumford

S Krag	
H Goodfellow	
L Condron	
D Georgiou	
R Legg	(Appointed 16 March 2020)
A Clancy	(Appointed 1 April 2020 and resigned 14 April 2021)
C Carter	(Appointed 1 April 2020)
E Cowan	(Appointed 24 August 2021)
N Longworth	(Appointed 27 August 2021)
L Nylander	(Appointed 24 August 2021)

None of the Trustees has any beneficial interest in the company. All of the Trustees are members of the company and guarantee to contribute £10 in the event of liquidation.

The Trustees continue to keep the Charity's activities under review, particularly with regard to any major physical or financial risks that may arise from time to time, and to monitor the effectiveness of the system of internal controls and other variable means, including insurance cover where appropriate, by which those risks already identified by the Trustees can be mitigated.

Auditor

Disclosure of information to auditor

Each of the Trustees has confirmed that there is no information of which they are aware which is relevant to the audit, but of which the auditor is unaware. They have further confirmed that they have taken appropriate steps to identify such relevant information and to establish that the auditor is aware of such information.

The Trustees' report was approved by the Board of Trustees.

nicola mumford (Sep 23, 2021 13:08 GMT+1)

.....

N Mumford

Chair of Trustees

Dated: 23/09/2021

PANCREATIC CANCER ACTION

STATEMENT OF TRUSTEES' RESPONSIBILITIES

FOR THE YEAR ENDED 31 DECEMBER 2020

The Trustees, who are also the directors of Pancreatic Cancer Action for the purpose of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company Law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that year.

In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;

- observe the methods and principles in the Charities SORP;

- make judgements and estimates that are reasonable and prudent;

- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and

- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The Trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 (as amended). They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

PANCREATIC CANCER ACTION

INDEPENDENT AUDITOR'S REPORT

TO THE TRUSTEES OF PANCREATIC CANCER ACTION

Opinion

We have audited the financial statements of Pancreatic Cancer Action (the 'charity') for the year ended 31 December 2020 which comprise the statement of financial activities, the balance sheet, the statement of cash flows and the notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2020 and of its incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended).

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The Trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

- the information given in the Trustees' report, which includes the directors' report prepared for the purposes of company law, for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the directors' report included within the Trustees' report has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the charity and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report included within the Trustees' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 (as amended) require us to report to you if, in our opinion:

- adequate and proper accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the Trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemptions in preparing the Trustees' report and from the requirement to prepare a strategic report.

Responsibilities of Trustees

As explained more fully in the statement of Trustees' responsibilities, the Trustees, who are also the directors of the charity for the purpose of company law, are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the Trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with the Acts and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Extent to which the audit was considered capable of detecting irregularities, including fraud
Our approach to identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows:

- the engagement partner ensured that the engagement team collectively had the appropriate competence, capabilities and skills to identify or recognise non-compliance with applicable laws and regulations;
- we identified the laws and regulations applicable to the company through discussions with Trustees and other management, and from our knowledge and experience of the sector;
- we focused on specific laws and regulations which we considered may have a direct material effect on the financial statements or the operations of the charitable company, including the Companies Act 2006, the Charities Act 2011, the Charities SORP, taxation legislation, data protection, anti-bribery, employment, environmental and health and safety legislation;
- we assessed the extent of compliance with the laws and regulations identified above through making enquiries of management and inspecting legal correspondence; and
- identified laws and regulations were communicated within the audit team regularly and the team remained alert to instances of non-compliance throughout the audit.

We assessed the susceptibility of the charitable company's financial statements to material misstatement, including obtaining an understanding of how fraud might occur, by:

- making enquiries of management as to where they considered there was susceptibility to fraud, their knowledge of actual, suspected and alleged fraud; and
- considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations.

Audit response to risks identified
To address the risk of fraud through management bias and override of controls, we:

- performed analytical procedures to identify any unusual or unexpected relationships;
- reviewed all transactions listed;
- assessed whether judgements and assumptions made in determining the accounting estimates were indicative of potential bias; and
- investigated the rationale behind significant or unusual transactions.

In response to the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to:

- agreeing financial statement disclosures to underlying supporting documentation; and
- enquiring of management as to actual and potential litigation and claims.

There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the Trustees and other management and the inspection of regulatory and legal correspondence, if any.

Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealment or collusion.

INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE TRUSTEES OF PANCREATIC CANCER ACTION

Use of our report

This report is made solely to the charity's Trustees, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's Trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's Trustees as a body, for our audit work, for this report, or for the opinions we have formed.

A further description of our responsibilities is available on the Financial Reporting Council's website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Stephen Meredith BA FCA DChA (Senior Statutory Auditor)
for and on behalf of Alliotts LLP

23/09/2021
.....

Chartered Accountants
Statutory Auditor

Friary Court
13-21 High Street
Guildford
Surrey
GU1 3DL

PANCREATIC CANCER ACTION

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2020

	Notes	Unrestricted funds 2020 £	Restricted funds 2020 £	Total 2020 £	Unrestricted funds 2019 £	Restricted funds 2019 £	Total 2019 £
Income from:							
Donations and legacies	**3**	532,104	623,639	1,155,743	734,707	12,345	747,052
Charitable activities	**4**	-	92,236	92,236	1,300	25,500	26,800
Other trading activities	**5**	7,697	-	7,697	11,179	-	11,179
Investments	**6**	801	-	801	1,474	-	1,474
Total income		540,602	715,875	1,256,477	748,660	37,845	786,505
Expenditure on:							
Raising funds	**7**	270,766	37,849	308,615	292,879	-	292,879
Charitable activities	**8**	312,399	125,439	437,838	513,135	95,796	608,931
Total resources expended		583,165	163,288	746,453	806,014	95,796	901,810
Net (expenditure)/income for the year/ Net movement in funds		(42,563)	552,587	510,024	(57,354)	(57,951)	(115,305)
Fund balances at 1 January 2020		351,966	67,947	419,913	409,320	125,898	535,218
Fund balances at 31 December 2020		309,403	620,534	929,937	351,966	67,947	419,913

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

PANCREATIC CANCER ACTION

BALANCE SHEET

AS AT 31 DECEMBER 2020

	Notes	2020 £	£	2019 £	£
Fixed assets					
Tangible assets	**13**		18,571		34,086
Current assets					
Stocks	**14**	14,892		29,456	
Debtors falling due after one year	**15**	-		12,990	
Debtors falling due within one year	**15**	113,325		71,349	
Cash at bank and in hand		840,651		306,960	
		968,868		420,755	
Creditors: amounts falling due within one year	**16**	(57,502)		(34,928)	
Net current assets			911,366		385,827
Total assets less current liabilities			929,937		419,913
Income funds					
Restricted funds	**18**		620,534		67,947
Unrestricted funds					
Designated funds	**20**	15,485		17,107	
General unrestricted funds		293,918		334,859	
			309,403		351,966
			929,937		419,913

The financial statements were approved by the Trustees on 23/09/2021

nicola mumford (Sep 23, 2021 13:08 GMT+1)

.....

N Mumford

Trustee

Company Registration No. 07272699

PANCREATIC CANCER ACTION

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 DECEMBER 2020

	Notes	2020 £	2020 £	2019 £	2019 £
Cash flows from operating activities					
Cash generated from/(absorbed by) operations	**25**		532,890		(119,330)
Investing activities					
Purchase of tangible fixed assets		-		(4,599)	
Investment income received		801		1,474	
Net cash generated from/(used in) investing activities			801		(3,125)
Net cash used in financing activities			-		-
Net increase/(decrease) in cash and cash equivalents			533,691		(122,455)
Cash and cash equivalents at beginning of year			306,960		429,415
Cash and cash equivalents at end of year			840,650		306,960

1 Accounting policies

Charity information

Pancreatic Cancer Action is a private company limited by guarantee incorporated in England and Wales. The registered office is Unit 9, Oakhanger Farm Business Park, Oakhanger Road, Oakhanger, Hampshire, GU35 9JA.

1.1 Accounting convention

The financial statements have been prepared in accordance with the charity's [governing document], the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)". The charity is a Public Benefit Entity as defined by FRS 102.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

Gifts of assets and services are recognised at market value to the charity.

1.5 Expenditure

Expenditure has been allocated between the main headings in the Statement of Financial Activities on the basis of the type of activity to which they relate, including irrecoverable V.A.T.

1 Accounting policies **(Continued)**

Income and expenses have not been netted off.

1.6 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures, fittings & equipment	25% on cost
Computers	25% on cost

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in net income/(expenditure) for the year.

1.7 Impairment of fixed assets

At each reporting end date, the charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

1.8 Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition. Items held for distribution at no or nominal consideration are measured the lower of replacement cost and cost.

Net realisable value is the estimated selling price less all estimated costs of completion and costs to be incurred in marketing, selling and distribution.

1.9 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.10 Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

1 Accounting policies **(Continued)**

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

1.11 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.12 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.13 Leases

Rentals payable under operating leases, including any lease incentives received, are charged as an expense on a straight line basis over the term of the relevant lease.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Key sources of estimation uncertainty

Covid-19

The full impact following the recent emergence of the global coronavirus pandemic is still unknown. It is therefore not currently possible to evaluate all the potential implications for the charity's activities, suppliers, beneficiaries and the wider economy at the date of approval of these financial statements. However, the trustees are closely monitoring the impact of COVID-19 on the charity.

3 Donations and legacies

	Unrestricted funds	Restricted funds	Total	Unrestricted funds as restated	Restricted funds	Total
	2020	**2020**	**2020**	2019	2019	2019
	£	**£**	**£**	£	£	£
Donations and gifts	501,104	623,639	1,124,743	707,221	12,345	719,566
Grants receivable for core activities	31,000	-	31,000	6,878	-	6,878
Donated goods and services	-	-	-	20,608	-	20,608
	532,104	623,639	1,155,743	734,707	12,345	747,052

4 Charitable activities

	Grants	Grants	Other	Total 2019
	2020	**2019**	**2019**	
	£	**£**	**£**	**£**
Performance related grants	33,455	25,500	-	25,500
Government Grant	58,781	-	-	-
Other income	-	-	1,300	1,300
	92,236	25,500	1,300	26,800
Analysis by fund				
Unrestricted funds	-	-	1,300	1,300
Restricted funds	92,236	25,500	-	25,500

5 Other trading activities

	Unrestricted funds	Unrestricted funds as restated
	2020	2019
	£	£
Sales of merchandise	7,697	11,179

6 Investments

	Unrestricted funds	Unrestricted funds
	2020	2019
	£	£
Interest receivable	801	1,474

7 Raising funds

	Unrestricted funds	Restricted funds	Total	Unrestricted funds
	2020	**2020**	**2020**	2019
	£	**£**	**£**	£
Fundraising and publicity				
Advertising	2,508	-	2,508	2,892
Other fundraising costs	44,265	-	44,265	85,631
Staff costs	165,990	37,849	203,839	147,998
Depreciation and impairment	5,096	-	5,096	4,824
Support costs	37,103	-	37,103	41,266
Fundraising and publicity	254,962	37,849	292,811	282,611
Trading costs				
Other trading activities	15,804	-	15,804	10,268
	270,766	37,849	308,615	292,879

8 Charitable activities

	Raising awareness	Supporting research	Medical education	Patient support/ information	Total 2020	Total 2019
	2020	2020	2020	2020		
	£	£	£	£	£	£
Staff costs	133,330	39,581	18,624	39,759	231,294	319,279
Depreciation and impairment	5,982	1,817	836	1,784	10,419	10,406
Other costs	67,989	21,418	9,848	21,024	120,279	217,516
	207,301	62,816	29,308	62,567	361,992	547,201
Share of support costs (see note 9)	34,428	10,459	4,809	10,267	59,963	51,239
Share of governance costs (see note 9)	9,119	2,770	1,274	2,720	15,883	10,491
	250,848	76,045	35,391	75,554	437,838	608,931
Analysis by fund						
Unrestricted funds	181,974	52,981	26,558	50,886	312,399	513,135
Restricted funds	68,874	23,064	8,833	24,668	125,439	95,796
	250,848	76,045	35,391	75,554	437,838	608,931

8 Charitable activities **(Continued)**

For the year ended 31 December 2019

	Raising awareness	Supporting research	Medical education	Patient support/ information	Total 2019
	£	£	£	£	£
Staff costs	172,223	85,142	53,272	8,642	319,279
Depreciation and impairment	5,613	2,775	1,736	282	10,406
Other costs	114,989	56,185	41,982	4,360	217,516
	292,825	144,102	96,990	13,284	547,201
Share of support costs (see note 9)	27,639	13,664	8,549	1,387	51,239
Share of governance costs (see note 9)	5,660	2,797	1,750	284	10,491
	326,124	160,563	107,289	14,955	608,931
Analysis by fund					
Unrestricted funds	237,669	155,563	107,289	12,614	513,135
Restricted funds	88,455	5,000	-	2,341	95,796
	326,124	160,563	107,289	14,955	608,931

9 Support costs

	Support costs	Governance costs	2020	Support costs	Governance costs	2019
	£	£	£	£	£	£
Rent	48,062	-	48,062	42,214	-	42,214
Office costs	3,076	-	3,076	7,253	-	7,253
Telephone costs	6,589	-	6,589	5,925	-	5,925
Computer costs	21,609	-	21,609	16,347	-	16,347
Insurance	3,758	-	3,758	383	-	383
Training, recruitment and internship costs	1,988	-	1,988	10,416	-	10,416
Book-keeping and Accountancy	1,747	-	1,747	1,687	-	1,687
Bank charges	2,468	-	2,471	3,418	-	3,418
Audit fees	-	6,960	6,960	-	3,288	3,288
Legal and professional	-	16,692	16,692	-	12,065	12,065
	89,297	23,652	112,952	87,643	15,353	102,996
Analysed between						
Fundraising	29,334	7,769	37,103	36,404	4,862	41,266
Charitable activities	59,963	15,883	75,846	51,239	10,491	61,730
	89,297	23,652	112,949	87,643	15,353	102,996

Governance costs include payments to the auditor of £2,040 (2019- £1,625) for accounts preparation fees and £4,920 (2019- £1,660) for audit (2019 - independent examination) fees.

10 Trustees

None of the Trustees (or any persons connected with them) received any remuneration during the year and none of them were reimbursed travelling expenses (2019- £Nil).

11 Employees

The average monthly number of employees during the year was:

2020 Number	2019 Number
13	15

11 Employees **(Continued)**

Employment costs	2020	2019
	£	£
Wages and salaries	392,647	421,215
Social security costs	31,655	37,483
Other pension costs	10,831	8,579
	435,133	467,277

From April 2020, the CEO salary was reduced by 50%.

The number of employees whose annual remuneration was £60,000 or more were:

	2020	2019
	Number	Number
£60,000 - £70,000	-	1

12 Taxation

The company is a registered charity and is, therefore, exempt from taxation on its charitable activities.

13 Tangible fixed assets

	Fixtures, fittings & equipment	Computers	Total
	£	£	£
Cost			
At 1 January 2020	31,237	41,911	73,148
At 31 December 2020	31,237	41,911	73,148
Depreciation and impairment			
At 1 January 2020	15,123	23,939	39,062
Depreciation charged in the year	7,255	8,260	15,515
At 31 December 2020	22,378	32,199	54,577
Carrying amount			
At 31 December 2020	8,859	9,712	18,571
At 31 December 2019	16,114	17,972	34,086

14 Stocks

	2020	2019
	£	£
Finished goods and goods for resale	14,892	29,456

15 Debtors

Amounts falling due within one year:	2020 £	2019 £
Other debtors	278	178
Prepayments and accrued income	113,047	71,171
	113,325	71,349

Amounts falling due after more than one year:	2020 £	2019 £
Prepayments and accrued income	-	12,990
Total debtors	113,325	84,339

16 Creditors: amounts falling due within one year

	2020	2019
	£	£
Other taxation and social security	30,432	12,046
Trade creditors	(6)	19,136
Accruals and deferred income	27,076	3,746
	57,502	34,928

17 Retirement benefit schemes

Defined contribution schemes

The charity operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the charity in an independently administered fund.

The charge to profit or loss in respect of defined contribution schemes was £10,831 (2019 - £8,579).

18 Restricted funds

The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

	Movement in funds				Movement in funds		
	Balance at 1 January 2019	Incoming resources	Resources expended	Balance at 1 January 2020	Incoming resources	Resources expended	Balance at 31 December 2020
	£	£	£	£	£	£	£
Pat & Paul	8,769	897	(9,666)	-	1,366	-	1,366
Early diagnosis challenge award (research)	-	5,000	(5,000)	-	-	-	-
POW app	17,200	-	-	17,200	-	-	17,200
Recipe Book	22,451	-	(2,341)	20,110	-	-	20,110
Noel	41,784	-	(41,784)	-	-	-	-
Patient Information Booklets	31,724	-	(4,587)	27,137	-	(9,150)	17,987
Awards for all	3,670	-	(3,670)	-	-	-	-
Hope is Contagious	300	190	(490)	-	6	-	6
NIPanC	-	13,258	(13,258)	-	14,706	(8,250)	6,456
PC Aware NI	-	15,000	(15,000)	-	-	-	-
PC Aware Wales	-	3,500	-	3,500	24,245	-	27,745
Hard to reach groups	-	-	-	-	6,000	-	6,000
Pancreatic Cancer Scotland	-	-	-	-	607,560	(87,106)	520,454
HMRC JRS Grant	-	-	-	-	58,782	(58,782)	-
Health information officer	-	-	-	-	2,250	-	2,250
Community volunteers	-	-	-	-	960	-	960
	125,898	37,845	(95,796)	67,947	715,875	(163,288)	620,534

Restricted funds relate to grants received for the specific purposes as set out above. Any amount unspent is carried forward to be spent in the next financial year.

19 Analysis of net assets between funds

	Unrestricted 2020	Restricted 2020	Total 2020	Unrestricted 2019	Restricted 2019	Total 2019
	£	£	£	£	£	£
Fund balances at 31 December 2020 are represented by:						
Tangible assets	18,571	-	18,571	34,086	-	34,086
Current assets/ (liabilities)	290,832	620,534	911,366	317,880	67,947	385,827
	309,403	620,534	929,937	351,966	67,947	419,913

20 Designated funds

The income funds of the charity include the following designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes:

	Movement in funds					
	Balance at 1 January 2019	Incoming resources	Resources expended	Balance at 1 January 2020	Resources expended	Balance at 31 December 2020
	£	£	£	£	£	£
Early diagnosis challenge award (research)	73,292	-	(56,185)	17,107	(1,622)	15,485
Core costs	-	8,878	(8,878)	-	-	-
	73,292	8,878	(65,063)	17,107	(1,622)	15,485

21 Financial commitments, guarantees and contingent liabilities

To date, the charity has received £30,187 in donations from solicitors relating to old monies held in client accounts which they have not been able to return. There is a possibility that in the future the clients in question could still return for these monies and, as such, the charity has agreed to refund part of the donation if this occurs. No provision has been made in these financial statements for any possible refund as the likelihood is remote and cannot be quantified.

22 Operating lease commitments

At the reporting end date the charity had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

	2020	2019
	£	£
Within one year	23,423	38,340

The leases relates to the rental of the premises over a 5 year period with a 3 year break clause included.

23 Exceptional items

Donations received in the year of £607,560 represents the transfer of Pancreatic Cancer Scotland's net assets of £25,965 and bank balance of £581,595, as per the Merger Transfer Agreement. As a result of this there is a significant increase in the restricted funds balance, driven by funds that are restricted for Scotland.

Legal fees of £13,104 were incurred in the year for professional services provided to PCA in relation to the merger of Pancreatic Cancer Action and Pancreatic Cancer Scotland. (2019 - £9,007)

£25,955 of staff costs relates to redundancy and pay in lieu of notice payments made during the year, as a result of the covid-19 pandemic.

PCA received funding of £58,781 through the Coronavirus Job Retention Scheme in 2020.

£10,810 of staff costs relates to holiday pay accrual as at 31st December 2020.

24 Related party transactions

Remuneration of key management personnel
The remuneration of key management personnel is as follows.

	2020 £	2019 £
Aggregate compensation	42,512	68,890

The key management personnel of the Charity is considered to be the CEO.

There were no other related party transactions.

25 Cash generated from operations

	2020 £	2019 £
Surplus/(deficit) for the year	510,024	(115,305)
Adjustments for:		
Investment income recognised in statement of financial activities	(801)	(1,474)
Depreciation and impairment of tangible fixed assets	15,515	15,230
Movements in working capital:		
Decrease/(increase) in stocks	14,564	(872)
(Increase) in debtors	(28,986)	(7,049)
Increase/(decrease) in creditors	22,574	(9,860)
Cash generated from/(absorbed by) operations	532,890	(119,330)

26 **Analysis of changes in net funds**

The charity had no debt during the year.